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Abstract
Microfluidic Transport Studies on Lipid Vesicles
Michael Schaich
The plasma membrane is the outermost layer of a cell and separates it from the extracellular
environment. The membrane, as well as the proteins that are anchored in it, plays a crucial
role in the uptake and efflux of molecules. Lipid bilayers are therefore an important object of
research in many fields of science, such as biophysics, pharmacology and synthetic biology.
In this thesis, we develop new microfluidic methods that allow us to study the laws that
govern the transport processes through lipid bilayers.
We use the novel microfluidic Octanol-Assisted Liposome Assembly (OLA) technique to
obtain lipid vesicles which serve as model membrane for our studies. We perform a literature
review, where we discuss OLA and other techniques to obtain liposomes in detail, before
we provide a biophysical analysis of liposomes generated with OLA and compare them to
vesicles obtained via traditional techniques. The biophysical analysis represents the first
systematic evaluation of the properties of GUVs produced with the OLA technique to date.
Using a fluorescence intensity assay, we show that OLA allows for the production of GUVs
with binary lipid mixtures of DOPC-DOPG and DOPC-DOPE in the 1:3, 2:2 and 3:1 lipid
ratio. GUVs with binary lipid mixtures of DOPG-DOPE are only stable in the 1:3 and 2:2
mixing ratio, but not in the 3:1 ratio. We attribute this behaviour to the high charge density of
this mixture and the lipid polymorphism which makes it energetically unfavourable for certain
lipid compositions to form lamellar structures. We furthermore investigate the lateral lipid
diffusivity of DOPC and POPC vesicles produced with OLA using fluorescence recovery
after photobleaching (FRAP) and compare it to that of vesicles obtained via the established
electroformation technique. We find the lateral diffusion coefficients to be quantitatively
similar and in the range of 1 µm2/s for the different lipid systems and techniques tested.
Finally, using a dithionite bleaching assay, we quantitatively show the unilamellarity of OLA
vesicles, confirming previous results.
vi
After examining OLA vesicles for their suitability for transport measurements, we expand the
OLA technique and develop a platform that allows for the on-chip fabrication and controlled
exposure of liposomes to a solute of interest. This novel microfluidic platform combines OLA
with a flow through system that enables us to measure transport and other membrane-active
processes that occur in time scales of tens of seconds on chip. In this platform, we either use
fluorescent labels or exploit the solute molecule’s autofluorescence to visualise the transport
across the vesicle membrane. Using this new method, we investigate the permeability of
small antibiotic molecules of the fluoroquinolone family and quantify the transport of the
drugs ciprofloxacin and norfloxacin through liposome membranes. For PGPC membranes,
we measure median permeability coefficients of 3.57 × 10−6 cm/s for norfloxacin and
4.83 × 10−6 cm/s for ciprofloxacin in a PBS buffer at pH 7.4. These values correlate with
the partition coefficients of the drugs, as well as previous studies on their permeation into
lipid vesicles.
In a second series of experiments, we investigate whether or not DNA nanostructures can
act as ion channels and increase the membrane’s permeability towards protons. For these
studies, we use a microfluidic perfusion assay that was previously developed by the Keyser
group. In this assay, OLA-generated vesicles are immobilised on chip via vesicle traps and
are either incubated with DNA nanopores or a buffer control, before being perfused with a
low pH solution. By means of the fluorescent pH indicator HPTS, encapsulated inside the
GUVs, the intravesicular proton concentration is monitored throughout this exposure. Our
results do not suggest substantial enhancement of proton flux as a result of the incubation
with the DNA nanopore. We attribute this behaviour to the low insertion efficiency of the
DNA nanopore and the temporal resolution of the assay, which might be too low when put in
context with the timescale of passive proton permeation to show a potentially flux enhancing
effect of the DNA nanostructure.
Finally, we widen the scope of our technique by taking the first steps towards a new visu-
alisation method based on the deep UV absorbance of molecules rather than fluorescence.
Our results indicate that this new visualisation method can in principle be incorporated into
a microfluidic assay and used to measure membrane permeability, however this imaging
mode features a substantially lower signal to noise ratio compared to the design based on
fluorescence, limiting its capabilities. The issue of low signal to noise ratio must be overcome
before the absorbance assay can provide a true alternative to fluorescence-based microfluidic
assays as a means to study membrane permeation.
vii
All in all, our studies show that GUVs obtained with the novel OLA technique are viable
alternative to vesicles generated with established methods such as electroformation. We suc-
cessfully use OLA-generated vesicles to study a series of biophysical membrane parameters
and conduct measurements on membrane permeability. We also demonstrate the versatility
of the OLA technique by successfully incorporating it into complex microfluidic assays,
exemplifying its potential for the investigation of membrane properties and its use in transport
studies.
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Chapter 1
Introduction
By the means of Telescopes, there is nothing so far distant but may be represented
to our view; and by the help of Microscopes, there is nothing so small as to
escape our inquiry.
Robert Hooke, 1665 (in the preface of Micrographia)
The British philosopher and polymath Robert Hooke was the first human to observe a living
microorganism under a microscope when he described the fungus Mucor on a piece of
leather in his 1665 published Micrographia as “microscopical mushrooms” [1]. It was also
Hooke who coined the term “cell” in his Micrographia, as the honeycomb-like structures he
observed when looking at cork under his microscope reminded him of the cells of monks
in a monastery [2]. At the time, Hooke did not realise that what he was seeing were the
remaining cell walls of dead cork cells. It wasn’t for almost another 200 years, until the cell
as the fundamental unit of life was recognised with the works of Schleiden, Schwann and
Virchow in the mid 19th century [3]. Naturally, the envelope surrounding the cells was of
particular interest from early on, as it sets the boundary of the cell and controls what goes
into and out of the cell [4]. The theories regarding the function of the cell envelope go back
to the 19th century. One of the earliest theories was proposed by the German botanist and
plant physiologist Wilhelm Pfeffer in 1877. He conducted studies on the osmotic pressure
within cells and concluded that the protoplasm of cells is surrounded by a thin layer that
he called the “plasma membrane” [5, 6]. Pfeffer was not able to deduce the makeup of the
plasma membrane from his experiments. However, he did speculate that the membrane is
at least partially made up of proteins [5]. Due to his early work on cell membranes, he is
sometimes referred to as father of membrane theory [6].
2 Introduction
Gaining a better understanding of molecule transport through biological membranes is also
the aim of the research presented in this thesis. However, before we begin to lay out our own
research, let us briefly look into the past and see how our understanding of cell membranes
has evolved since the days of Wilhelm Pfeffer.
The next crucial figure for the refinement of our understanding of cell membranes was the
British biologist Ernest Overton. In his permeability measurements, 1899 published, Overton
observed that ether soluble (nonpolar) substances can enter cells. In contrast, water soluble
(polar) substances caused shrinking of cells [7]. Moreover, he recognised that the permeation
of molecules correlates to their partition coefficient between water and oil [6] and concluded
that the membrane is made from phospholipids and cholesterol [6, 7]. Phospholipids were
known to Overton, as the French chemist Theodore Gobley had extracted phosphatidylcholine
from several organic tissues and identified their chemical structure some 50 years earlier [8].
The structure of a phospholipid molecule is displayed in Figure 1.1. Phosphatidylcholines
consist of two fatty acid chains, glycerophosphoric acid and choline. The remarkable feature
of these molecules is their amphiphilic nature. Whereas the two fatty acid tail groups are
hydrophobic, the glycerophosphocholine forms a hydrophilic head group [4]. From works by
Langmuir in 1917, it was also known that phospholipids could form molecular layers [6].
Fig. 1.1. (A) Structural formula of a phospholipid molecule. The combination of a hy-
drophilic head group and two hydrophobic tail groups give rise to the amphiphilic nature of
the molecule. (B) Calotte modell of a phospholipid molecule. The hydrophobic tails consist
of two fatty acid chains. The head group is made up of a glycero-3-phosphate to which other
moieties such as choline can attach to. (C) Lipid molecules can form bilayers where the
hydrophobic tails face each other and the headgroups face outwards. Image adapted from [9].
3All these findings led Gorter and Grendel to propose the first membrane model of cells
in 1925, according to which a single lipid bilayer covers the cell surface [6, 10]. The
arrangement of lipid molecules in such a bilayer is depicted in Figure 1.1C. The phospholipid
molecules are oriented in a way that the hydrophobic tail groups face each other, whereas
the hydrophilic head groups face outwards [11]. This model was developed further in 1935,
when Danelli and Davidson proposed that a protein layer is absorbed to each side of the
bilayer [6]. Early electron microscopy studies by Robinson seemed to confirm this picture
of biomembranes. In his 1959 review, he concluded that all membranes of biological cells
follow a similar construction principle. According to him, they form a 7.5 nm thick three-
layered structure where two protein layers are adsorbed to each side of the bilayer [12]. He
called this structure the unit membrane [7]. Today, we believe that the triple layered structure
observed by Robinson was likely an artefact stemming from the preparatory techniques of
the time [11]. These caused extensive denaturing of the proteins and led to the structure
that Robinson observed [11]. Robinson’s unit membrane was also not universally accepted
in the field at the time and throughout the 1960s, several other membrane models were
discussed [7, 11].
Fig. 1.2. Schematic of the fluid mosaic model. The backbone of the cell membrane is a lipid
bilayer. Membrane proteins can be adsorbed to either side of the membrane, or span through
the entire lipid bilayer. The proteins can freely diffuse laterally within the lipid membrane.
Image from [9].
The next major refinement of the membrane model came from two scientists called Nicolson
and Singer. Work on proteins throughout the 1960s let them to believe that proteins can also
span through membranes. Furthermore, they observed labelled proteins as isolated spots on
electron microscopy images [6]. In 1972 they proposed their highly influential membrane
model called the fluid mosaic model, schematically drawn in Figure 1.2 [13]. According
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to this model, the structure forming unit of the membrane is a single lipid bilayer. Proteins
may be either adsorbed to the membrane, or span through it. The lipids are predominantly
in their fluid state, allowing the proteins to freely diffuse laterally in the membrane [6].
Although this model has seen some refinement in the years since, the fluid mosaic model
is still a widely accepted and highly useful model of biological membranes [6, 14]. Singer
and Nicolson’s picture of the fluid mosaic is also the underlying model that our theories of
membrane transport are based on.
Fig. 1.3. Schematic of membrane transport mechanisms. (A) Driven by a concentration
gradient, small nonpolar molecules can cross the membrane via passive diffusion. (B) Larger
molecules or ions cannot permeate the membrane direcly, but require channel proteins that
allow them to cross the lipid bilayer. (C) With consumption of ATP, active transporters can
move molecules against an existing concentration gradient. Image modified from [9].
Understanding transport across biomembranes is crucial and a very active field of re-
search [15]. The main motivations for this type of research are to improve our understanding
of drug delivery [16], cell signalling [17], cell homeostasis [18] and diseases such as chan-
nelopathies [19]. As it is the outer boundary of the cell, every substance that enters or leaves
the cell must pass the membrane. Schematically drawn in Figure 1.3, there are several
mechanisms by which transport can occur. The simplest mechanism is passive diffusion. The
driving force for the transport is a concentration or charge gradient between the two sides
of the membrane. However, the permeability of membranes towards different molecules
varies enormously depending on the polarity and size of the molecule [4, 15]. Whereas
small nonpolar molecules such as oxygen transverse the membrane almost unhindered, the
permeability of larger molecules is many orders of magnitude below that of oxygen [15].
Ions and most large molecules cross the membrane via different mechanisms and do not rely
on passive diffusion. Instead, they require transporter proteins to pass the membrane [4, 15].
The two major classes of membrane transport proteins are channels and carriers. Channel
proteins form aqueous pores that allow specific molecules to cross the membrane [4] via a
process called facilitated diffusion. Carrier proteins on the other hand convey active transport.
5They bind the specific solute and transfer it to the other side of the bilayer via a series of
conformational changes, typically requiring ATP or other sources of energy to do so [4, 15].
Furthermore, there are several endocytic pathways that allow for molecules to enter and leave
cells [15]. Today we know that many molecules in fact pass the membrane via more than
just one pathway [20].
The work presented in this thesis aims to develop a better understanding of passive membrane
transport. In the first part of the thesis, we will develop the necessary tools to measure
membrane transport, before we look at the transport of small antibiotic molecules and
protons in detail. However, we will not use cells to conduct our experiments, but instead
use objects known as lipid vesicles, or liposomes. Lipid vesicles are small aqueous droplets
that are encapsulated by a lipid bilayer. By stripping the membrane of proteins and using a
simple bilayer with a well-defined lipid composition as our model membrane, we reduce the
possible pathways of molecules to pass the membrane to simple diffusion. This reductionist
approach allows us to precisely measure the membrane’s permeability to the molecules in
question without the interference of proteins or active processes that might occur in living
cells. In a bottom up approach, the complexity of the membrane can then be expanded, for
instance by inserting proteins or DNA structures into the liposome membrane and studying
the effect of this inserted structure on transport [21].
We will use a recently developed technique called Octanol-Assisted Liposome Assembly
(OLA) as the main source of liposomes in this thesis. We will perform a literature review,
where we discuss OLA and other techniques to obtain liposomes in detail, before we provide
a biophysical analysis of liposomes generated with OLA and compare them to vesicles
obtained via traditional techniques. After examining OLA vesicles for their suitability for
transport measurements, we expand the OLA technique and develop a platform that allows
for the fabrication and controlled exposure of liposomes to the molecule whose transport is to
be investigated. The methods we use to visualise the transport and determine the permeability
rates can be summarised under the term optofluidics. Optofluidics is an approach which
combines microfluidic methods with optical systems [22]. In our case, we will either use
fluorescent labels and indicators or exploit the molecule’s autofluorescence to visualise the
transport. As pointed out above, we will then go on to investigate membrane transport with
our newly developed methods. First, we will look at the permeability of small antibiotic
molecules of the fluoroquinolone family. After that we expand our model membrane by
inserting DNA structures into the bilayer to investigate whether or not this increases the
membrane’s permeability towards protons. Finally, we widen the scope of our technique by
developing a new visualisation method based on the deep UV absorbance of molecules rather
than fluorescence.
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The thesis is structured as follows1
In Chapter 2, we provide a literature review of liposome formation techniques. Specifically,
we will look at the traditional electroformation method, as well as the newly developed
Octanol-Assisted Liposome Assembly (OLA) technique. We will lay specific emphasis
of the solute composition necessary to form liposomes with OLA and investigate how the
chemical environment might affect membrane properties.
In Chapter 3, we perform a biophysical analysis of vesicles derived from OLA and compare
them to liposomes obtained via the traditional electroformation method. By demonstrating
the quantitative similarity of the membrane properties, we show that OLA vesicles qualify
for use in transport studies.
In Chapter 4, we develop the OLA technique further to obtain an integrated platform that
allows for the formation and controlled exposure of lipid vesicles to an aqueous solute
containing the molecule whose transport is to be investigated. Using this platform, we
measure the permeability coefficient of two antibiotics of the fluoroquinolone family.
In Chapter 5, we use a novel microfluidic perfusion assay to study the transport of protons
through lipid membranes. Furthermore, we modify our model membrane by incorporating
DNA nanostructures into the bilayer and investigate whether or not these can act as ion
channels, enhancing proton permeation.
In Chapter 6, we expand the scope of our technique to non-fluorescent molecules. We
design and construct a new optical setup that exploits deep UV absorbance to visualise and
measure the membrane transport and perform preliminary transport measurements.
In Chapter 7, we summarise our findings and provide an outlook on future studies with the
microfluidic tools we developed in this thesis.
1In this thesis, I have consistently used the first-person plural (“we”) when describing the work I performed.
I opted for this style in order to be consistent with my journal publications and improve readability. Despite
using “we” consistently in this thesis, all results described here are product of my own work and I designed,
conducted and analysed all the experimental data myself, unless it is indicated by a footnote.
Chapter 2
Review of Lipid Vesicle Formation
Techniques
2.1 Introduction
In this chapter, we will introduce lipid systems called lipid vesicles. Lipid vesicles are
small aqueous droplets that are encapsulated by a lipid bilayer. Over the past decades, these
structures have been an important tool in studying the properties of lipid membranes and
have contributed fundamentally to our knowledge of these structures.
In the following sections we will first discuss the origins of vesicle-based research and
introduce two traditional fabrication techniques. Subsequently, we will focus on a novel
method to generate lipid vesicles called Octanol-Assisted Liposome Assembly (OLA). This
technique is the main source of lipid vesicles in the studies presented in this thesis.
2.2 Classification and History
Lipid vesicles come in many shapes and sizes. Figure 2.1 illustrates their most common
classification [23]. Vesicles are generally classified by their lamellarity and their size. If
the membrane is made up of a single bilayer, the vesicle is called unilamellar. Membranes
consisting of several bilayers are called multilamellar [24]. Unilamellar vesicles of up to
100 nm are typically called small unilamellar vesicles (SUVs), whereas vesicles of several
hundred nanometres up to a micron are termed large unilamellar vesicles (LUVs). If the
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diameter is greater than 1 micron, the term giant unilamellar vesicles (GUV) is used. [23, 24].
Vesicles can furthermore encapsulate other, smaller vesicles, in which case they are called
multivesicular [23].
In the scientific literature, lipid vesicles are also often referred to as liposomes. Throughout
this thesis, we will use the two terms interchangeably. Moreover, we will primarily focus on
giant unilamellar vesicles (GUVs) in our studies. GUVs have several advantages associated
with them, which we will look at in more detail later. First, we present a short overview of
the origins of liposomes, and vesicle research.
Fig. 2.1. Classification of lipid vesicles. Vesicles are classified as unilamellar if the liposome
consists of a single bilayer, and multilamellar if several bilayers make up the membrane.
Unilamellar vesicles are further classified according to their size. Unilamellar vesicles with a
diameter under 100 nm are denoted as small unilamellar vesicles (SUVs), whereas vesicles
with diameters ranging from several hundred nanometres up to a micron are called large
unilamellar vesicles (LUVs). Vesicles of more than 1 micron in diameter are called giant
unilamellar vesicles (GUVs). Vesicles that encapsulate other smaller vesicles are termed
multivesicular. Image adapted from [23].
The story of liposomes begins in Cambridge in the year 1964. At the Babraham Institute,
a partner facility of the University of Cambridge, Bangham and Horne recorded the first
electron microscope images of multilamellar lipid vesicles [25, 26]. Bangham and Horne
called the structures they observed “multilamellar smectic mesophases” and stated the
extreme similarities to previous studies on nerve myelin in their original paper [25]. In the
following years, Bangham et al. performed more ground breaking research on membranes,
for instance, when they showed that bilayers could maintain ion concentration gradients
and that detergents disrupt the bilayer [27, 28]. Bangham’s research therefore provided
important evidence for the theory that lipid bilayers are the primary permeability barrier
of cell membranes, a finding that has been called “the membrane equivalent of finding the
double helix structure of DNA” [26]. We must not forget that Bangham and Horne published
their findings before there was consensus on the structure of biological membranes, and eight
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years before Singer and Nelson proposed the fluid mosaic model [13]. Research in the years
following the 1964 paper often referred to the structures observed by Bangham and Horne
as “Banghasomes” or “lipid spherules” [26]. These names stuck until 1968, when Sessa
and Weissmann published their influential paper “Phospholipid spherules (liposomes) as a
model for biological membranes”, which led to the establishment of term “liposome” for
these structures [26, 29].
Over the past decades, liposomes have found widespread use in many branches of science.
They provide an ideal model membrane and allow for the systematic measurement of
membrane properties [30]. This is especially the case for giant unilamellar vesicles, as their
large size allows us to observe them using optical microscopy techniques and manipulate
them individually, for instance using micro pipettes or optical tweezers [30, 31]. Unlike
cells, vesicles are formed from a well-defined lipid mixture in a controlled environment.
This reductionist approach enables us to deconvolute the myriad effects that happen at a
natural cell membrane and study them individually. In fact, in the first paper describing
GUVs in 1969, the authors stated that their motivation was to create a controlled system to
study membrane permeation [32]. Since then, other model techniques such as supported lipid
bilayers, black lipid membranes, lipid stacks and monolayers at the water-air interface have
emerged [30]. However, GUVs remain a widely used model. One of the main advantages of
GUVs over other techniques is their curvature resulting from their size, which is similar to
that of cells [30]. Moreover, GUV membranes are typically free standing bilayers, and are
not hindered sterically by a support or mechanical contraption [30].
2.3 Traditional Fabrication Techniques
Due to their widespread use as model membrane, many different techniques to form GUVs
have emerged. These can be broadly classified into two categories and either form GUVs
via swelling from a solid substrate, or are assembled from fluid interfaces, usually an oil
phase [30]. Of the swelling approaches, a technique called electroformation has found
especially widespread use. We will look at this technique in more detail below, as it is
one of the techniques we use in this thesis to generate liposomes. Of the second category,
many make use of microfluidics to form GUVs [23, 30]. We will have a short look at a
previously published microfluidic technique, before we turn to Octanol-Assisted Liposome
Assembly (OLA), the microfluidic method we used throughout this thesis to create GUVs on
chip.
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2.3.1 Electroformation
In the swelling approaches to form GUVs, the liposomes form spontaneously and bud off
a lipid film in an aqueous environment. For this to happen, the lipids are dissolved in a
volatile solvent, usually chloroform, and spread onto a solid substrate. The solvent is then
evaporated and the lipid films hydrated. The liquid solution runs between the lipid lamellae
on the substrate, which leads to the budding off of vesicles [30, 32].
This process, first published by Reeves and Dowben in 1969, occurs naturally without any
external forces applied to the system [32]. However, this process is very slow and GUV
formation protocols can last up to 1-2 days [30]. Strongly related to this method is the
electroformation method, which is also often called electroswelling [30]. This technique was
presented by Angelova and Dimitrov in 1986 [33]. They observed that external electric fields
can influence the swelling of lipid films by exerting attraction and bending forces on the
membrane. Applied to the lipid films when forming GUVs, this proved to drastically increase
the yield and decrease the preparation time to several hours [30, 33]. The widespread use of
this technique has even led to the development of a commercial bench-top device (Vesicle
Prep Pro, Nanion Technologies GmbH, Germany), which facilitates GUV production via
electroformation; this was also used in the studies presented in this thesis.
For the electroformation method, depicted in Figure 2.2, the lipid film needs to be spread
on a conducting surface, in our case Indium Tin Oxide (ITO) coated glass slides. After the
organic solvent (chloroform) has been evaporated away, the liquid solution is added on top
of the lipid film and held in place by a rubber O-ring. Another ITO coated slide is placed
on top of that and alternating current (AC) electric fields are applied to the lipid film via the
conductive coatings [33].
GUVs formed via electroformation have been used for numerous studies and drastically
increased our knowledge of lipid membranes. For instance, the method proved very useful
to investigate membrane phase behaviour [35] and the mechanical properties [36] of lipid
bilayers. Electroformed GUVs have also been a tool for drug permeation studies [37]. In
addition, electroformation has been used for the creation of liposomes with complex binary
and ternary lipid mixtures [35, 38]. However, there are drawbacks associated with this
technique. Electroformation suffers from large batch-to-batch variation, as the spreading of
the lipid film is crucial to the quality of the liposomes produced. Yet, the way the lipid film
is deposited on the substrate is not easily reproducible [39]. Furthermore, the presence of
ions in the solution interferes with the electric fields, which is why electroformation buffers
usually require low ionic strengths [39]. Similarly, the method poses restrictions on the
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Fig. 2.2. Schematic of the electroformation process. After evaporating the lipid-carrying
organic solvent, the lipids form structured films on the conducing surface substrate. The lipid
films are hydrated and sandwiched by another coating surface from the top. The application
of alternating currents via the conducting surfaces leads to lipid swelling and the eventually
budding off of vesicles. Image adapted from [34].
choice of lipids, as it can promote oxidation in poly-unsaturated lipids [40] and has to be
adapted for the use of charged lipids [39, 41]. A 2012 study even found that demixing of
lipid mixtures can occur in the dried form, leading to heterogeneity in lipid composition of
the resulting liposomes [42]. The nature of the method, furthermore, makes it hard to exert
control over the size of the created liposomes [39], although a recently published protocol
to swell the vesicles from a 2D-patterned surface seems to enhance control over the GUV
size [43]. Finally, the electroformation method does not allow for the easy encapsulation of
an aqueous solution inside the vesicle that is different from the surrounding fluid [44].
Notwithstanding these limitations, electroformation remains a useful technique for the
formation and study of lipid vesicles. Yet, some of the limitations listed above can be
overcome by novel microfluidic techniques, which we will discuss next.
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2.3.2 Microfluidic Techniques
As the name implies, microfluidics is a field that deals with fluid systems in which the
channels are scaled down to the micro domain [23]. The decrease of the characteristic
dimensions to the micro and nano scale leads to an environment that is drastically different to
the macro world. As the characteristic lengths decrease, the different physical forces do not
decrease proportionally, leading to some effects of the macro world becoming negligible in
the microchannels, whereas others dominate and vice versa [45]. In the testing of engineering
models, the effects resulting from miniaturisation are often summarised under the term
scaling laws [45, 46]. For us, what is important is that fluid flows in the micro world
occur in a low Reynolds number regime [23, 45, 46]. The Reynolds number describes the
relationship between viscous forces and inertial forces [47]. This means that fluid flows
in a microfluidic chip are dominated by viscous forces and are therefore characterised by
stable hydrodynamics and laminar flows [45, 46]. These conditions allow for precise process
control and the use of smaller reagent volumes, shorter reaction times and the possibility
of parallel operation [48, 49]. Many microfluidic applications aim to achieve a so called
lab-on-a-chip, meaning the miniaturisation and integration of an entire experiment on a single
micro device [48, 49]. We have done this ourselves, when we developed our own microfluidic
platform to study membrane permeability. We will deal with the theoretical background of
microfluidics in more detail in Chapter 4, when we discuss the development of this platform.
For now, we describe a prominent microfluidic method that has been developed to obtain
GUVs.
Figure 2.3 shows an example of a microfluidic device used to produce GUVs on chip
following the double-emulsion approach. In these microfluidic systems, the GUVs are
assembled stepwise. First, the microfluidic chip is used to create water in oil droplets.
Typically, this occurs at a 4-way junction, where an inner aqueous phase is flanked by two oil
carrying channels and the water-oil-immersion flows along the remaining channel. The lipids
are dissolved in the oil phase and assemble into a monolayer at the water-oil interface [39].
In a second step, the outer lipid monolayer is assembled. This is done by flanking the W/O
immersion again, this time by two channels carrying the external aqueous phase. What results
is a W/O/W double emulsion, with a lipid monolayer on each side of the water interface [39].
In a final step, the residual solvent is removed to obtain GUVs [23, 39]. Different organic
phases have been used to carry the oil, namely oleic acid [50, 51], squalene oil [52] or
dodecane [53].
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Fig. 2.3. Schematic and images of microfluidic chip to form double emulsion vesicles.
(A) Formation of monodisperse water in oil (W/O) droplets. The internal aqueous phase
(Aqin) is flanked by two oil carrying channels (scale = 70 µm). (B) Delay line allowing
for the lipid dissolved in the oil to assemble into a monolayer at the water-oil interface
(scale = 80 µm). (C) Transfer of W/O droplets into external aquesous (Aqex) phase. The
lipids dissolved in the oil phase form the second leaflet of the bilayer at the exterial oil-water
interface (scale = 100 µm). Image from [52].
To date, different techniques have been developed to aid the removal of the residual oil phase
from the GUV [23]. Whereas the first published methods still extracted the GUVs to remove
the residual solvent off chip [54], later publications incorporated the removal procedure
on chip [51]. The GUVs were immersed in a solution of water and ethanol, whereby the
ethanol dissolved the organic compound. It is also possible to remove excess solvent via
non-chemical methods, as is shown by a 2016 publication that was able to remove 93%
of a fluorinated oil from a double emulsion via controlled mechanical squeezing inside a
microfluidic chip [55].
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The vesicles produced via this double emulsion approach have the advantage that they are
monodisperse, unilamellar and can be formed in chemical environments that are difficult for
other techniques such as electroformation [23]. Furthermore, since the aqueous substance
that makes up the inside of the GUV is separated from the outer aqueous solution as of
formation, these techniques allow for the selective encapsulation of an “inner” phase inside
the liposomes [23]. On the other hand, these methods require extensive washing of the
obtained liposomes, to remove the residual solvent from the double emulsion and form a true
bilayer liposome [23, 54, 56].
In 2016, a novel method was presented that found a very elegant solution to the prob-
lem of residual oil removal. This microfluidic method, called Octanol-Assisted Liposome
Assembly (OLA) is discussed in the next section.
2.4 Octanol-Assisted Liposome Assembly
In this section, we take a closer look at the Octanol-Assisted Liposome Assembly (OLA)
technique. Introduced by Deshpande et al. in 2016 [56], we adapted this technique and it
will prove to be our primary method for obtaining GUVs in the experiments to come. As we
pointed out above, this method found a very elegant solution to the problem of residual oil in
the GUV via modifications of the junction design and the choice of solvent.
2.4.1 Chip Design and Vesicle Formation
A schematic of the basic chip design is shown in Figure 2.4A. The chip has three fluid inlets
and one outlet. OLA allows for the precise control of the solutions in the inside and outside of
the vesicle. The aqueous substance which is to be encapsulated in the inside of the vesicle’s
lumen enters the chip via the inner aqueous (IA) inlet. The outside solution is flushed in
via the outer aqueous (OA) inlet. The lipid making up the GUV’s membrane is dissolved
in 1-octanol and enters the chip via the Lipid-Octanol (LO) inlet. The channels leading
towards the OLA junction are artificially elongated, running in spirals before reaching the
junction. These long channel lines act as low-pass filters in the fluid system. They buffer
spontaneous pressure peaks and slow down flows in general by increasing fluid resistance,
thereby increasing pressure and flow control.
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Fig. 2.4. (A) Schematic of the microfluidic chip used to produce the liposomes. The chip
has three inlets for the inner (IA) and outer aqueous (OA) and the lipid-octanol (LO) phases,
respectively. The vesicles are formed at a six-way junction (I) and flow along a long channel
to the outlet where they can be extracted or imaged directly. (B) Schematic of the OLA
junction, where liposome formation occurs. The IA fluid stream is flanked by two channels
with the lipid-carrying LO phase. The OA flows pinch off double emulsion droplets. Different
lipid types, as well as fluorescent lipids can be dissolved in the octanol. (C) Fluorescent
OLA GUVs in different stages after formation. A double emulsion droplet is formed at the
OLA junction in a process similar to blowing soap bubbles. Further downstream, the double
emulsion self-assembles into a vesicle with a 1-octanol pocket attached to it. Seconds to
minutes after formation. The octanol pocket completely buds off the vesicle, resulting in
separate GUV and an octanol droplet. Subfigure (C) modified from [56].
The first innovation introduced by this technique is the junction design. In contrast to the
previous double emulsion techniques, OLA does not use two 4-way junctions to assemble
the inner and outer lipid leaflet in distinct and separate steps. Instead, these two junctions
were combined into a single six-way junction, where the formation of the double emulsion
occurs [56]. This junction design allows for the production of double emulsions using
substantially less solvent, resembling some glass capillary approaches which, similarly,
allow the formation of ultra-thin shelled double emulsions [57]. The six-way junction is
schematically depicted in Figure 2.4B. By jetting a stream of inner aqueous (IA) solution
into a meniscus of the lipid-octanol (LO) phase and pinching it off by the streams of the
outer aqueous (OA) solution, the process of double emulsion formation is similar to blowing
a soap bubble [56].
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After the double emulsion is formed, the second innovation introduced by OLA comes into
play. Unlike the other double emulsion techniques, OLA does not use oil or alkanes as
the lipid carrying organic phase, but the aliphatic alcohol 1-octanol [56]. Deshpande et al.
observed that this substance does not form stable long lasting double emulsions. Instead, the
droplets quickly form an intermediate complex of an aqueous compartment surrounded by
a lipid bilayer and a 1-octanol pocket attached to it [56]. As the liposome flows along the
channel, the octanol pocket separates from the structure, resulting in a seemingly solvent-free
liposome and a separate octanol pocket. Several effects must come together to result in this
remarkable effect. One element is surely the chemical structure of octanol itself, shown in
Figure 2.9. Unlike the previously used alkanes, octanol is amphiphilic by nature, resembling
lipid molecules in this respect, although, unlike lipids, octanol cannot form bilayers [58].
The inventors furthermore attribute the separation to a combined effect of surface energy
minimisation, shear stress induced by the surrounding fluid streams as well as contact with
the channel wall [56]. We will discuss the properties of octanol in more detail below.
Figure 2.4C shows microscopy images of OLA vesicles in different stages after formation at
the junction. In their original paper, Deshpande et al. state that after 5 minutes, 85% of the
double-emulsion droplets separated into GUVs and octanol droplets, respectively [56]. As
we will see later, the process of octanol separation depends on several elements, namely the
speed of the fluid streams and the channel height. After separation, the GUVs and octanol
droplets flow further downstream, towards the outlet. From the outlet, the GUVs can either be
extracted or imaged directly. In Chapters 4 and 5, we will describe how we altered this basic
OLA design and included downstream operations to handle the GUVs within the microfluidic
chip.
In the next section, we will discuss the process of OLA chip production, preparation and
GUV formation using microfluidic pumps.
2.4.2 Chip Fabrication and Flow Control
Photo and Soft Lithography
Since its emergence in the early 1990s, many different techniques and materials have been
developed for use in microfluidic chips [59]. For instance, different groups have used various
etching techniques, injection moulding or in situ construction for chip fabrication [48, 60].
However, for use with biological systems, most groups rely on a two-step process of photo
and soft lithography [61]. Their material of choice for the soft lithography part is poly-
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dimethylsiloxane (PDMS). Its main advantages are its transparency, its oxygen permeability
and its relatively cheap price [62]. Similarly, we used the combination of photo and soft
lithography for the production of the OLA chips.
Fig. 2.5. Schematic of the fabrication of microfluidic chips. In the photo lithography step,
photoresist is spin coated onto a silicon wafer. The resist is then selectively exposed with UV
light. The exposed structures crosslink and solidify, whereas the unexposed structures are
washed by a subsequent developer bath. This leaves the desired structures imprinted on the
substrate. In the soft lithography step, liquid PDMS is poured onto the silicon master. After
curing, the PDMS with the structures embossed in it is removed from the mold. The PDMS
chip is bonded to a glass coverslip after plasma treatment. Image modified from [63].
In a first step, standard photo lithography is used to deposit a negative of the desired structures
on a silicon wafer. To obtain this, negative photoresist such as SU-8 is spin-coated onto a
silicon wafer and baked on a hot plate. The photo resist is then selectively exposed to UV
radiation. Selective exposure is either achieved by shining the UV light through a mask
blocking parts of the light, or by direct exposure systems, which focus UV light on the
desired spots on the wafer. In the case of a negative photo resist, such as SU-8, the exposed
parts crosslink and solidify thereby becoming insoluble to a developer solution. After another
baking step, the wafer is washed in the developer, removing the unexposed SU-8 and leaving
the UV-exposed structures remaining on the wafer.
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In the soft lithography step, the wafer is used as a mold for liquid PDMS. The liquid PDMS
adapts the structures that are deposited on the wafer and maintains these, as it sets. Once
the PDMS has hardened, the structures are embossed in it and the chip is removed from the
mold. In most cases, the final microfluidic device is obtained by bonding the PDMS chip to a
glass coverslip. This is achieved by exposing both the surface of the coverslip and the PDMS
to air plasma. The plasma causes silanol groups (Si-OH) to form on both surfaces. When
the two surfaces are brought in contact with each other, the silanol condenses and forms an
Si-O-Si bond, which fuses the PDMS and the glass slide together [62]. As we will see below,
parts of the OLA chip have to undergo a coating procedure, which requires all channel walls
to be made of PDMS, rather than having one side of glass. For this reason, OLA chips are
made by bonding a PDMS coated coverslip on the PDMS chip, rather than a glass coverslip
directly onto the chip.
PDMS coated coverslips and PVA treatment
To this end, a coverslip is coated with a thin film of PDMS before it is plasma bonded to the
chip. This provides a homogeneous all-PDMS surface which is necessary for the coating
procedure that is described below. The PDMS coated coverslips are obtained by pouring
liquid PDMS onto a silanised wafer. The glass slides are placed on top of the PDMS and
then pressed down to the surface of the wafer until they are completely immersed in PDMS.
A thin layer of PDMS remains between the wafer and the glass slide. After curing, the excess
PDMS can be peeled off the topside of the wafer, leaving the glass slides on the wafer, with
the thin PDMS layer sandwiched between the two. Using a blade, the glass slide with the
PDMS layer attached to it can carefully be removed from the wafer [64].
As shown in Figure 2.6B, the hydrophobic nature of PDMS typically leads to non-polar
substances adhering to the glass and PDMS surfaces and spreading out on them [65, 66].
However, in the OLA system this has to be prevented in order to allow for the formation of
double emulsion droplets. For this reason, the PDMS chip is flushed with a PVA solution via
the OA channel, thereby rendering both the OA and the outlet channel hydrophilic [56, 66].
Importantly, as shown in Figure 2.6A, it is crucial not to render the IA and LO channels
hydrophilic. Entering of PVA into these channels likewise impedes complete encapsulation
of the inner aqueous phase by the non-polar LO phase; this is why the PVA is prevented from
entering these channels by applying air pressure via the IA and LO inlets. After flushing the
PVA through the chip, the PVA is removed by applying suction with a vacuum pump. The
chip is then baked in the oven to cristallise and immobilise the PVA [67].
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Fig. 2.6. (A) PVA coating of the OLA junction. A PVA solution is flushed through the
channel via the OA inlet for approximately 15 minutes. The PVA is stopped from entering
the IA and LO channels by applying air pressure via these two inlets. The PVA renders the
OA and outlet channels hydrophilic. (B) Schematic of LO phase in untreated PDMS chip.
Due to its hydrophobic nature, the LO phase adheres to the PDMS surface. (C) LO phase in
PVA treated channel. The hydrophilic coating, shown in red, prevents octanol adhesion to
the surface and enables the formation of double emulsion droplets which later self-assemble
into the GUVs. Figure modified from [56] and [66].
Microfluidic Pumps
The flows in the OLA chip are controlled by pressure-driven microfluidic pumps. The
microfluidic flow control system (MFCS-EZ) in combination with the Fluiwell-4C (both
Fluigent SA, France) has proven very successful for the operation of the OLA chip [64,
68, 69]. In this system, the IA, LO and OA flows can individually be adjusted to create
the necessary flow environment at the OLA junction, to form vesicles. The solutes are
kept in a Fluiwell liquid reservoir and enter the microfluidic chip via polymer tubing and
metal connector tips. Holes that are punched into the PDMS chip act as access ports for the
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fluids. The individual pressures are adjusted using the MAESFLO 3.3.1 software. Figure 2.7
exemplarily shows an OLA chip as well as the Fluiwell system.
Fig. 2.7. (A) Photo of OLA chip connected to Fluiwell system. The Fluiwell is connected to
the microfluidic pump which drives the flows via the polymer tubings and metal connectors
into the microfluidic chip. (B) Detailed view of the OLA chip. The OA, LO and IA solutions
(from left to right) enter the chip via the inlets and meet at the 6-way junction where the
liposomes are formed. The large hole on the right serves as outlet reservoir, where the GUVs
can be extracted or imaged directly.
The right pressure settings to achieve stable vesicle formation depend on several factors;
namely the width of the junction, the height of the channels, the downstream chip design and
the viscosity of the fluids. As a rule of thumb, the IA and LO pressures are roughly the same
magnitude, and lower by a factor of 2-5 than the OA flows. Increased channel height and
width of the OLA junction generally decreases the fluid resistance within the chip and leads
to higher flow and vesicle production rates [68]. Furthermore, a larger gap at the junction
generally leads to larger vesicles. The size of the vesicles can furthermore be fine-tuned by
adjustment of the individual fluid streams, whereby an increase of the OA flow with respect
to the IA and LO flows lead to smaller liposomes [56].
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2.4.3 Solution Composition
In the following section, we take a closer look at the solution composition of the inner and
outer aqueous, as well as the lipid-octanol phases that are used in OLA. Deshpande et al.
presented several different solution compositions in their original and subsequent papers,
mostly varying in the content of glycerol and poloxamer P-188 [56, 70, 71]. However, the
following components turned out to be the basis necessary for robust GUV formation.
• Inner Aqueous: 15% glycerol in milli-Q water
• Outer Aqueous: 15% glycerol, 50 mg/mL P-188 in milli-Q water
• Lipid-Octanol: 2-4 mg/mL lipid in 1-octanol (lipid stock 100 mg/mL dissolved in
EtOH)
One of the great advantages of OLA that sets it apart from many bulk techniques like
electroformation is its capability to form GUVs in complex buffer solutions and at high salt
concentrations [68, 69]. While most protocols for electroformation require ionic strenghts
below 50 mM, we were able to successfully use OLA with in different chemical environments
and at physiological ionic strength (>140 mM) [72]. The solutions we used include HEPES,
PIPES, TRIS, acetic acid and potassium buffers, PBS as well as sucrose and glucose solutions.
Before we finish our brief review of OLA and come to our own biophysical analysis of
OLA vesicles, we describe what the existing literature says about the crucial components of
OLA: Glycerol, Octanol and the Poloxamer P-188, with respect to liposome and microfluidic
systems.
Poloxamer P-188
Poloxamers are a class of block co-polymers first developed by the Wyandotte Chemical
Corporation in the early 1950s [73, 74]. These non-ionic detergents found widespread use
in different industries, such as the textile, paper and cosmetics industries, where they are
mainly used as emulsifiers [75]. What we now know as Poloxamer P-188 was originally
named Pluronic F-68, and is sometimes still found under this or its other trademark names:
Synperonics®, Lutrol®, or Kolliphor® [73–75]. The chemical structure of P-188 is shown
in Figure 2.8A. It consists of a hydrophobic polypropylene oxide (PPO) block centred around
two hydrophilic polyethylene oxide (PEO) blocks. The different poloxamers vary in the
length of the respective PPO and PEO block chains. In the case of P-188 (MW ≈ 8400 Da),
the PEO blocks make up around 80% of the molecule’s weight [74, 75] which corresponds to
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approximately 31 PPO groups and 75 PEO blocks on either side [76]. Since its introduction,
P-188 also found several applications in medicine. For instance, it is used as an emulsifier for
contrasting agents in biomedical imaging [75], and received FDA approval as a therapeutic
to reduce the viscosity of blood before transfusions nearly 50 years ago [74]. Among
other diseases, purified P-188 even underwent clinical trials for the treatment of sickle cell
disease [77–79]. However, P-188 ultimately failed to meet its primary endpoint in a phase
III study in 2016 (trial NCT01737814).
More important for us though, was the observation of P-188’s effect on membranes. In
the early 1990s and 2000s, it was found that P-188 aids the sealing of membranes that
were electroporated or damaged by ionising radiation [80, 81]. The origin of the membrane
sealing property of P-188 has since been the field of study of several groups. In 2002,
Mascarinec et al. investigated the effect of P-188 on DMPC and DMPG monolayers using a
Langmuir–Blodgett trough [82]. They measured P-188 insertion into the monolayer at low
surface pressures (< 22 mN/m), but not at higher pressures. From this they concluded that the
membrane healing property of P-188 stems from the insertion of the hydrophobic midsection
into damaged parts of the membrane where the lipid packing density is reduced [82]. They
interpret the fact that the P-188 cannot remain inserted in the membrane under the surface
pressure equivalent of a normal membrane, in a way that suggests that the P-188 is “squeezed
out” [82] once membrane integrity is restored. It is noteworthy that the ejection of P-188
from the monolayer has previously also been observed by another group [83].
Fig. 2.8. (A) Chemical structure of poloxamers. A hydrophobic polypropylene oxide (PPO)
core is attached to two hydrophilic polyethylene oxide (PEO) side chains. For P-188, the
PEO chains make up about 80% of the molecule’s mass (n ≈ 75 and m ≈ 31). (B) Proposed
mechanism of interaction between P-188 and a lipid bilayer. P-188 adheres to the membrane,
however the long PEO chains prevent the P-188 from entering the lipid bilayer. Image
adapted from [83].
More recently, the effect of P-188 on DOPC LUVs was investigated by Cheng et al. by
observing the hydration dynamics close to the bilayer using a newly developed NMR
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technique [83]. They conclude that “poloxamer–membrane interaction is of subtle and weak
nature” [83]. Their study furthermore implies “that the polymer–lipid interactions is (sic) too
weak to cause measurable changes in lipid dynamics” [83]. Their proposed mechanism of
membrane interaction is schematically drawn in Figure 2.8B. Like the previous studies, they
also found that P-188 adsorbs to the membrane, but does not enter the bilayer within the time
scale of their experiment, which lasted up to 45 hours [83].
Due to their emulsifying and membrane sealing properties, poloxamers are increasingly being
adapted in the microfluidics community, especially by groups working with droplets, double
emulsions and liposomes [51, 84, 85]. The emulsifying and membrane sealing properties of
P-188 are also required for GUV formation with OLA. Attempts to form OLA vesicles both
by us and Deshpande et al. without the presence of P-188 failed due to droplet fusion and
immediate vesicle bursting [64]. In Chapter 3 we investigate the effect of P-188 on membrane
properties ourselves, by studying the lipid lateral diffusion of GUVs in the presence of P-188
and without it.
Glycerol
Glycerol, also known as glycerine, is depicted in Figure 2.9. It is the simplest 3-carbon sugar
alcohol. It is used for a myriad of purposes in different fields of science and can be found in
everyday household items such as food additives, cosmetics and antifreeze [86]. In the field
of microfluidics, glycerol has previously been used to modulate solution viscosities [87] and
it found several applications in the microfluidic production of droplets [87–89]. The viscosity
modulating property is also the main reason for the use of glycerol in OLA [64]. At room
temperature, the addition of 15% glycerol increases the dynamic viscosity of water by over
60% from 1.005 mNs/m2 to 1.6458 mNs/m2 [90]. The higher viscosity of the OA improves
shearing on the LO phase and thereby facilitates the separation of the octanol pocket from
the liposome [64, 91, 92]. Furthermore, more viscous fluids reduce the Reynolds number,
leading to more laminar flows and thus facilitating encapsulation [47, 92].
In addition, glycerol has also been found to have a stabilising effect on lipid membranes [92].
The increase in membrane stability is attributed to an increased membrane hydration caused
by the glycerol [93, 94]. Since glycerol is membrane permeable, we can also expect it to
balance potential differences in osmotic pressure between the GUVs inside and outside upon
formation. Deshpande et al. have reported that the removal of glycerol from the solution
composition impacts liposome formation [64] which is the reason why it is contained in our
standard OLA protocol.
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Fig. 2.9. Chemical structures of (A) glycerol and (B) 1-octanol.
Octanol
Finally, we take a look at the eponymous element of OLA, the octanol itself. Note that
throughout this thesis, when we are speaking of octanol, we always mean 1-octanol and do
not speak of its isomers (2-octanol, 3-octanol, etc.).
The chemical structure of octanol is shown in Figure 2.9B. Octanol is an aliphatic 8-carbon
alcohol. Its most prominent application is its use in the determination of a metric known as the
water-octanol partition coefficient [95]. The partition coefficient, described by Equation 2.1,
is the ratio of equilibrium concentrations of a solute in a mixture of two immiscible solvents,
in this case water and octanol [95].
P =
[solute]orgphase
[solute]aqphase
(2.1)
As such, the partition coefficient is a metric for the lipophilicity of a substance. Interestingly,
the partition coefficient is used by the pharmaceutical industry to estimate the membrane
permeability of drugs. The hydrophobicity of the octanol is used as a model to approximate
the non-polar hydrophobic layer of a lipid membrane which is the main barrier for drugs
or other compounds entering a cell [37]. Importantly, the partition coefficient only takes
the equilibrium of un-ionised compounds into consideration [96]. The value is therefore
a constant and independent of properties like the pH [96]. However, as we will see later,
many compounds dissociate in water and the degree of ionisation depends on the pH and
the pKa [97]. Furthermore, we wish to point out that this method of estimating membrane
permeability disregards elements such as the lipid composition, a crucial factor determining
the actual flux of molecules across the lipid membrane [98]. We will describe better methods
and measures to describe the permeability of membranes in Chapter 4.
In OLA, the octanol is the carrier phase for the lipid molecules and the solvent in which
they are presented to the aqueous streams within the microfluidic chip. To the best of
our knowledge, there is no study to date that investigates the conformation of the lipid
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molecules in the octanol phase in detail. Moreover, the exact structure of the individual
molecules in bulk octanol itself is topic of a debate [99, 100]. In the past, several groups
have investigated the structure of alkanol molecules in the liquid phase by means of X-ray
diffraction. Repeatedly, these experiments have shown a peak in diffraction stemming from
the lateral separation of the fatty acid chains. This main peak corresponds to that observed
for an alkane with the same chain length, indicating that the fatty acid separation of octanol is
similar to that of octane [100]. However, next to the main peak, alkanols additionally express
a side peak stemming from correlations between H-bonded molecules [99]. This side peak
has been interpreted differently by several groups. A 1993 study came to the conclusion that
the individual octanol molecules aggregate into spherical clusters resembling reverse micelles
with the hydrocarbon chains pointing outward [101]. Other groups interpreted the data as
octanol forming linear chains of about 10 molecules [102]. More recent studies conclude
that the structure of the molecules depends on the degree of hydration of the octanol, neat
octanol forming long and thin chains and hydrated octanol forming more spherical clusters,
resembling inverse micelles [58, 100]. A recent publication even proposes that hydrated
octanol forms nanostructures [99]. In any case, there are regions within the octanol bulk that
are more polar and others that are more non-polar. Since they are amphiphilic by nature, the
lipid molecules are not too different in structure from the octanol itself, having a hydrophilic
head group and two fatty acid chains. One can therefore assume that the lipid molecules
align with the general structure of the surrounding octanol, placing their hydrophilic head
group in the more polar domains and aligning the fatty acid chains with that of the octanol
in the more non-polar regions. However, this is just a theory based on the structure of the
surrounding medium. It is clear that more research, specifically addressing the question of
the conformation of lipid molecules in octanol needs to be performed in order to be able to
give a more definite answer.
While the structure of lipids dissolved in alkanols such as octanol is not researched very well,
the effect of alkanols on lipid membranes has been an intensively debated and researched
topic [103, 104]. The larger interest of the scientific community in this question stems from
the fact that alkanols have an anaesthetic effect on organisms [103]. We should not forget that
the 2-carbon cousin of the 8-carbon octanol is simple ethanol whose anaesthetic effect has
been known for millennia [105]. One of the earliest theories of general anaesthetics links the
potency of an anaesthetic to its lipophilicity, a theory known as the Meyer-Overton rule [106].
Interestingly, this brings us back to the partition coefficient we discussed earlier, since the
partition coefficient is a measure of lipophilicity. We will discuss the Meyer-Overton rule in
more detail in Chapter 4, as it provides a helpful tool to interpret and predict the membrane
permeability of drugs and other small molecules [106].
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One of the most important effects that alkanols have on lipid membranes is their effect
on the phase transition temperature of the lipids. The phase transition temperature deter-
mines the fluidity of a membrane thereby strongly influencing the mechanical properties
of the bilayer [107] and the functionality of membrane proteins [108]. Early research on
lecithin and DPPC lipids revealed that shorter chain alkanols decrease the phase transition
temperature, whereas longer chain alkanols increase the phase transition temperature of
lipid membranes [109–112]. However, these early studies disagreed in the chain length
where the shift from increasing to decreasing starts, with values varying from 8 to 12
carbons [103, 110, 112]. Interestingly, this behaviour coincides with the so called cutoff
effect, which describes the sudden decrease in anaesthetic potency of long chained alkanols,
after the potency initially increased with growing chain length [103]. As before, the cutoff
length seems to change from investigated system to system. For instance, experiments on
Xenopus oocytes showed a cutoff as low as 4-carbon butanol [113], whereas tadpoles showed
a cutoff after 12-carbon dodecanol [103].
More recent research sheds light on this phenomenon and showed that not only the chain
length of the alkanol, but also of the investigated lipid influences the cutoff length [104,
114, 115]. Numerous studies suggest that the observed behaviour is rooted in a trade-off
between bilayer disordering and ordering effects of the alkanols. At short chain lengths, the
disordering effect dominates, as the alkanol molecules perturb the bilayer-solution interface.
However, with increasing chain length of the alkanol, its fatty acids reach further into the
hydrocarbon layer of the membrane where they interact with the acyl chains of the lipids
thereby stabilising the membrane [103, 109]. A recent study by Ingolfsson et al. concluded
that the cutoff effect appears when the alkanol reaches about half the chain length of the
bilayer forming lipid, which is in accordance with previous works [104, 114, 115].
The effect of the phase transition temperature should always be considered, especially when
studying transport processes across the membrane, as numerous studies suggest enhanced
permeability of membranes to ions and small molecules close to the phase transition tem-
perature of lipids [116]. Blicher et al. provide a nice example for this in their experiments
with SUVs and BLMs [117]. In their work, Blicher et al. directly measured a change in
permeability towards ions and fluorophores by shifting the phase transition temperature
closer or further away from their operating temperature via the addition of octanol [117].
One has to keep this effect of octanol in mind when using OLA and depending on the desired
experiment, should consider choosing lipids which are far away from the phase transition
regime to avoid any undue influence of octanol on membrane transport.
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2.5 Conclusion
In this chapter we briefly discussed the classification and history of liposomes. Furthermore,
we looked at electroformation, perhaps the most widespread technique used to obtain GUVs,
and discussed its drawbacks. We saw how microfluidic double emulsion techniques have the
potential to overcome some of these drawbacks. Nonetheless, microfluidic techniques have
their own downsides, namely the presence of organic solvents in the membrane, which need
to be removed in extensive protocols.
We introduced Octanol-Assisted Liposome Assembly (OLA), a novel microfluidic technique
that seemingly solves this problem by using the aliphatic alcohol 1-octanol as the lipid
carrying organic phase, instead of alkanes. Octanol has the property of separating from
the GUVs inside the microfluidic chip and does not require a separate cleaning protocol,
making it ideal for lab-on-chip applications. However, the OLA technique has its own unique
requirements that potentially influence membrane properties. First, although OLA GUVs
do not have a visible octanol residue, it cannot be ruled out that traces of octanol are still
present in the membrane. This is especially important, as our literature review revealed
that octanol is known to influence the phase transition temperature of lipids. Furthermore,
the technique requires the addition of glycerol and the poloxamer P-188, both of which
potentially influence lipid behaviour.
In the next chapter, we will perform a biophysical characterisation of OLA vesicles and
compare a selection of its membrane properties to that obtained by the established elec-
troformation technique. We perform this to quantify whether OLA GUVs are suitable for
membrane permeation studies.

Chapter 3
Biophysical Characterisation of OLA
Vesicles 1
3.1 Introduction
In Chapter 2, we looked at GUVs as model systems for membranes and introduced OLA as
a novel method for GUV production. We saw that this new microfluidic method of GUV
generation has many advantages associated with it, which makes it a great candidate for
implementation in lab-on-chip applications. As pointed out in the outline of this thesis,
our overall aim is to develop a microfluidic platform that allows us to study membrane
permeation using GUVs. However, before we begin to modify and expand OLA for this
purpose, we want to investigate several biophysical properties of OLA derived GUVs, to
ensure they are suitable for membrane permeation studies. Since OLA was only presented in
2016, no such detailed biophysical characterisation was performed on OLA vesicles to date.
In some of the studies in the following chapter, we compare the properties of OLA derived
GUVs to that of GUVs made with the established electroformation method. The reason for
this lies in the fact that vesicles obtained via electroformation have been successfully used
for permeability measurements, both in our group and elsewhere [37, 119]. Quantitatively
similar characteristics of vesicles obtained from the two techniques thus provide a strong
argument for the feasibility of OLA vesicles for this purpose.
1Elements of this chapter have previously been published in Schaich et al., Mol. Pharmaceutics, 16(6),
2494-2501, 2019 [68] and Schaich et al., BBA-Biomembranes, 183359, 2020 [118].
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The experiments described in the following sections were predominantly performed on a
confocal microscope using extracted GUVs. Before we report the outcomes of the individual
experiments, we briefly describe the protocols for chip design and fabrication, as well as GUV
formation and extractions, since they are similar or identical for each of the experiments. An
exact list of solution composition is given in Appendix Tables A.4 and A.5.
3.1.1 Materials and Methods
Chip Design and Fabrication
The microfluidic chip design used to create the liposomes is depicted in Figure 2.4A. We
modified the original design geometry published by Deshpande et al. [56]; we scaled up
the channel dimensions by a factor of ~2. Whereas the original chip design has a junction
width and a channel height of 10 µm, our design has a channel width of 20 µm and a height
of approximately 16 µm. By scaling up the dimensions, we were able to obtain larger
liposomes than typically possible with the originally published chip design [56]. The scaled-
up channels furthermore lead to higher flow rates and higher liposome production rates than
the original device [68]. However, if operated in a high flow rate regime, the vesicles often
only have approximately 30-40 seconds from their production until they reach the outlet of
the microfluidic chip, compared to up to several minutes in the original design. The vesicles
in our chip design are therefore exposed to the shear stress from the PDMS channel wall as
well as the fluid streams for a much shorter period of time. Importantly, Deshpande et al.
found that these two effects are at least partially responsible for the separation of the octanol
pocket [56]. Depending on the flow conditions, as well as the size of the octanol pocket
attached to the GUV upon production, the time period that the vesicles are exposed to the
shear stress does not suffice for every single vesicle to separate from its octanol pocket until
it reaches the outlet. The number of resulting vesicles with octanol pocket attached can vary
drastically and ranges from as little as 5% up to well over 50%, depending on the flow speed.
We always attempted to obtain as little vesicles connected to their octanol pocket as possible
with an estimate 85% of the vesicles being octanol free in the studies in this chapter.
The microfluidic chips were fabricated from polydimethylsiloxane (PDMS) using established
photo- and soft lithography techniques as described in Section 2.4.2. A master mold with the
structures of the microfluidic chip was produced by spin coating a thin layer of SU-8 2025
(MicroChem, USA) on a 4-inch silicon wafer (University Wafer, USA). The wafer was spun
at 1800 rpm for 60 s with a ramp of 100 rpm/s in a spin coater (WS-650-23NPP, Laurell
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Technologies, USA) to obtain features of 16 µm height. The wafer was then pre-baked on
a hot plate at 65°C for 1 min and at 95°C for 6 min and placed in a table-top laser direct
imaging (LDI) system (LPKF ProtoLaser LDI, Germany). The LDI system exposes the
structures specified in the software directly to UV light, causing the photoresist to crosslink
and solidify. Following the exposure, the wafer was post-baked for 1 min at 65°C and for 6
min at 95°C. By rinsing the wafer with propylene glycol monomethyl ether acetate (PGMEA),
the unexposed photoresist was flushed away leaving the desired structures imprinted on the
substrate. Finally, the wafer was hard baked for 15 min at 120°C.
The silicon wafer was then used as a mold to fabricate the microfluidic devices. A 9:1
ratio mixture of liquid elastomer (Sylgard 184, DowSil) and curing agent was desiccated to
remove air bubbles and cast into the mold. After curing for 60 min at 60°C, the PDMS was
removed from the mold. Biopsy punches (0.7 mm diameter, WPI, UK) were used to cut fluid
access ports into the chip at the position of the inlets. Larger biopsy punches (4 mm diameter,
WPI, UK) were used to cut the outlet reservoir. The PDMS chip was then plasma-bonded to
PDMS-coated coverslips using a standard plasma bonding protocol (100 W, 10 s exposure,
25 sccm, plasma oven from Diener Electric, Germany).
We note that the liposome formation for the subsequent experiments were generated on
microfluidic chips made from two different molds. The chip designs are depicted in Appenix
Figure A.1 and Figure B.1. The latter design contains downstream features to handle the
vesicles which we will discuss in the next chapter. By placing the outlet punch before the
vesicles reach this part of the chip, the two chip designs are functionally identical, consisting
of an OLA junction with a straight outlet channel leading the outlet reservoir.
Vesicle Formation and Extraction with OLA
The microfluidic chip was set up on a commercial epifluorescence microscope (either Nikon
TE 2000U or Olympus IX 73) equipped with an EMCCD camera (Evolve 512 Delta, Pho-
tometrics). The liquid flows were controlled with a pressure-driven microfluidic pump
(MFCS-EZ, Fluigent) equipped with a Fluiwell-4C reservoir kit. Polymer tubes (Micrewtube
0.5 mL, Simport) containing the OLA solutions were screwed into the Fluiwell-4C. The
solutions entered the microfluidic chip via tygon tubing (microbore tubing, 0.020” x 0.060”
OD, Cole Parmer). Cut dispensing tips (Gauge 23 blunt end, Intertronics) were used as
metal connectors between the tubing and the chip. Liposome formation was performed
by adjusting the respective fluid pressures. Typically, pressures of 40 mbar for the inner
aqueous, lipid-octanol and 70 mbar for the outer aqueous phases lead to a stable production
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of liposomes. However, the pressures that lead to a stable GUV production can vary from
chip to chip. Either 15 µL or 20 µL of the aqueous stock were added to the outlet reservoir
after the pressures were adjusted for stable vesicle formation. The larger volume in the outlet
allows for the easier separation of octanol droplets and vesicles, as the droplets rise to the
surface, due to their lower density of 0.827 g/l [64]. After approximately 1-3 hours of vesicle
formation, the GUVs could be extracted from the outlet using a wide bore pipette tip.
Electroformation 2
The GUVs were formed using the Vesicle Prep Pro (Nanion Technologies GmbH, Germany)
using an established electroformation protocol [33]. 80 µL of a 5 mg/mL lipid suspension
(containing a fraction of fluorescently labelled lipid) in chloroform was spin coated (660 rpm
for 2 min) on an Indium Tin Oxide (ITO) coated glass slide (Visiontek) and desiccated for
60 min to evaporate the solvent. 600 µL of the IA solution was added and held in place by a
rubber O-ring and sandwiched by another ITO slide. An A/C voltage was applied via the
conducting surfaces of the ITO slides inducing swelling of the lipid film and the formation
of vesicles [33]. The electroformation process was performed at 37°C and ran through the
following protocol: the A/C voltage linearly increased from 0 V to 3.2 V peak-to-peak (p-p)
at 10 Hz over a time period of 1 hour. Then the voltage stayed at 3.2 V p-p and 10 Hz for
50 minutes. Finally, the frequency decreased linearly to 4 Hz over a time window of 10 min
and was held at 4 Hz for another 20 min. The vesicle suspension was then removed and
stored in an Eppendorf tube.
The exact solutions used for GUV formation with OLA and electroformation in the experi-
ments discussed below are summarised in Appendix Table A.4. Unless otherwise specified,
the chemicals were obtained from Sigma-Aldrich.
3.2 Validation of Membrane Unilamellarity
The first properties of OLA liposomes that we want to investigate are their lamellarity and
vesicularity. As discussed in Chapter 2, bulk techniques such as electroformation suffer from
polydispersity and often yield liposomes that are multilamellar or multivesicular [23]. We
will compare the appearance of OLA GUVs to electroformed GUVs in order to assess if they
suffer from a similar spread in composition.
2Electroformation performed for the experiments presented in this chapter were performed by D. Sobota
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By observing fluorescently labelled vesicles in a confocal microscope, we can draw conclu-
sions on the structure of the membranes. As shown by Figure 2.1 in the previous chapter,
multilamellar vesicles consist of more than a single lipid bilayer. If these are present, one
therefore expects to see vesicles with highly varying fluorescence and thicker membranes
within the population of GUVs. The distinguishing feature of multivesicular liposomes is
that they are not isolated GUVs, but have several GUVs encapsulated within each other.
Since confocal microscopy allows us to image distinct slices, we can therefore easily identify
whether there are vesicles encapsulated within other vesicles.
3.2.1 Comparison of Confocal Micrographs
The IA and OA solutions for this experiment consisted of 200 mM sucrose in milli-Q water
with 15% v/v glycerol. The OA phase additionally contained 50 mg/mL P-188. The LO
phase consisted of 4 mg/mL 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) lipid with
0.5% m/m 18:1 NBD-PC in octanol. The aqueous solution used for the electroformation
protocol was identical to the IA stock. Additionally, we prepared a 200 mM glucose solution
in milli-Q water with 15% v/v glycerol which we used as a low-density dilution stock.
After a few hours of vesicle production with OLA, we extracted 20 µL of the vesicle stock
from the outlet and mixed it with 50 µL of the low-density dilution stock in a microscopy
chamber (Grace Bio-Labs FlexWell™, Sigma Aldrich) and incubated for an hour. The higher
density of the sucrose-containing liposomes causes them to sink to the bottom of the imaging
chamber. There, the GUVs can be imaged more easily with the confocal microscope. The
same procedure was performed for the electroformed vesicles. The imaging chambers were
glued to either a BSA-coated or a PDMS coated cover slip, to prevent adhesion and bursting
of the liposomes on the glass surface. Imaging was performed on an Olympus FluoView
FV1000 Confocal Laser Scanning Microscope equipped with a 60× oil immersion objective
(Olympus PlanApo, N.A. 1.4).
Representative confocal scans of GUVs created via the two techniques are shown in
Figure 3.1. The GUVs formed by electroformation show a wider spread in diameter, as
well as a larger variety in appearance, compared to the OLA vesicles. While the latter show a
diameter range of 27-36 µm, the diameters of the electroformed GUVs range from 2-30 µm.
The heterogeneity of electroformed vesicles is displayed in Figure 3.2. While a large number
of unilamellar vesicles can be obtained by this technique, it also yields multilamellar and
multivesicular vesicles. Examples of these are shown in Figure 3.2B and 3.2C. In contrast to
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that, OLA does not show clustering of vesicles, or GUVs engulfed inside others, as can be
seen in the confocal scan in Figure 3.1B3.
Fig. 3.1. Comparision of electroformed and OLA vesicles. (A) Electroformation results in
heterogeneous vesicles and a wide range in vesicle sizes. The diameters of the electroformed
vesicles range from 2 µm to 30 µm. (B) OLA results in more homogeneous vesicles with a
smaller spread in liposome size. The diameters range from 27 µm to 36 µm.
3The confocal micrographs of electroformed and OLA-derived vesicles shown in this figure were obtained
by D. Sobota and R. Tivony, respectively.
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Fig. 3.2. Confocal images displaying the heterogeneity of electroformed vesicles. Image (A)
shows a presumably unilamellar vesicle. The left vesicle in image (B) is clearly multilamellar,
indicated by the thicker membrane and higher brightness, comapred to the other vesicles in
the image. Picture (C) shows three multivesicular liposomes.
3.2.2 Dithionite Bleaching Assay
Although the images in Figure 3.1 suggest that the OLA-derived vesicles consist of a single
bilayer, they do not provide quantitative evidence for the unilamellarity of these liposomes.
For this reason, we subjected OLA vesicles to a dithionite bleaching assay. In this assay,
the membrane impermeable anion dithionite is added to a population of vesicles which
contain a fraction of nitrobenzoxadiazole (NBD) labelled lipids. It is assumed that the NBD
labelled lipids are evenly distributed among the outer and inner leaflet of the bilayer. If
brought in contact, the dithionite reduces and thereby irreversibly bleaches NBD. However,
the dithionite cannot enter the inside of the vesicle and thereby only bleaches the outermost
leaflet of the membrane. If the vesicles indeed consist of a single bilayer, the fluorescence
is expected to drop to half of its original value, as the inner leaflet of the GUV remains
fluorescent [120, 121]
The IA and OA for this experiment consisted of 200 mM sucrose and 15% v/v glycerol in
PBS. Again, the OA contained 50 mg/mL P-188, whereas the IA had no P-188. The LO
phase consisted of 2 mg/mL of a 3:1 DOPC-DOPG lipid mixture (1,2-dioleoyl-sn-glycero-
3-phosphocholine and 1,2-dioleoyl-sn-glycero-3-phospho-1’-rac-glycerol) with 0.5% 16:0
NBD-PC in octanol. As before, the extracted vesicle stock was diluted with a low-density
solution of 200 mM glucose with 15% v/v glycerol in PBS for imaging. We mixed 15 µL of
the vesicle stock with 35 µL of the low-density dilution stock and similarly left the GUVs
to settle on the surface of the imaging chamber. We prepared a dithionite stock solution of
1 M sodium dithionite in Tris pH 10 buffer. We then diluted the concentrated dithionite stock
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solution further by mixing it with the glucose buffer to obtain a final dithionite concentration
of 15 mM. After starting imaging, we added 30 µL of the 15 mM dithionite solution to
the chamber containing the vesicles. Imaging was performed on a confocal microscope
(Olympus IX83, FV10-MCPSU laser system, 20× objective UPLSAPO Olympus, 5 s frame
interval). Image analysis was performed using the open source software Image J. The mean
intensity of the fluorescent rings was extracted using the software’s band tool, explained in
more detail below.
Fig. 3.3. Normalised intensity traces of the liposome membranes. (A) Intensity drop of
the liposome membranes (N = 10) upon addition of dithionite. The mean intensity of the
observed liposomes is shown in black with the standard deviations depicted in grey. The drop
to half of the initial value is caused by the bleaching of the outer membrane leaflet by the
dithionite. (B) Liposome intensity (N = 3) stays stable throughout the entire experiment upon
addition of buffer without dithionite, suggesting a negligible effect of photo bleaching. The
insets show a representative liposome at the beginning of the measurement and after 2000 s.
Scale bars = 10 µm.
The intensity traces of the liposomes normalised to their initial intensity value are depicted
in Figure 3.3. Figure 3.3A shows the intensity drop upon addition of dithionite, whereas
Figure 3.3B shows the results of the bleaching control experiment upon the addition of buffer
without dithionite. The mean intensity of the observed liposomes is shown as a black line
with the standard deviations depicted in grey. The intensity of the liposomes subjected to
dithionite (N = 10) drops to half of the initial intensity after about 500 seconds and then
stays steady at that value. These results suggest that the liposomes indeed consist of a single
lipid bilayer, whose outer leaflet is bleached by the dithionite [120]. Since the dithionite
anion cannot penetrate the membrane, the inner leaflet of the membrane is not affected by the
dithionite and remains fluorescent. The control experiment without dithionite in Figure 3.3B
shows a stable intensity signal over the timespan of the entire experiment (N = 3). This
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suggests that photo bleaching does not play a significant role in the observed drop in the
intensity and that we are indeed observing the bleaching of the outer leaflet of a single bilayer.
Liposomes produced by OLA have previously been tested for their unilamellarity via the
incorporation of the pore forming toxin α-hemolysin [56]. Additionally, the antimicrobial
peptide cecropin B was found to permeabilise and lyse OLA-produced liposomes, again
suggesting that the liposomes are unilamellar [69]. The dithionite assay performed by us
provides an additional, quantitative proof that the liposomes formed with OLA are indeed
unilamellar.
3.2.3 Conclusion on Membrane Lamellarity
To recapitulate, in this section we investigated the appearance of OLA vesicles using con-
focal microscopy in order to infer conclusions about their lamellarity and vesicularity. We
compared the images of OLA vesicles to images of electroformed GUVs that we formed
in the same solutions. While we found that both techniques yield unilamellar vesicles,
electroformation also yielded multilamellar and multivesicular vesicles, whereas we did not
observe these with OLA. Since the appearance alone does not suffice to safely claim the
unilamellarity of the OLA GUVs, we also performed a dithionite bleaching assay on the
vesicles, in order to assess the unilamellarity quantitatively. Our results support previous
investigations that reported the unilamellarity of OLA liposomes [56, 69].
3.3 Investigating the Membrane Lipid Composition
In the previous section we tested OLA generated vesicles for unilamellarity and multivesicu-
larity. In order to visualise the lipid membrane in these experiments, a fraction of the lipids
we added to the LO phase was fluorescently labelled. Since we were able to observe the
fluorescence in the resulting GUVs, it is clear that these fluorescently labelled lipids translate
into the GUV membrane together with the unlabelled lipids. However, from the experiments
above, we cannot deduce whether or not the lipid composition of the resulting GUVs actually
matches the composition of the lipid mixture in the LO phase. Theoretical and experimental
studies suggest different partition coefficients of octanol into bilayers of PG, PE and PC
lipids, respectively [122, 123]. A lipid type with a higher affinity to octanol could therefore
potentially remain in the LO phase during liposome formation. It is important to quantify
that no such demixing occurs and that the membrane composition of the obtained liposome
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matches the lipid mixture in the LO phase. The emergence of the field of lipidomics [124]
highlights the increasing importance attributed to membrane composition. When using
GUVs as a tool to study membrane transport or other membrane processes, knowledge of
this property is therefore of great importance [98].
In the following section, we demonstrate comprehensively the feasibility of the OLA tech-
nique in forming GUVs of binary lipid mixtures of DOPC, DOPG and DOPE lipids in
different lipid ratios. Via a mean intensity analysis performed on the OLA vesicles, we were
able to assess the lipid composition of the liposomes.
3.3.1 Experimental Procedure
We tested whether or not the lipid composition of OLA liposomes matches the lipid mixture
in the LO phase for three different binary lipid mixtures. This was done by doping one
of the lipids of the binary lipid mixture with a fluorescent derivate and forming GUVs at
different mixing ratios. By assessing the fluorescence of the resulting GUVs, we can deduce
the makeup of the lipid bilayer, as we expect to observe the fluorescence of the resulting
GUVs to scale according to the percentage of fluorescently tagged lipid in the mixture. Our
proposed mechanism is schematically drawn in Figure 3.4.
The lipids used to form the lipid systems were 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-
glycerol)sodium salt (DOPG), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). In each of the lipid systems, two of the
lipids were combined in 2:2, 1:3 and 3:1 mixing ratio. One lipid contained a small proportion
of a fluorescently labelled lipid (18:1-12:0 NBD PC or 16:1 Liss Rhod PE), causing the
fluorescence of the GUVs to scale in a defined manner. Aliquots of the individual lipids were
combined to form binary lipid systems in three different ratios. The lipids were dissolved
in 1-octanol to a final concentration of 3.6 mg/mL to form the LO phase. The exact lipid
mixing protocols can be found in Appendix A.3. The investigated binary lipid systems were
as specified in Table 3.1.
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Fig. 3.4. Schematic of liposome production and proposed mechanism of lipid mixture
conversion from the LO phase to the liposomes. A binary mixture of lipid A and lipid B is
dissolved in the octanol phase, whereby a fixed proportion of lipid B is fluorescently labelled.
The mixing ratio of lipid A to B is maintained from the LO phase to the resulting GUV. By
changing the mixing ratio of lipid A to B, the fluorescence intensity of the resulting GUVs
should scale proportionally to the content of lipid B in the mixture.
A mixture of 200 mM sucrose and 15% v/v glycerol in PBS buffer was used as the standard
solution for the inner aqueous (IA) phase of the lipid mixture experiments. The base
solution of the outer aqueous (OA) phase was identical to the IA but contained an additional
50 mg/mL poloxamer Kolliphor P-188. For all experiments containing DOPE lipid, P-188
was also added to the IA phase, as we found this increased liposome stability, confirming the
membrane-stabilising properties of P-188 we discussed in Section 2.4.3. As in our previous
experiments, a low-density solution with the same composition as the IA, but containing
200 mM glucose instead of sucrose was prepared. All solutions used are again summarised
in Appendix Table A.4.
40 Biophysical Characterisation of OLA Vesicles
Table 3.1. Lipid stocks forming the binary lipid systems used to create GUVs with the OLA
technique. Lipid A and Lipid B were combined in 1:3, 2:2, and 3:1 volume ratios each.
Lipid B contains a small fraction of fluorescently labelled lipids. The membrane composition
was evaluated by observing if the fluorescence intensity of the liposomes scales as expected
from the lipid mixture.
Binary Lipid
System Lipid A Lipid B
PGPC
DOPG - DOPC 90 mg/mL DOPG
90 mg/mL DOPC
with 0.1% m/m NBD-PC
PCPE
DOPC - DOPE 90 mg/mL DOPC
90 mg/mL DOPE
with 0.05% m/m Liss Rhod PE
PGPE
DOPG - DOPE 90 mg/mL DOPG
90 mg/mL DOPE
with 0.05% m/m Liss Rhod PE
We formed the GUVs as described in the sections above. However, the GUVs were not
transferred into an imaging chamber. Instead, the outlet reservoir was used to both collect
and image the created vesicles directly. After adjusting the pressure such that a stable vesicle
formation was established, 15 µL of the low-density dilution stock was pipetted into the
outlet. After 1-3 hours of vesicle formation, the microfluidic chip was disconnected from the
microfluidic pump and the vesicles imaged on a confocal microscope.
3.3.2 Microscopy Parameters and Image Processing 4
Standard epifluorescence microscopes (Nikon TE 2000U or Olympus IX 73) were used
for imaging the microfluidic devices during vesicle production and the PVA treatment of
the microfluidic chips [68]. The recording of the fluorescence data of the lipid mixtures
was performed on commercial inverted confocal microscopes. Images were obtained with
the focal plane of the microscope set to the centre of the vesicles in order to capture the
fluorescence at the equator of the vesicles. A Leica TCS SP5 Confocal was used to image
PGPC liposomes fluorescently labelled with nitrobenzoxadiazole (NBD), excited by a 488 nm
laser. An Olympus FluoView FV1000 Confocal Laser Scanning Microscope was used to
image PGPE and PCPE liposomes fluorescently labelled with Liss Rhod PE, which were
excited by a 559 nm laser. Importantly, all optical parameters were kept the same for
the measurement of each lipid system. The detailed imaging parameters can be found in
Appendix A.3.
4The measurement of the PGPC lipid mixture, as well as the image analysis was performed by H. Sleath, as
part of her Part III project supervised and instructed by M. Schaich.
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The mean intensity values of the fluorescent ring of a vesicle were extracted using the open
source software ImageJ as depicted in Figure 3.5. Using the software’s band tool, the intensity
of the fluorescent ring was extracted. The band width was 2 µm. Overlaps with other vesicles,
or bright fluorescent spots stemming from residual octanol in the membrane, were excluded
from the analysis using the software’s brush tool.
We performed a linear regression for each lipid system (PGPC, PCPE and PGPE) with the
fluorescence intensities of the liposomes on the y-axis and relative concentrations of the
fluorescently tagged lipid in the LO phase on the x-axis. The y-intercept for the regression
was fixed at zero. We then normalised the fluorescence intensities of each lipid system
with the slope of the linear function we obtained from the regression. By normalising to
the slope of the regression, the new values scale directly with the relative concentrations of
the fluorescently doped lipid in the mixture. This results in expected values of 1, 2 and 3
for the 3:1, 2:2 and 1:3 (non-fluorescent: fluorescent lipid ratio) systems, which facilitates
comparison of the fluorescence intensity ratios.
Fig. 3.5. Extraction of the mean average fluorescence of GUVs. A 2 µm thick band (shown
in yellow) engulfing the fluorescent ring of the liposome was used as the region of interest.
Areas of overlapping liposomes, or bright fluorescent spots stemming from residual octanol
or lipid aggregates in the membrane were excluded.
Importantly, the images were acquired with identical optical parameters for all three volume
ratios of the binary lipid systems. The difference in fluorescence is therefore not the result of
a difference in excitation power or camera sensitivity, but of a higher number of the fluores-
cently labelled lipids in the GUV membranes. When choosing the microscope parameters,
we were careful to eliminate the possibility of PMT saturation, which would have skewed our
measurements. We always performed the measurement with the liposomes containing the
largest amount of fluorescently labelled lipids first, which was expected to have the highest
fluorescence intensity. After calibrating the microscope properties with this set and making
sure no PMT saturation occurred, the GUVs with lower expected intensities were imaged.
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3.3.3 Results of the Mean Intensity Analysis
Figure 3.6 shows representative images obtained for the lipid mixtures PCPE (DOPC – DOPE)
in three different volume ratios. In this case, the DOPE stock contained 0.05% Liss Rhod PE
lipids. As can be seen in the images, the fluorescence intensity of the liposomes increases
with larger DOPE content in the LO phase, as expected. We also observed this behaviour for
the other two lipid systems PGPE (DOPG – DOPE) and PGPC (DOPG – DOPC), where the
DOPC phase was doped with 0.1% of the fluorescent NBD-PC. Representative images of all
three binary lipid systems are shown in the Appendix Figures A.2, A.3 and A.4.
Fig. 3.6. Confocal images of the PCPE (DOPC-DOPE) lipid system in different volume ratios.
The fluorescence intensity of the liposomes scales according to the content of fluorescently
labelled DOPE in the lipid-octanol phase. PCPE 3:1 (A) vesicles with the least amount of
DOPE show the lowest fluorescence intensities, whereas PCPE 1:3 (C) vesicles with the
highest content of DOPE in the octanol expresses the strongest fluorescence. PCPE 2:2 (B)
with equal amounts of DOPC and DOPE lies in between the two.
We performed a mean fluorescence intensity analysis on each of the binary lipid systems
under investigation in order to quantify the shift in fluorescence between the different lipid
mixing ratios. The results are depicted in Figure 3.7. We performed a linear regression
on the fluorescence intensities of each lipid system and then normalised the fluorescence
values to the slope of the linear function we obtained. This results in a gradient of +1
for the normalised intensity values with increasing relative concentrations of fluorescently
doped lipid. For the 3:1, 2:2 and 1:3 lipid mixtures this translates into values of 1, 2 and 3,
respectively, if the lipid composition of the LO phase is maintained in the vesicles produced.
We observe the expected linear scaling in our experiments. The PCPE vesicles showed values
(mean ± std. dev.) of 1.01 ± 0.1, 2.01 ± 0.68 and 2.98 ± 0.62 for the mixing ratios 3:1, 2:2
and 1:3, respectively. The PGPC vesicles yielded mean normalised intensities of 0.81 ± 0.13,
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2.06 ± 0.25 and 3.02 ± 0.32 for the mixing ratios 3:1, 2:2 and 1:3, respectively. Note that we
were not able to form stable PGPE liposomes in the 3:1 lipid ratio. However, we were able
to form PGPE vesicles in the ratios 2:2 and 1:3, which followed the expected scaling with
values of 1.99 ± 0.29 and 3.00 ± 0.33.
We attribute the small deviations we observed from a linear increase to pipetting error,
photo bleaching as well as low signal-to-noise ratio. The latter affects primarily the vesicles
with low amounts of fluorescent lipid, as we imaged all lipid systems with constant optical
parameters and did not change the signal-to-noise ratio by adjusting the gain setting of the
microscope.
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Fig. 3.7. Results of the mean fluorescence intensity analysis for the binary lipid mixtures
studied. The scatter plots on the left show the raw intensities of the individual vesicles. In
these graphs, the y-axis shows the average fluorescence intensity and the x-axis the relative
amount of fluorescently doped lipid in the LO phase. The respective linear regression line
for every lipid system is shown in grey with the gradient given inset. Boxplots of the mean
normalised intensity for every lipid mixture are shown in the graphs on the right. For the
boxplots, we normalised the fluorescence intensities of the individual vesicles to the slope of
a the linear fit line. The normalised intensities of the lipid systems increase in accordance
with their larger fraction of the fluorescently doped lipid. The increase in fluorescence for
PCPE (A), PGPC (B) and PGPE (C) scales in a linear manner, as expected from the relative
concentration of the fluorescently doped lipid in the LO phase. It was not possible to form
PGPE lipid vesicles in a 3:1 mixing ratio. The upper and bottom ends of the box indicate
the top and bottom quartile, whereas the upper and lower whiskers indicate the smallest and
largest value of the set. Outliers ± 3/2 of the upper and lower quartiles are not shown in the
plot but are included in the analysis. The line in the middle of the box indicates the median
value.
3.3.4 Discussion
The electroformation technique is a widely used method in the biophysics community [125].
It has also been used for the creation of liposomes with complex binary and ternary lipid
mixtures [35, 38]. Our experiments show that OLA is likewise able to form GUVs of different
binary lipid mixtures. However, our experiments revealed that it is not possible to form
PGPE vesicles of 3:1 lipid ratio with OLA. The issue impeding our measurements of these
vesicles was their low stability. Although it was initially possible for us to form these vesicles
at the OLA junction, they appeared to be less resistant to mechanical stress compared to
the PCPE and PGPC vesicles. The vast majority of PGPE (3:1) vesicles that were created
at the OLA junction burst as they flowed through the microfluidic chip towards the outlet
reservoir. The likely reason is that these vesicles burst when subjected to shear stress from
the PDMS channel walls [68]. Although occasionally individual vesicles survived to the
end of the outlet channel in the reservoir, we noticed bursting events for these vesicles after
several minutes as well.
We partially attribute this behavior to the lipid polymorphism of PGPE (3:1) vesicles. PE
lipids are known to have a cone like shape which makes it energetically unfavourable for them
to form lamellar structures [126]. If forced into a GUV forming bilayer, the acyl chains are
pressed together, increasing the lateral pressure at the centre of the membrane, a state coined
the ‘frustrated bilayer’ [127, 128]. In nature, this pressure can be balanced by the enrichment
of the PE lipid in the inner leaflet of the membranes of cells [127, 129]. The fact that we
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could produce PCPE liposomes in all three lipid ratios suggests that other effects in addition
to the lipid shape are responsible for the low stability of PGPE (3:1) vesicles. Additionally,
there are reports that PG stabilises PE membranes, which seemingly contradicts our findings
[130]. However, these studies only looked at PG fractions of up to 30 mol% , whereas the
PGPE (3:1) GUVs in our experiments predominantly consist of PG. MD simulations by
Murzyn et al. on POPG-POPE (1:3) bilayers revealed that the prevailing interactions between
lipid molecules are water bridges and H-bonds [131]. While PE predominantly forms all
these bonds with PG lipids, PE also bonds to other PE molecules. PG on the other hand
barely bonds with other PG molecules [131]. The low H-bonding capacity of PG lipids has
also been observed in MD simulations on pure PG bilayers by Zhao et al., who attribute
this to the net negative charge and electrostatic repulsion of the individual molecules [132].
However, the two simulations diverge on the role of ion bridges between lipids. Whereas
Murzyn et al. found that Na+ ion bridges are only a minor contributor to membrane stability,
Zhao et al. found strong ion-mediated interactions between the lipid molecules causing
attractive forces that overcome the electrostatic repulsion between the negatively charged PG
headgroups [132]. Our findings suggest that in addition to the effect of PE, the high content
of charged PG in the PGPE (3:1) GUVs further destabilises the membrane. However, more
research is needed to explain the low stability behaviour of the PGPE (3:1) vesicles that we
observed.
3.3.5 Conclusion on Lipid Mixtures
Future experiments involving the use of lysolipids could provide further evidence to indicate
whether the cone shape of PE lipids and the charge density of PG are responsible for the low
stability of the PGPE (3:1) vesicles we observed. Lysolipids, such as LPC, only have one acyl
chain and add a high positive curvature to the membrane. As such, they can counterbalance
the negative curvature induced by the PE lipids (18, 19). A tertiary lipid mixture of LPC,
DOPG and DOPE should therefore have a higher stability than binary PGPE mixtures. Other
potential methods to yield GUVs of arbitrary compositions involve stabilising the membrane
mechanically using nanostructures. Since OLA allows for the efficient encapsulation of
substances in the interior of the vesicles, as well as coating from the exterior in well-defined
conditions [69], an artificial cytoskeleton, for instance made of DNA [133], could be applied
to the membrane.
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3.4 Lateral Diffusion Coefficient
In the previous two sections, we validated the unilamellarity of OLA derived liposomes
and furthermore tested OLA for its capability in forming GUVs of defined lipid mixtures.
In the following section, we want to investigate the dynamics of the lipid molecules in the
membrane itself. For this, we performed fluorescence recovery after photobleaching (FRAP)
measurements on fluorescently labelled OLA and electroformed GUVs.
In the FRAP technique, depicted in Figure 3.8A, a small region of the GUV membrane,
doped with fluorescent lipids, is irreversibly bleached using a confocal microscope. As
the surrounding non-bleached lipid molecules diffuse into the area, the fluorescence of the
previously bleached region of interest recovers. From the recording and analysis of this
recovery, it is possible to calculate the lipid lateral diffusion coefficient of the lipids [134].
FRAP is a powerful biophysical technique and has been used on cells and GUVs in the past,
for instance to investigate protein diffusion on cellular surfaces [135] or lipid rafts [136].
Using FRAP, we will directly compare the lipid lateral diffusion coefficients of OLA-
derived GUVs to those obtained from vesicles generated by the established electroformation
technique. By comparing the lateral diffusion coefficients in different chemical environments,
we will assess whether or not the presence of the poloxamer P-188 or residual octanol
affects lipid lateral diffusion. We thus provide an important biophysical characterisation of
liposomes produced using microfluidics. Quantitative similarity of OLA derived GUVs and
electroformed GUVs will encourage the wider uptake of this novel liposome production
method in the field. Furthermore, quantitative similarity provides a strong argument for the
use of microfluidic GUVs for the study of membrane properties such as permeability.
3.4.1 Experimental Procedure
We formed GUVs of two different PC lipid types by both electroformation and OLA to obtain
and compare their lateral lipid diffusion coefficients. The tested lipids were 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) and 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine
(POPC). The LO phase consisted of 4 mg/mL PC lipid with 0.5% m/m NBD-PC in octanol.
The aqueous solutions (200 mM sucrose, 15% glycerol) were prepared in milli-Q water, as
the formation of GUVs using electroformation fails at high salt concentrations [23, 39]. We
extracted the GUVs as described in Section 3.1.1 and imaged them on confocal imaging
chambers, after mixing them with a low-density glucose stock.
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Table 3.2. P-188 concentrations in the respective environments that the FRAP measurements
were performed in. Vesicles of the high P-188 environment were formed in 50 mg/mL. For
imaging, they were diluted in the low density stock devoid of P-188 lowering the outside
concentration to 14 mg/mL. OLA vesicles could not be formed in a solutions completely
devoid of P-188.
Encapsulated
P-188 concentration
Outside
P-188 Concentration
Electroformation
no P-188 environment 0 mg/mL 0 mg/mL
Electroformation
high P-188 environment 50 mg/mL 14 mg/mL
OLA
low P-188 environment 0 mg/mL 14 mg/mL
OLA
high P-188 environment 50 mg/mL 14 mg/mL
Two sets of vesicles for each technique were investigated. The lateral diffusion coefficient
of one set was measured in a high P-188 environment, the other set was measured in a low
P-188 environment. The P-188 concentrations in the respective environments are given in
Table 3.2. The solutions furthermore contained glycerol, sucrose and glucose; these were
left out in Table 3.2 for the sake of clarity. The full solution compositions used for liposome
formation and FRAP measurements are listed in Appendix Tables A.4 and A.5. Note that
since OLA requires the addition of P-188 at least in the OA phase to form vesicles, we
were not able to create an environment for OLA vesicles that was completely devoid of the
poloxamer.
In a second series of experiments, we performed FRAP measurements on electroformed
DOPC vesicles at varying levels of glycerol (0% vs 15% glycerol, each in the IA and OA)
and different temperatures (approximately 20°C vs. 37°C). For these experiments, we used
similar sucrose solutions, devoid of ions and P-188 as laid out in Appendix A.4 but with
varying glycerol content.
3.4.2 Microscopy Parameters and Image Analysis
The FRAP measurements were performed on an Olympus FluoView FV1000 Confocal Laser
Scanning Microscope equipped with a cellVivo Incubation System. The field of view was
focused on the bottom of a GUV. By adjusting the pinhole diameter, the slice thickness
was increased such that the lower part of a GUV was observed as a fluorescent disc. Using
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the FRAP function of the microscope’s software, a spot of Ø 4 µm was bleached and the
fluorescence recovery observed. 8 images were collected pre-bleaching. Bleaching was
performed over 0.1 s with 98% laser power and the fluorescence recovery was recorded for
100 frames (2 µs/pixel exposure).
Fig. 3.8. (A) Example of a vesicle in the different stages of a FRAP measurement. The
fluorescence intensity of a circular disk is recorded pre-bleaching (i), bleached (ii) and
recovered (iii). The bleached region manifests itself as a dark circle on the vesicle membrane.
(B) Fractional recovery trace of a vesicle. An exponential curve is fit to the trace from
which the half-life recovery time t1/2 is extracted. The lateral diffusion coefficient of the
lipids is calculated using the extracted half-life time and the area of the bleaching spot.
Scale bar 10 µm.
We calculated the fractional fluorescence recovery trace fK(t) for each vesicle, according to
the formula below (30, 31):
fK(t) =
FK(t)−FK(0)
FK(∞)−FK(0) (3.1)
where FK(t) is the measured fluorescence intensity, FK(0) is the intensity just after bleaching
and FK(∞) is the recovered intensity. The recovered intensity was defined as the average
of the last 8 frames of the fluorescence trace. Furthermore, the mobile fraction M of each
vesicle was calculated:
M =
FK(∞)−FK(0)
FK(t < 0)−FK(0) (3.2)
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The fluorescence intensity before bleaching FK(t < 0) is defined as the average of the 8
frames recorded pre-bleaching. An exponential function of the form y = y0× (1−exp(−at))
was fit to the fractional recovery curve of each vesicle and the half-life recovery time t1/2
was extracted, as shown in Figure 3.8. We calculated the lipid lateral diffusion coefficient of
each vesicle, following the approach of Axelrod et al.[137] and Soumpasis [138]:
D = 0.224× w
2
t1/2
(3.3)
where w is the radius of the bleaching spot.
3.4.3 Results of the FRAP Measurements
We followed the guidelines for FRAP analysis recommended by Chen et al. [139] and
Tocanne et al. [140], only including diffusion measurements performed on vesicles where
the radius of the bleached spot w was small compared to the diffusion area A ( Aw > 5).
Furthermore, we kept the bleaching pulse tB short compared to half-life recovery time t1/2
(tB < 110t1/2) and used tB = 0.1s, as recommended by Guo et al. [141]. Additionally, we
excluded vesicles that moved during the FRAP measurement, as well as vesicles whose
fluorescence did not recover to at least 75% of the pre-bleaching intensity (exclude mobile
fraction of M < 0.75). For the latter, the assumption of an infinite lipid reservoir is not met,
and the diffusion coefficient can be underestimated due to the bleaching of substantial parts
of the membrane. The vesicles we excluded due to a mobile fraction M < 0.75 typically also
did not meet the criterion of a small bleaching spot w compared to the diffusion area ( Aw > 5).
The lateral lipid diffusion coefficients of DOPC vesicles obtained with the different for-
mation techniques are compared in Figure 3.9A. Without the presence of P-188 in the IA,
the FRAP experiments revealed values (mean ± std. dev.) of 1.0 ± 0.2 µm2/s (N = 17) and
1.1 ± 0.2 µm2/s (N = 34) for electroformed and OLA vesicles, respectively. Note that in the
above case, the outside solution of the OLA vesicles contained 14 mg/mL P-188, whereas
the outside solution of the electroformed vesicles was devoid of P-188. As pointed out
above, the reason for this lies in the fact that GUV formation with OLA is not possible
without the presence of P-188 in the OA phase. GUVs formed with 50 mg/mL P-188 encap-
sulated within the vesicle showed values of 1.2 ± 0.4 µm2/s (N = 14) for electroformation
and 1.0 ± 0.3 µm2/s (N = 30) for OLA. The measurements on POPC vesicles yielded similar
results as the DOPC measurements in the range of 1 µm2/s. Electroformed and OLA vesicles
without the presence of P-188 had lateral diffusion coefficients of 0.8 ± 0.2 µm2/s (N = 28)
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and 1.0 ± 0.3 µm2/s (N = 49), respectively. With 50 mg/mL P-188 encapsulated in them, the
GUVs yielded diffusion values of 1.3 ± 0.4 µm2/s (N = 20) and 0.9 ± 0.3 µm2/s (N = 27) for
electroformation and OLA, respectively.
We furthermore conducted FRAP measurements on electroformed DOPC vesicles with
varying glycerol content (0% vs. 15%) and temperatures (20°C vs. 37°C), shown in
Figure 3.9B. We found a stronger difference between the lateral diffusion coefficients with
varying glycerol and temperatures than between the different formation techniques or varying
P-188 concentrations. The diffusion coefficient (mean ± std. dev) increases from 1.0 ± 0.2
µm2/s (N = 17) at 20°C and 15% glycerol to 1.6 ± 0.2 µm2/s (N = 12) without the presence
of glycerol. At 37°C, the coefficients rise to 1.9 ± 0.6 µm2/s (N = 19) with 15% glycerol and
2.2 ± 0.5 µm2/s (N = 7) without glycerol.
Fig. 3.9. Boxplots of the lipid lateral diffusion coefficients obtained via FRAP. (A) Compari-
son of DOPC vesicles produced by OLA and electroformation with varying concentrations
of encapsulated P-188. The lateral diffusion coefficients are on the order of 1 µm2/s for all in-
vestigated systems, irrespective of the production method or the presence of P-188. (B) Lipid
lateral diffusion coefficients of electroformed DOPC vesicles at varying temperatures and
glycerol concentrations. We found a significant (p < 0.001) increase in lateral diffusion with
rising temperature and decreasing glycerol concentration, compared to the base line at room
temperature (approximately 20°C) and 15% glycerol.
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3.4.4 Discussion of the Results
Lateral lipid diffusion values reported in the literature vary greatly, as these are strongly af-
fected not only by the chemical and physical environment [133], but also by the choice of mea-
surement technique. Different techniques like Fluorescence Correlation Spectroscopy (FCS),
FRAP and NMR have yielded different lateral diffusion coefficients [142]. For instance,
Filippov et al. obtained values of 9.32 µm2/s for DOPC and 8.87 µm2/s for POPC with NMR
[143], both higher than the values obtained by us. Furthermore, the choice of membrane
platform, e.g. supported lipid bilayer (SLB) vs. GUV [144] can influence the measurement.
Guo et al. report POPC lateral diffusion coefficients of 1.8 ± 0.2 µm2/s on supported lipid
bilayers and 3.3 ± 0.2 µm2/s on GUVs [141] while Pincet et al. measured DOPC lateral
diffusion coefficients of 1.9 ± 0.4 µm2/s on supported lipid bilayers and 3.4 ± 0.7 µm2/s on
GUVs [144]. All values are again summarised in Table 3.3. The values above are in good
agreement with the values we obtained for OLA vesicles, albeit still significantly elevated.
We explain this by the presence of 15% v/v glycerol in the OLA solution, as both previous
research and our control experiments reveal that glycerol lowers the lateral diffusion coeffi-
cient [145]. Our FRAP measurements at elevated temperatures and without the presence of
glycerol match the above-mentioned values more closely. Furthermore, differences in the
exact shape of the bleaching profiles, the imaging parameters and data analysis can skew
the obtained diffusion values [146]. Interestingly, our control experiments also reveal that
varying the glycerol concentration and temperature both have a stronger effect on the lateral
diffusion coefficient of lipids in electroformed DOPC vesicles than variations in the P-188
concentration or the formation technique.
Table 3.3. Lateral diffusion coefficients measured with different techniques and lipid systems.
NMR measurements were performed on multivesicular vesicles. The GUV and supported
lipid bilayer (SLB) values were obtained via FRAP.
NMR GUV SLB
DOPC 9.32 µm2/s [143] 3.4 ± 0.7 µm2/s [144] 1.9 ± 0.4 µm2/s [144]
POPC 8.87 µm2/s [143] 3.3 ± 0.2 µm2/s [141] 1.8 ± 0.2 µm2/s [141]
3.4.5 Confocal Imaging of Octanol Pocket
Interestingly, we were able to find vesicles with and without an attached octanol pocket
amongst the population of extracted OLA vesicles for both DOPC and POPC. Figure 3.10
shows isometric and confocal sliced views of GUVs with and without the octanol attached.
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Fig. 3.10. (A) Isometric view of three GUVs produced with OLA. Two vesicles have a bright
octanol pocket attached to their surface. (B) Sliced view of two of the vesicles. The white
lines indicate the slice planes. The upper image shows the top view, whereas the bottom
image shows the vesicle from the side. A bright octanol pocket can be seen on the side view
of the left vesicle. It is not visible in the top view, as it is not within the slice plane. The view
on the right shows a vesicle without a visible bright octanol pocket attached to it.
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The octanol typically manifests itself as a bright spot on the top side of the vesicle. We did
not observe a significant (p < 0.01) difference between the lateral diffusion coefficients of
vesicles with and without octanol pockets attached. The FRAP measurements of both DOPC
and POPC, as well as the measurements with varying temperature and glycerol content
are summarised again in Appendix Tables A.6 and A.7. Statistical analyses for the FRAP
measurements are reported in Appendix Tables A.8-A.17.
In the confocal scan of a vesicle, the octanol pocket manifests itself as a bright spot at the
top side of a GUV. This location is plausible, due to the lower density of octanol compared
to the surrounding aqueous solution. The higher brightness can be explained by the large
number of lipid molecules in the bulk of the octanol droplet, compared to the single bilayer
of the vesicle membrane. 3D reconstructions of confocal scans of both types of vesicles are
depicted in Figure 3.10. Remarkably, we found no significant differences (p < 0.01) in lateral
lipid diffusion coefficients between vesicles with or without an octanol pocket. This is an
interesting parallel to research by Karamdad et al. who compared the bending rigidity of
vesicles obtained with a microfluidic technique (using squalene oil) to electroformed vesicles.
They also found that the presence of residual oil in the membrane did not alter the biophysical
properties of the membrane [52].
While most studies report octanol having a lowering effect on the phase transition temperature
of lipids [104, 117, 147], conflicting reports exist on its effect on lateral lipid diffusion coeffi-
cients. Molecular Dynamics simulations by Griepernau et al. on DMPC membranes showed
a decrease in lateral diffusion of the lipids in presence of 1-octanol [104], whereas NMR
experiments by Rifici et al. on the same lipid revealed an increase in lateral diffusion [147].
They furthermore reported sudden changes in lateral diffusion near the phase transition
temperature Tm [147]. A possible explanation for why we did not observe a strong shift in
lateral diffusion coefficients between OLA vesicles containing octanol vs. electroformed
vesicles without octanol might lie in the phase transition temperature of the lipids used in
our experiment. According to the manufacturer, DMPC lipids investigated by the previously
mentioned groups have a melting temperature of 24°C, whereas the DOPC and POPC lipids
we investigated have melting temperatures of -17°C and -2°C, respectively. Since we per-
formed our experiments at room temperature (approximately 20°C), the lipids are well in the
fluid phase and the effect of altered phase transition temperature due to the octanol might
have diminished. Furthermore, it is possible that the diffusion lowering effect of the glycerol
dominates our system. In addition, the cutoff effect of anesthetics, described in Section 2.4.3,
could play a role in modulating membrane properties. The cutoff effect describes the phe-
nomenon of the increasing anesthetic potency of alcohols with increasing chain length, which
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suddenly levels off and even reverses for much longer chain lengths [104, 115, 147]. Since
the investigated DOPC and POPC lipids have 18:1c9 and 16:0-18:1 acyl chains, respectively,
octanol with a chain length of 8 might reach into the domain where membrane modulation
changes from a destabilising to a stabilising effect. However, in this case, the effect should
have also been observed in the 14:0 DMPC system.
3.4.6 Conclusion on Lateral Diffusion
Overall, our experiments suggest that neither the formation technique, nor the presence
of P-188 changes the lateral diffusion coefficients in a substantial manner (see Appendix
Table A.6). However, we did find a significant effect of glycerol and temperature on the lipid
lateral diffusion. Future experiments to characterise OLA produced vesicles could involve
the quantification of the actual content of octanol left in the membrane (if any) after the
budding off process, for instance by mass or Raman spectroscopy. A follow up investigation
would involve OLA vesicles of different lipid types with higher chain melting temperatures,
as they are likely to show more pronounced changes in membrane properties due to the
presence of any residual octanol.
3.5 Conclusion
In this chapter, we conducted a biophysical analysis of lipid vesicles generated by the novel
Octanol-Assisted Liposome Assembly (OLA) technique. The comparison of confocal images
showed the homogeneity of the GUVs obtained with this technique. In comparison to other
techniques, OLA yields a narrower size distribution and does not produce multivesicular
or multilamellar GUVs. We furthermore showed the unilamellarity of the OLA GUVs by
conducting a dithionite bleaching assay.
Using the fluorescence recovery after photobleaching (FRAP) technique, as well as a mean
fluorescence analysis, we investigated the membrane composition and the lateral diffusion
of lipid molecules of GUVs generated by OLA. In recent years, we have gained a better
understanding of the importance of both parameters on cellular processes. For instance,
simulations by Duncan et al. show that clustering of certain channel proteins is modulated by
the compositional complexity as well as the lateral diffusion coefficient of the lipids in the
membrane [148]. Other studies have revealed that lateral lipid diffusion is rate limiting for
many cellular processes [149]. The proposition of different modes of lateral mobility [150],
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as well as the emergence of the field of lipidomics [124], furthermore highlight the increasing
importance attributed to membrane composition and the lateral mobility of lipids in the
membrane. When using GUVs as a tool to study proteins, precise knowledge and control of
these two parameters is therefore of great importance.
Our fluorescence analysis revealed that the lipid composition of OLA-generated vesicles
matches the composition of the lipids in the LO phase. We did not observe any demixing
effects, or cases with one element preferentially remaining in the octanol phase upon li-
posome production, showing that the technique reliably produces vesicles of desired lipid
compositions. In addition, our lipid composition experiments revealed the stable vesicle
production of binary lipid mixtures of DOPG-DOPC as well was DOPC-DOPE in 1:3, 2:2
and 3:1 ratios. However, DOPG-DOPE lipid mixtures could only be formed in 2:2 and 3:1
ratios. We hypothesise that the low stability of PGPE vesicles with high (>50%) PG content
is due to the polymorphism and charge density of the PE and PG lipids, respectively.
The FRAP measurement showed lateral diffusion coefficients of approximately 1 µm2/s for
all the chemical compositions and formation protocols studied. The lateral lipid diffusion co-
efficients of the vesicles generated by the two techniques, OLA and electroformation, showed
relatively minor deviations from one another, and additionally most of these differences were
found to be statistically insignificant (Appendix Tables A.8-A.17). In contrast, an increase in
temperature and the removal of glycerol from the vesicle solution resulted in a more than two
fold increase in the lateral lipid diffusion coefficient (p < 0.001). Moreover, we were able
to compare the lateral lipid diffusion coefficients of OLA vesicles with and without octanol
pockets and found that the octanol pocket does not alter the lateral diffusion properties in a
statistically significant manner (at the p < 0.01 significance level).
Overall, this set of biophysical characterisations demonstrates the similarities in membrane
properties for vesicles produced using OLA and electroformation, suggesting that the added
functionality of the OLA platform does not involve any compromise in membrane quality.

Chapter 4
Development of a Microfluidic Platform
to Measure Membrane Permeation 1
4.1 Introduction
In the previous chapters, we reviewed different methods to obtain GUVs and conducted a
biophysical analysis of GUV membranes obtained from the microfluidic Octanol-Assisted
Liposome Assembly method. In this chapter, we want to develop the OLA chip design further.
Our aim is to obtain an integrated total analysis platform that will allow GUV production and
membrane permeability measurements on the same chip. In the sections below, we explain
how we adapted the microfluidic chip design to allow handling and controlled exposure of the
OLA GUVs to a drug solute. Furthermore, we introduce the optical setup used to visualise
drug transport.
However, before we go into the details of the platform, we must introduce the metric that we
use to describe transport through the membrane, the so-called permeability coefficient P. It
is the phenomenological expression for the flux of molecules J, across a unit area per unit
time [106, 151, 152]. With cin and cout being the concentrations of solute in the inside and
outside of the vesicle, we obtain:
J = P× (cout− cin) (4.1)
1Elements of this chapter have previously been published in Schaich et al., Mol. Pharmaceutics 2019, 16, 6,
2494-2501 [68]
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The permeability coefficient is a quantity that depends on both the properties of the membrane
and on the solute molecules. When we speak about the permeability coefficient, we therefore
always refer to a value of a specific molecule for a specific membrane in a certain chemical
environment [151].
In order for a molecule to passively cross the membrane, it first needs to dissolve in the
membrane from one side, diffuse through the hydrocarbon layer and leave the membrane on
the other side again. The permeability is thus determined by both the predisposition of the
molecule to dissolve in the hydrocarbon phase of the bilayer and the actual diffusion through
the thickness of the membrane. We already discussed a quantity that describes the tendency
of a molecule to dissolve in an organic phase in Chapter 2. It is the partition coefficient K.
The permeability coefficient P is thus defined as
P≡ KD
d
(4.2)
which relates the permeability coefficient to the partition coefficient via the diffusion co-
efficient of the solute in the hydrocarbon phase D and the thickness of the membrane
d [151, 152].
This definition relates directly to the observations by Ernest Overton that nonpolar substances
cross biomembranes more easily than polar molecules. Research has shown that this cor-
relation holds true for many molecules, such as the small antibiotic molecules we will be
focussing on below [37, 106, 153]. Due to this correlation, the partition coefficient is often
used as a metric to assess the permeability of a compound. However, as we already discussed
previously, the partition coefficient cannot be more than a rough estimate of the permeability.
First of all, we can see from the definition of P that a focus solely on the partition coefficient
K neglects the factor Dd of the equation. Yet, the diffusion coefficients are not the same for all
compounds and should not be neglected [154]. Second, the partition coefficient only looks at
the equilibrium of un-ionised molecules. However, the charge state of a molecule is strongly
affected by the chemical environment such as presence of other ions and the pH [37, 153].
Also, the partition coefficient is typically measured in octanol and not a lipid system that
respects the lipid composition of the membrane. The lipid composition, however, has been
shown to have a strong effect on the permeability [98]. Finally, for complete crossing, the
compound must dissociate from the membrane into the aqueous phase on the other side of
the bilayer. However, compounds with high partition coefficients often express low aqueous
solubility, which can limit the dissociation process. Certain long-chained free fatty acids,
for instance, have lower permeability coefficients than their shorter chained counterparts,
despite having a higher partition coefficient. This behaviour is at least partially explained
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by the decreasing aqueous solubility for longer chained fatty acids, which remain in the
hydrocarbon part of the bilayer rather than to dissociate and enter the aqueous phase on the
other side of the membrane [155–157].
We are not the first to see the need for platforms that allow the measurement of membrane per-
meation directly. Several other attempts to create such methods have been made. The earliest
studies go back to the 1960s and 1970s and were performed on black lipid membranes (BLM)
[158, 159].
In these experiments, two static aqueous reservoirs are separated by a lipid bilayer. The
transport can be quantified by adding the target molecule in one reservoir and observing
the increase in concentration on the other side of the bilayer. Though generally regarded
as good model to study membranes and especially membrane proteins [158, 160], BLMs
did not meet the demands for passive permeation studies. Researchers observed a region
depleted of solute molecules close to the planar bilayer in transport studies. This depleted
region, referred to as the unstirred water layer, forms an additional diffusion barrier for the
molecules [159, 161]. As a result, the bulk concentrations of the permeant in the reservoirs
are believed to substantially differ from the actual transmembrane concentration difference,
skewing the permeation measurement [106, 159].
Modern techniques such the parallel artificial membrane permeability assay (PAMPA) found
workarounds to this problem. PAMPA still relies on the separation of two aqueous reservoirs
by a membrane, however, the assay can be equipped with a stirrer that corrects for the
additional diffusion barrier. Yet, PAMPA comes with its own drawbacks. In this assay, the
reservoir of microtiter plates is separated by a porous filter material, which is impregnated
by a lipid solution [162]. The lipid solution is typically an alkane such as dodecane or
hexadecane that only contains 1-20% lipid and some researchers argue that residual solvent
influences the permeation kinetics [163]. A review of the technique concluded in 2007 that
PAMPA “may be a very limited asset to a drug discovery effort” [164].
An alternative approach was developed by Cama et al. in 2014. They presented a microfluidic,
label-free method to study drug permeation using GUVs as model membranes [37]. In their
system, a stream of liposomes is mixed with a stream of drug solute, engulfing the GUV in a
bath of the molecules. The GUVs are observed as they flow through a channel surrounded
by the solute molecule. The transport across the membrane is visualised label-free by
exploiting the target molecule’s autofluorescence upon excitation in the UV. The permeability
coefficient of the membrane is determined by analysing the increase of a vesicle’s intensity,
as fluorescing molecules diffuse through the bilayer into the GUV.
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Importantly, confocal studies by Cama et al. found no evidence of a micron scale unstirred
water layer in this assay [37]. Moreover, since the method of Cama et al. is a flow through
system, one would expect the effect of an unstirred water layer on membrane permeation
to be dependent on the vesicle’s velocity. However, no correlation between permeability
and vesicle speed has been found [37]. We used the method ourselves, to show that the
permeability of different drugs from the fluoroquinolone family can span over 2 orders of
magnitude at different pH levels [153]. Before that, Purushothaman et al. used the assay to
show that the liposome lipid composition influences fluoroquinolone transport [98]. These
results further strengthen the argument that the rate limiting element in this assay is indeed the
permeation through the lipid membrane and not the diffusion through an unstirred water layer.
In 2015, Cama et al. managed to study the transport behaviour of proteoliposomes containing
the E.coli outer membrane protein OmpF [21], which shows the potential of this method to
study flux through porins. However, the technique still relied on the electroformation method
for GUV production with all its associated drawbacks that we discussed earlier.
In the following sections, we describe how we combined the fluorescence based approach of
the optofluidic permeability assay with OLA to develop a lab-on-chip total analysis platform
that enables the continuous production and screening of drug transport into vesicles on the
same device. We will first discuss the microfluidic chip design, before we turn towards the
optical methods and the diffusion model used to calculate the permeability.
4.2 Development of the Chip Design
As a robust, on-chip method to form liposomes, there are many potential ways to integrate
OLA into a molecule transport assay. One seemingly obvious idea is to add the substance of
interest to the IA phase and encapsulate it with a lipid bilayer upon the vesicle’s formation.
The molecule transport across the membrane could then be studied as the drug molecules
diffuse from the inside of the vesicle, to the outside. However, we previously showed
that this approach is not feasible to study drug transport [68]. The reason for this is the
1-octanol pocket that is initially attached to the liposome. Instead of moving through the
membrane, the drug molecules partition into the octanol, distorting the measurement. The
octanol pockets must hence be separated from the GUVs before the measurement. Another
element to consider is the exposure of the vesicle to the drug itself. Ideally, the vesicles are
exposed to the substance of interest in a well-defined manner to enable a precise permeability
measurement that is not diffusion limited or skewed by a slow exposure of the substance
with relation to the transport rate of the molecule. In the section below, we will discuss two
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possible methods for octanol droplet separation as well as our design of controlled exposure
to drug solutes, before we discuss the final chip design and our validation experiments.
4.2.1 On-Chip Liposome Purification
Density-based Purification of Liposomes
The problem of residual octanol was also identified by Deshpande et al. shortly after their
initial presentation of the OLA technique. A purification protocol for OLA vesicles was
therefore one of the first published follow-ups to the original OLA paper [70]. The separation
method is based on the lower density of the octanol compared to the surrounding water. With
a density of ρ = 0.817 g/cm3, octanol will rise to the surface in an aqueous environment
(ρ = 1 g/cm3) [70]. A water filled punch in the microfluidic chip can therefore act as a
shunt for the octanol droplets, as schematically drawn in Figure 4.1A. This separation hole
must be placed far enough away from the formation junction for the GUVs to have lost
their octanol droplets before they reach the separation hole. Within the separation hole,
the octanol droplets will rise to the surface, whereas the liquid filled GUVs remain at the
bottom. Figure 4.1B and 4.1C show micrographs of vesicles pre-separation that have their
octanol pockets attached to them, as well as vesicles after the density-based purification
occurred [70].
However, the purified vesicles at the bottom of the separation hole do not continue to flow into
the post-hole channel automatically. In order for the GUVs to keep moving and be available
for downstream operations, they have to be driven into the post-hole channel. This can occur
by suction via the outlet, for instance with syringe pumps, or by using pressure driven pumps
with a suction function [70]. The flow control after the separation hole is decoupled from
the pressures that are used for liposome formation. Depending on the application and the
downstream operation this can be either advantageous or an impediment for microfluidic
handling. In any case, it has to be kept in mind that this mechanism of liposome purification
changes the mode of operation from pushing the vesicles through the microfluidic chip to
sucking them through via the outlet.
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Fig. 4.1. Density based separation of OLA vesicles. (A) Schematic of the separation principle.
After production, the GUVs have an octanol pocket attached to them which separates as the
vesicles flow down the pre-hole channel. After separation, both the GUVs and the separated
octanol droplets enter a separation hole. Due to their lower density, the droplets rise to the
surface, whereas the GUVs remain at the bottom of the separation hole. By applying suction
via the outlet, the octanol-free GUVs can be driven back into the microfluidic chip and are
available for operations in the post-hole channel. (B) Micrograph of fluorescently labelled
GUVs before octanol separation. The octanol pocket can be identified as bright fluorescing
spot. A large octanol droplet is indicated by the red arrow. (C) Octanol-free GUVs sucked
in from the separation hole. The vesicles do not contain visible octanol pockets attached to
them. However, small residual octanol droplets are also sucked into the chip, indicated by an
arrow. Image modified from [70].
Speed-based Purification of Liposomes
In addition to the difference in density between octanol droplets and GUVs, the two popu-
lations can also be separated by flow speed. As demonstrated in Figure 4.2A, the vesicles
are generally much larger than the octanol droplets. The GUVs are therefore subjected to
substantially more shear from the PDMS channel walls compared to the smaller octanol
droplets. The latter hence travel through the microfluidic chip with a much higher speed than
the liposomes. An existing population of GUVs in the outlet channel can thus be purified
by simply lowering the IA and OA pressures and stopping the LO flow completely. By
halting the vesicle production this way, no new octanol droplets are added to the existing
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population of vesicles. The lower IA and OA pressures lead to generally slower flow speeds,
ensuring that the octanol droplets have sufficient time to completely bud off the vesicles.
After the octanol droplets separate from the GUV, they are automatically flushed through the
chip towards the outlet, while the GUVs are kept back due to the shear-induced mechanism.
The GUVs are hence available for downstream operations in the chip. After the purified
GUVs have been used or flushed through the chip, the vesicle production can be restarted by
increasing the fluid pressures again.
Fig. 4.2. Principle of liposome purification based on flow speed. (A) Upon formation
the GUVs are subjected to shear with the PDMS channel walls which slows down the
GUVs considerably. Since the octanol droplets are much smaller than the GUVs, they can
flow through the microfluidic chip without interacting with the channel wall, which can be
exploited to separate a population of GUVs present in the post-junction channel. (B) An
increase in channel height allows the purified GUVs to detach from the PDMS channel wall
in order to ensure that downstream operations are not impeded by the shear stress applied to
the liposome membranes.
However, for the downstream transport measurements, we want to ensure that the vesicle
membrane is not impeded by shear, as this could lead to membrane damage and leakage,
which would skew the transport measurement. To avoid this, an increase in height in the
microfluidic chip can be introduced to detach the vesicle from the PDMS channel wall, as
illustrated in Figure 4.2B. After the step in channel height, the vesicles are no longer in
contact with the channel walls and can be handled without PDMS-induced shear.
One side effect of this technique of liposome purification is the loss of the monodispersity of
the GUV population, as demonstrated in Figure 4.3. Upon formation, the GUVs are typically
all equal in size, as can be seen in the micrograph that shows GUVs 9 mm away from the
formation junction. 4 mm further downstream from that position, the octanol pockets are
seen to have bud off and were flushed through the microfluidic chip. However, some of the
remaining vesicles have split into two or have partially burst, indicated by the rising presence
of vesicles that are 50% of the initial diameter. Further downstream, the GUVs have lost
even more of their homogeneity with GUV diameters ranging down to 25% of the original
diameter.
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Fig. 4.3. Size distribution of liposomes in different parts of the channel. The GUVs are
geometrically confined by the PDMS channel which causes shearing of the membrane. The
shearing leads to the splitting of the vesicles into smaller diameter GUVs, as they flow
downstream. The bright field images in the top row show liposomes at the indicated distances
from the formation junction. The histograms below the micrographs show the diameter
distribution of the vesicles at that position. The diameters in all histograms are normalised to
the maximum diameter present in the leftmost image in order to highlight the increase in size
dispersity. Scale bar 50 µm.
Both methods of liposome purification have advantages and disadvantages and should be
chosen depending on the application. The purification by flow speed has the advantage that
it maintains the modus of operation. The flows remain pressure-driven and the vesicles are
pushed through the chip, rather than being pulled through via suction. Furthermore, it does
not require additional modifications of the microfluidic chip, like the hole punch, needed
for the separation based on density. The shear-induced purification is also easier and faster
to implement. On the downside, the GUVs lose their monodispersity when separated by
speed and the vesicle production must be stopped for the purification, as continuous liposome
formation introduces new octanol droplets into the system. One is therefore required to
work with the number of vesicles that are present in the channel after the GUV formation
has stopped. In the case of density-based GUV formation, the liposome formation can be
maintained because the flows downstream of the separation hole are decoupled from the
GUV formation. Another factor to consider is the fact that the density-based purification
requires additional pumps capable of applying suction, such as syringe pumps, whereas the
speed-based purification does not require additional equipment.
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4.2.2 Controlled Exposure to the Drug
The second design choice we must make concerns the exposure of the vesicles to the drug.
Figure 4.4 shows the T-junction design we opted for to expose the GUVs to a drug solute in
a controlled manner.
Fig. 4.4. Controlled exposure of the vesicles to the substance of interest. (A) Brighfield
image of T-junction design. Two flows, one containing the GUVs and the other the drug, face
each other head on and mix in a common channel leading to the outlet. (B) Fluorescence
micrograph showing a fluorophore flushed in via the drug inlet channel and the equal mixing
in the outlet channel.
The original T-junction design stems from the GUV permeability assay designed by Cama et
al. in 2014 [37]. In this design, the stream of vesicles and a stream of the substance which
is to be investigated encounter head on and then flow sideways along a common channel
towards the outlet. Immersed in a bath of the compound, the individual vesicles and the
interaction of the membrane with the added solute can be observed. The advantage of this
design is the immediate exposure of the GUV to the drug stream. Due to the small dimensions
of the channel heading to the outlet, the drug diffuses across the entire width of the channel,
completely engulfing the GUV within several hundred milliseconds. The fast exposure to the
drug makes this kind design suitable for the investigation of permeation studies that occur
within seconds up to minutes [37]. Cama et al. previously showed that the fluid streams
which the vesicles are exposed to, do not affect the permeability measurement [37]. The
drawback of this design is the restrictions it sets on flow control, particularly if it is to be
combined with OLA. The stream containing the vesicles and the stream from the drug inlet
have to be precisely matched to ensure equal mixing at the T-junction. This limits the degrees
of freedom involved in adjusting the pressure at the OLA junction to form the liposomes and
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poses limits on the frequency of GUV production and vesicle size. The pressures cannot
be increased at will without running the risk of pushing the vesicles into the drug inlet
channel. This factor makes it harder to adjust the correct pressure regime for stable vesicle
production. However, we have observed that increasing the fluidic resistance of the drug inlet
channel by elongating it, improves the flow environment at the OLA junction and allows for
a greater freedom to adjust the pressures. We explain this with more closely matching fluidic
resistances from the channels as well as a generally higher resistive preload, which has been
shown to lead to hydrodynamic flow stabilisation in microfluidic chips [165]. All in all, it is
possible to balance the pressures such that vesicle production is possible without impeding
the mixing of the flows at the T-junction.
4.2.3 Integration into the Final Transport Assay and Chip Operation
A schematic of the final chip design is shown in Figure 4.5. For our transport assay, we have
chosen to work with the octanol separation based on flow speed and exposure to the drug via
a T-junction.
4.2 Development of the Chip Design 67
Fig. 4.5. Microfluidic total analysis system for quantifying drug permeability across liposome
membranes. The microfluidic chip features four inlets, one outlet and two different channel
heights. The outer aqueous, inner aqueous and lipid-octanol inlets are needed for liposome
production on chip. The fourth inlet is used to flush in the drug whose permeability is to be
measured. The liposome production occurs at a 6-way junction, where the aqueous flows
meet the lipid-octanol phase (I). The 1-octanol pocket which is initially attached to the
liposome separates from it in the post-junction channel (II) within minutes after production.
In the post junction channel, the GUVs are separated from the octanol droplets. Due to
their larger diameters, the GUVs are subjected to shear from the PDMS channel walls
which slows them down and keep them in the microfluidic chip, whereas the smaller octanol
droplets are flushed through towards the outlet. The purified liposomes then encounter a
step in the chip (III), where the channel height is increased from 16 µm to 35 µm. The
increase in channel height frees the liposomes from the geometric confinement and enables
transport measurements across the membrane without the risk of shear-induced leakage. The
GUVs continue to flow downstream without shearing against the PDMS channel walls. The
liposomes are then mixed with the drug solute at a T-junction (IV) and flow along a common
outlet channel. The transport measurement takes place as the liposomes flow towards the
outlet, immersed in a bath of the drug (V).
As in the previous chapters, we use pressure-driven microfluidic pumps and the Fluiwell
system to control the liquid flows within the microfluidic chip. The microfluidic device has
four inlets and one outlet. In addition to the traditional inlets for the inner aqueous (IA),
lipid-octanol (LO) and outer aqueous (OA) flows, the transport assay features a drug inlet.
However, the operation principle is identical to the chips we used in the previous chapters.
The vesicles are created at the OLA junction with a width of 20 µm. This width allows us to
form liposomes in a size range suitable for our application. In our case, we typically aim to
form liposomes with radii between 15-18 µm. The necessary pressures for GUV formation
vary from chip to chip, however, we have experience that pressures around 40 mbar for the
IA, LO and drug inlets and 70 mbar for the OA phase have a high success rate [68]. The
height of the chip at the OLA junction and the subsequent channel is 16 µm. We designed
and fabricated two different versions of the chip with varying lengths of the channel after the
junction. The two versions feature channel lengths of 13.5 mm and 34 mm respectively. In
both chips, the width of the channel is approximately 200 µm. Both designs are shown in
Appendix Figure B.1.
When operating the chip, we fill the large channel after the OLA junction with GUVs. Both
versions of the chip are equivalent in their working principle, however, the chip version with
the longer channel provides a larger reservoir for the GUVs and is therefore able to hold
more vesicles than the shorter chip. After we filled the post-junction channel with GUVs, we
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set the LO pressure to 0 mbar and lower the IA, OA and drug inlet pressures to 15 mbar. This
stopps new generation of GUVs at the OLA junction and considerably slows down the flows
in the remaining chip. At this pressure regime, the liposomes present in the large channel
typically move with speeds of 0.05 mm/s, whereas the octanol droplets move at 0.2 mm/s
in this region of the chip. The GUVs are separated from the octanol droplets, as explained
above.
After the octanol pockets have split off the GUVs and separated from the population of
GUVs, the purified GUVs reach a step in the microfluidic chip where the channel height
increases from 16 µm to 35 µm. Here, the GUVs detach from the PDMS channel walls and
continue to flow downstream without being subject to shear from the PDMS surface. As the
vesicles reach the T-junction, they are mixed with a stream of a drug solute. The vesicles and
drug solute flow along the common outlet channel. The channel winds in a serpentine-like
manner towards the outlet. The overall length of the common outlet channel is 28 mm. As
we will see below, the GUVs are typically driven through the channel with a speed of 0.4 -
1.0 mm/s, so that the interaction between the GUV and drug solute can be observed for time
scales up to a 70 s, before the liposomes reach the outlet.
We use fluorescence video microscopy to record the GUVs passing through the channel
towards the outlet using the optical setup explained below. Since the outlet channel winds
back and forth, we can set the field of view in our optical setup in such a way that we
can observe two parts of the channel at the same time. Typically, we observed the GUVs
immediately after they were exposed to the drug solute and at a second point in the channel
where the vesicle has been exposed to the solute for several seconds. From this we can
work out the permeability coefficient according to a diffusion model, which we discuss in
Section 4.3.3.
Importantly, while recording the videos, no new GUVs are generated. We are still operating
the chip with the pressures we used for the separation of the octanol pockets (0 mbar for the
LO and 15 mbar for the remaining inlets). The vesicles we are screening are the ones that
were present in the long outlet channel before we lowered the flow rate. The chip with the
longer channel allows us to screen over 400 vesicles, whereas the shorter version typically
allows us to screen up to approximately 150 vesicles per vesicle production run. Once all
vesicles have run through towards the oulet, the vesicle production with OLA can be restarted
and the process repeated.
We were not able to perform transport measurements while we maintained continuous vesicle
production with OLA. The reasons are the high pressures necessary to form GUVs and the
resulting high flow rates. During vesicle formation, the GUVs move too fast to be precisely
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captured with our EMCCD camera, as it can only operate with a maximum of 100 fps.
Furthermore, maintaining GUV production with OLA continuously introduces new octanol
droplets to the system. However, we want to minimise the amount of octanol during our
experiment. By stopping the vesicle production, the octanol droplets can be flushed through
the chip and effectively separated from the population of GUVs, as explained in Section 4.2.1.
4.3 Optical Methods and Permeability Calculation
In the previous section we have spoken about liposome handling and exposure to the drug
solute. In this section we will explain the method we use to visualise the transport itself,
perform our measurements and calculate the permeability coefficient.
4.3.1 Drug Molecule Visualisation
Our assay relies on fluorescence to visualise the solute molecules, whose permeability we
want to study. We used fluoroquinolone antibiotics for the validation experiments of the
platform we present below. Fluoroquinolones are an ideal candidate for this purpose, due to
their autofluorescence [37]. The solute molecules themselves fluoresce upon excitation in
the UV and they do not have to be conjugated to a fluorescent dye to visualise their presence.
Using the optical setup explained below, the microfluidic device is illuminated with UV light
(λex = 350 nm) and the induced fluorescence (λem = 440 nm) is detected. Importantly, the
fluorescence signal scales linearly with the concentration up to 2 mM, as has been shown
before [37]. The mixing of the vesicle and the drug flow at the T-junction is shown in
Figure 4.6A, with the drug flow appearing bright and the vesicle flow dark. When we mix
the GUVs with the stream of autofluorescent drug molecules at the T-junction, the liposomes
initially appear dark on a bright background, as shown in Figure 4.6B. The reason for this
is the lack of fluorescent molecules in the inside of the vesicles. As the fluorescent drug
molecules diffuse through the membrane, the liposomes get brighter. We record and analyse
the increase in fluorescence intensity using the MATLAB routine explained below. From the
increase in fluorescence, we can quantify the permeability coefficient of the drug molecule
for the specific lipid composition under investigation.
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4.3.2 Optical Setup
The microfluidic chips for our validation measurement are operated on a custom-built UV
epifluorescence setup, to induce autofluorescence in the drug molecules and to capture the
experimental video data. In this setup, white light from a broadband light source (EQ99FC,
Energetiq, USA) enters a monochromator (Monoscan 2000, OceanOptics, USA) where
the excitation wavelength (λex = 350 nm) for the target drug molecule is selected. The
UV light passes through a Köhler illumination pathway and illuminates the microfluidic
device via a quad band dichroic mirror (BrightLine full-multiband filter set, Semrock, USA)
and a microscope objective. The fluorescence signal is detected by an EMCCD camera
(Evolve 512 Delta, Photometrics). The camera and recording settings (exposure 10 ms, bin 2,
gain 150) are controlled using the open source software µManager 1.4 [166]. A 60× water
immersion objective (UPLSAPO NA 1.2, Olympus) is used for data recording, whereas
lower magnifications (4×, 10×, 20×, Plan Achromat, Olympus) are used for optimising the
vesicle formation and PVA treatment of the chip.
Fig. 4.6. Liposomes at different positions in the microfluidic chip. (A) Liposomes experience
a controlled exposure to a drug solute at a T-junction where the two flows mix. Note that
the image shows the T-junction at higher flow rates than typically used for in the experi-
ments, resulting in a homogenous mixing of the drug and vesicle flows further downstream.
(B) Liposomes, surrounded by the autofluorescing drug (λex = 350 nm), can be monitored at
different parts of the channel, corresponding to different times that the liposome has been
exposed to the drug. The increase in liposome intensity as the fluorescing drug diffuses
across the membrane is used to determine the permeability coefficient of the drug across the
lipid membrane under investigation.
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Alternatively, the microfluidic devices can also be run on commercial epifluorescence mi-
croscopes if they are equipped with filter sets suitable to induce fluorescence in the target
molecule.
4.3.3 Diffusion Model
Our transport platform uses the same liposome-based principle for the measurement of
membrane permeability as the original microfluidic platform, published by Cama et al. in
2014 [37]. Since the fundamental transport principle is identical, we can use the diffusion
model Cama et al. developed for small fluorescent molecules for our platform [68].
The starting point for the permeability model is Fick’s law of diffusion. We know that the
flux of molecules across a membrane J is described by the equation
J = 4πR2×P×∆c = 4πR2×P× (cout− cin(t)) (4.3)
Where P is the permeability coefficient, our desired quantity, which is defined as P≡ KDd [151].
Furthermore, the flux across a spherical vesicle’s membrane is equivalent to the change of
drug concentration within a vesicle over time.
J =
dcin
dt
× 4
3
πR3 (4.4)
⇔−3P
R
=
1
cout− cin(t) ×
dcin
dt
(4.5)
And upon integration:
− 3Pt
R
= ln(cout− cin(t))+C (4.6)
We know that the initial concentration inside the vesicle is zero. Our boundary condition is
therefore cin(t = 0) = 0.
0 = ln(cout−0)+C⇔C =− ln(cout) (4.7)
⇒−3Pt
R
= ln
(
cout− cin(t)
cout
)
(4.8)
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Which we can easily solve for the permeability coefficient P
P =− R
3t
×
(
cout− cin(t)
cout
)
(4.9)
For our data analysis, it is necessary to link the concentration values cin(t) and cout to
the autofluorescence light intensities, which is the quantity we capture with our camera.
Without a vesicle present and the fluorescent drug filling the entire channel, the case is
simply cout ∝ Iout . For the case of a vesicle in the channel, we cannot simply assume direct
proportionality as we are not obtaining a confocal measurement. We have to consider the
background intensity I0 from the fluorescing drug surrounding the vesicle and subtract this
from the intensity of the vesicle cin(t) ∝ (I(t)− I0).
For the expression in brackets in Equation 4.8, we thus receive
cout− cin(t)
cout
=
Iout− (I(t)− I0)
Iout
(4.10)
With our setup, we measure the intensity inside a vesicle (Iin) and outside (Iout) at two distinct
time points. The first measurement is always immediately after exposure of the vesicle to
the drug (t = 0) and we assume that there are no fluorescent molecules in the inside of the
vesicle at this time point. The fluorescent signal Iin we obtain at this timepoint is therefore
equivalent to the signal coming from the fluorescent drug surrounding the vesicle I0. The
second measurement of the inside and outside intensities occurs at a later timepoint t f .
If we normalise the intensities at the two time points to the outside fluorescence, we obtain.
∆I1(t = 0) =
Iout− Iin
Iout
=
Iout− I0
Iout
(4.11)
and
∆I2(t = t f ) =
Iout− Iin
Iout
=
Iout− I(t)
Iout
(4.12)
We can now reshape the expression in the brackets of Equation 4.10. By adding and
subtracting ±Iout , in the numerator we do not change the validity of the expression, but attain
Iout− I(t)+ Iout + Iout
Iout
=
Iout− I(t)
Iout
− Iout− I0
Iout
+
Iout
Iout
= ∆I2−∆I1+1 (4.13)
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We finally receive our equation for the permeability coefficient expressed by autofluorescence
intensity as
P =− R
3t
× ln(∆I2−∆I1+1) (4.14)
The acquired videos are analysed using a newly developed MATLAB script. It extracts the
relevant vesicle data from the images and calculates the permeability coefficient according to
the diffusion model explained above. In the next section we will briefly explain the analysis
routine and debug features of the code.
4.3.4 Data Processing and Permeability Calculation
The MATLAB script is optimised for video files in the TIFF format. In every experiment, we
typically record 15-30 movies of 5000 frames each. With a frame rate of 100 fps, each movie
is 50 seconds long. The analysis explained below is performed for each video. If problems
occurred during data recording, such as exposure to stray light or obstructions in the flow,
the respective videos can be identified from the debugging files and excluded from further
analysis.
The video files must show two channels, as depicted in Figure 4.6B. The code will auto-
matically recognise the channel and define each as a specific region of interest (ROI). The
vesicles passing in each of the respective channels represent two different time points that the
vesicle has been exposed to the drug. Next, the frames with vesicles present in the channel
are identified. This is achieved by observing the mean fluorescence intensity over time. As a
vesicle enters the ROI, the mean fluorescence intensity decreases, since the vesicle is darker
compared to the background, due to the lack of fluorescent antibiotic molecules in the inside
of the vesicle. When the vesicle leaves the field of view, the fluorescence is restored to the
initial level.
From the frames we identified as a vesicle event, all the necessary information required for
the diffusion model is extracted. Using MATLAB’s imbinarize function, we identify the
contour of the vesicle and extract the radius, the coordinates of the centre point, and the
circularity using the regionprops function. Most importantly, we identify a 5×5 pixel box
around the GUV centre and measure the mean intensity of this square for every frame of the
vesicle event. The average intensity over all the frames is the quantity Iin from the diffusion
model above. In order to extract the outside intensity Iout , the frames before and after the
vesicle event are merged into one image. The GUV is not present in this image. The same
5×5 pixel boxes used to obtain the Iin signal are now measured in the frame without the GUV
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present, to obtain Iout . To avoid errors in the extraction of the intensity values, we introduced
a debugging option in this part of the code. A debugging proof, as seen in Figure 4.7, is
generated for every vesicle event. It shows the background image that was generated to
extract Iout . Furthermore, it shows one of the frames of the vesicle event and the contour
identified which is used for the regionprops function. Obvious sources of error, for instance
two vesicles that are clustered together and are identified as one single vesicle, can easily be
detected and excluded from the analysis with the debugging option. Note that we subtract the
camera’s dark noise from all intensity values, as this baseline intensity is not a fluorescent
signal of the molecule.
Fig. 4.7. Debugging panel exported for every vesicle event. The panel consists of three
images. The left image shows the background which is used to determine Iout in the diffusion
model. The middle image shows the detected vesicle as it is recorded. The right frame shows
the vesicle after binarisation. The binarised image is used to identify the contour of the
vesicle and extract parameters such as radius and intensity. The exported panel allows for a
fast screening for errors, for instance when two vesicles clustered together are identified as
one. The scale bar 20 µm.
We extract the speed of the vesicle by its movement through the field of view. Since we set
the position of our detection points, we know the distance the GUV has travelled when it
reaches the second ROI and thereby the time t f it has been exposed to the drug.
We place the first t0 time point, where the drug had diffused across the entire channel width.
This was typically 200 microns downstream of T-junction point. The vesicles measured in
the second ROI have been exposed to the drug throughout their path towards the outlet. The
chip geometry is designed in such a way that the second ROI lies 7.5 mm after the first ROI.
With speeds between 0.4 mm/s and 1.0 mm/s, the vesicles have therefore been engulfed in
the bath of drug molecules for between 7.5 and 19 seconds when they are screened for the
second time to obtain ∆I2.
Figure 4.8 shows a typical scatter plot, as obtained from a permeability measurement. The
normalised intensity values ∆I on the y-axis and the vesicle radius on the x-axis make up
the coordinate plane. Every data point represents a single vesicle measurement. The dark
data points are ∆I1 measurements taken just after the vesicle encountered the drug at the
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T-junction. The coloured data points are the ∆I2 measurements obtained after the GUV has
been exposed to the drug for the time specified in the inset. The spread in liposome radius is
an effect of the method we used to purify the liposomes, as we pointed out above.
Fig. 4.8. Scatter plot of permeability measurements. The normalised intensity difference is
given on the y-axis, the radius on the x-axis. Every data point represents a single vesicle
measurement. The dark data points are taken at the first measurement point immediately after
the vesicle was exposed to the drug (t ~0 s). The coloured data points are vesicles measured
at the second position. The timespan between the two measurements as well as the total
number of data points at the second position is noted. The normalised intensity is lower at
the second time point, as fluorescing molecules diffused across the membrane reducing the
vesicle’s contrast to the outside.
If we remember our definition ∆I = Iout−IinIout , the distinct shape with two linear bands of
values becomes evident to us. ∆I1 is higher than ∆I2 since no fluorescing molecules have
crossed the membrane at the first measurement point. The normalised intensity difference
between the vesicle inside Iin and outside Iout is therefore larger than at the second time
point, when autofluorescing drug molecules have crossed the membrane and decreased the
difference Iout − Iin. We can also understand the linear increase of ∆I as a function of the
radius when we consider the design of the optical setup. Since we do not perform a confocal
measurement, the fluorescent drug molecules on top and below a vesicle on its vertical axis
(the optical axis) contribute to the Iin value we measure. With increasing radius, there are
fewer fluorescent molecules present surrounding the vesicle in the channel that contribute
to Iin. The difference Iout− Iin and therefore ∆I is hence higher for larger vesicles. In other
words, since the concentration of the drug solute is constant, the fluorescence is directly
proportional to the volume of the solute. As we always measure a 5×5 pixel area in the
centre of the vesicle, the volume occupied by the solute, and therefore the fluorescence,
scales directly with the distance between the channel ceiling/floor and the vesicle.
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The field of view we obtain using the 60× objective allows us to observe two channel
segments at the same time. The two channels segments correspond to two time periods which
the vesicle has been exposed to the drug. One crucial measurement according to our diffusion
model is the ∆I1 value taken the t0 time point. However, when the field of view is set to this
position, the second channel segment, where we measure ∆I2, is always 7.5 mm downstream
from the T-junction, due to the geometry of the chip. If we want to shift the field of view
down to positions in the channel that correspond to longer exposure times, we can no longer
obtain the corresponding ∆I1 for that individual vesicle.
We solved this restriction set to us by the chip geometry, by not comparing one and the same
vesicle at two time points directly. Instead, we exploit the linear relationship between ∆I1
and the radius R. We first measure a sufficient number of vesicles at the t0 position such that
we can fit a linear function to the values of ∆I1(R). The fitted linear function is depicted as a
solid black line in Figure 4.8. We then use this function to recalculate ∆I1 for any vesicle we
measure at a later timepoint. By recalculating ∆I1, can shift the field of view to any position
in the chip.
4.4 Permeability Measurement of Fluoroquinolone Antibi-
otics
After we introduced the chip design in the previous sections, we want to turn to the actual
measurement of small drug molecule permeation across defined lipid bilayers. We will
perform validation experiments using the fluoroquinolone drug norfloxacin and measure
the permeability of this drug in two chemical environments - one measurement in an acetic
acid buffer at pH 5 and one in a pH 7.4 phosphate buffered saline (PBS) solution. Next,
we compare the permeability values obtained with our assay to similar experiments which
were performed on electroformed vesicles to validate that permeability measurements using
OLA vesicles are quantitatively similar to those performed using electroformed GUVs.
Furthermore, we determine the permeability coefficient of a second drug, ciprofloxacin, at
pH 7.4 and physiological salt concentrations.
Before we begin, we want to briefly explain the relevance of antibiotic permeability measure-
ments using GUVs as model membranes.
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4.4.1 Motivation
Over the past decades, multidrug resistance (MDR) in microbial pathogens has developed
into a serious threat for public health, leading to a global medical crisis [167]. In 2016,
more than half (58.6%) of clinical Escherichia coli isolates in the European Union showed
resistance to at least one of the antimicrobial groups under regular surveillance [168]. One of
the major biochemical causes of antibiotic resistance is the reduced membrane permeability
of drug molecules [169–172].
This problem is especially apparent for Gram-negative bacteria, as their cell envelope con-
sists of a double membrane; drugs require seemingly contradictory chemical properties to
overcome these two barriers to reach their cytoplasmic targets [20, 170, 172]. The outer
bilayer is equipped with a highly charged layer of lipopolysaccharides (LPS), effectively
preventing the permeation of both hydrophilic and hydrophobic compounds [170]. Most
compounds therefore need to pass the outer membrane via water filled β -barrel channels
(porins) such as OmpF [21]. Many of these porins favour the passage of hydrophilic or
charged compounds [170, 173]. Once a compound crossed the outer membrane, it still needs
to penetrate the inner membrane. This membrane, however, behaves like a standard phos-
pholipid bilayer and provides a strong barrier for charged or hydrophilic molecules. The
properties that allow a molecule to pass the first membrane are hence what prevents it from
permeating through the second membrane. We see that the passive uptake of molecules is not
trivial. A deeper understanding of the mechanisms that govern passive drug transport across
lipid membranes is therefore of great importance in the context of solving the antibiotic
resistance challenge.
Bacterial cell membranes are very complex systems that are involved in numerous cellular
processes [174]. Drug permeability studies have not only proven very difficult due to the
small size of the bacteria, but also due to the convolution of active and passive effects that
simultaneously take place in the membranes of living bacteria [172, 175]. We therefore use
OLA derived GUVs as model membranes [175]. The GUVs offer the advantages of having
well-defined lipid compositions, being easy to image and also being more controlled systems
for studying transport processes than a living bacterium.
The lab-on-chip total analysis platform we presented above enables the continuous production
and screening of liposomes on the same device. This enabled us to efficiently screen an order
of magnitude more liposomes than the earlier platforms we discussed above. Importantly,
it also enables us to explore transport using physiological salt concentrations which was
challenging using electroformed GUVs [176]. We investigate the transport using biomimetic
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membranes, using a lipid mixture of DOPG-DOPC (1:3 ratio) to form the GUVs. The
net negative charge carried by this membrane mimics bacterial membranes more closely
than simple bilayers consisting of pure PC lipids and is often used to mimic bacterial
membranes [69, 177–179].
4.4.2 Material and Methods
Chip Fabrication
The microfluidic chips are made of polydimethylsiloxane (PDMS) following the protocol
we explained previously in Section 2.4.2. The generation of the master mold requires an
additional fabrication step, due to the multi-height (16 µm and 35 µm) features in this chip
design. The 16 µm features are obtained by spin coating a layer of SU-8 2025 photoresist
(MicroChem, USA) on a 4-inch Silicon wafer (University Wafer, USA). The wafer is pre-
baked on a hot plate at 65°C for 1 min and at 95°C for 6 min. The structures are imprinted
on the substrate using a table-top laser direct imaging (LDI) system (LPKF ProtoLaser LDI,
Germany). The LDI system exposes the structures specified in the software directly with UV
light, causing the photoresist to crosslink and solidify. After exposure, the wafer is post-baked
for 1 min at 65°C and for 6 min at 95°C. The substrate is developed by rinsing the wafer
with propylene glycol monomethyl ether acetate (PGMEA), which removes the unexposed
photoresist and leaves the desired UV-exposed structures on the substrate. The wafer is then
hard baked for 15 min at 120°C. The multi-height feature is achieved by performing this
photo-lithography process again on the same silicon wafer with different layers of photoresist
with varying heights. Feature heights of 16 µm and 35 µm respectively were obtained by
spinning the photoresist at 3800 rpm and 1800 rpm respectively (WS-650-23NPP, Laurell
Technologies, USA) for 60 s with a ramp of 100 rpm/s. The anchoring tool of the direct laser
writer is used for aligning the features in the two designs.
Solution Composition
The base solutions for the OLA aqueous phases consist of 200 mM sucrose and 15% v/v
glycerol in buffer. In accordance to previously published protocols, the outer aqueous phase
additionally contains 50 mg/mL poloxamer Kolliphor P-188, which facilitates the initial
double-emulsion formation [64]. We performed experiments on the fluoroquinolone drugs
norfloxacin and ciprofloxacin. Transport of both drugs is measured in phosphate-buffered
saline (pH 7.4) which mimics physiological pH and salt concentrations. Additionally,
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experiments using a 5 mM acetic acid buffer (pH 5) are performed for norfloxacin as controls
for membrane stability. At pH 5, norfloxacin molecules are primarily in their positively
charged form and hence show low permeability through lipid bilayers [37, 153]. The drug
solutes are prepared by diluting 48.5 mM norfloxacin and 49.5 mM ciprofloxacin stock
solutions, respectively, to a final concentration of 2 mM with the aqueous base stock. All
pH levels were adjusted and checked using a digital pH meter (Hanna Instruments, UK).
The lipid-octanol phase is obtained by dissolving a 100 mg/mL lipid stock mixture with
1-octanol to reach a final concentration of 2 mg/mL. The lipid stock is a 3:1 mixture of
DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) and DOPG (1,2-Dioleoyl-sn-glycero-3-
phosphorac-(1-glycerol) sodium salt) in 100% Ethanol. DOPG is an anionic lipid with a
net charge of -1. Lipid mixtures of DOPG with the net-charge neutral lipid DOPC roughly
mimic the negative charge density of bacterial lipid extracts and are typically used when
modelling bacterial membranes with GUVs [69, 177–179]. All chemicals are obtained from
Sigma-Aldrich, unless stated otherwise.
Optical Setup
The microfluidic chips for the norfloxacin measurements were run on the custom-built
UV epifluorescence setup we explained above. The ciprofloxacin measurements were
obtained on a commercial epifluorescence microscope (Nikon TE 2000U). The Nikon
epifluorescence microscope is equipped with a pE-1 LED lamp (λex = 365 nm (DAPI),
Cool LED, UK). We used the same water immersion objective (60×, UPLSAPO NA 1.2,
Olympus), dichroic mirror (BrightLine full-multiband filter set, Semrock, USA) and camera
(Evolve 512 Delta, Photometrics; exposure 15 ms, bin 2, gain 250) as in the custom built
setup for the ciprofloxacin measurements.
4.4.3 Results and Discussion
Norfloxacin transport measurements were performed in two different chemical environments.
One set of measurements was performed in PBS at physiological pH and salt concentrations.
The second set was taken as a control in an acetic acid buffer at pH 5. The scatter plots in
Figure 4.9A and 4.9B show representative results from our norfloxacin experiments. The
dark data points mark the normalised intensity difference levels ∆I1 of individual liposomes
at the first measurement point, when the liposomes have just encountered the drug flow and
hence do not contain any drug molecules within them. The coloured data points mark the
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normalised intensity difference ∆I2 of the individual liposomes after they have been exposed
to the drug for the time indicated inset. As we explained in Section 4.3.4, the drop in ∆I is a
direct result of the influx of fluorescent molecules into the GUV.
In Figure 4.9A, we can see no drop in ∆I for the vesicles at pH 5 between the two measurement
points. The technical repeats of this experiment shown in Appendix Figure B.2 report similar
results. Since the drop in ∆I is a direct result of the influx of fluorescent molecules, we can
conclude that no significant transport occurs at pH 5 over the observed timespans. Expanding
the exposure and observation time for the pH 5 measurement to 40 seconds yields the
same result of no significant transport, in line with our previous observations. This also
confirms that the liposome membranes are not being compromised due to shear or any other
interactions in our device.
In contrast to the pH 5 measurements, we observe a substantial decrease in ∆I for the vesicles
in PBS shown in Figure 4.9B. From these scatter plots, we can conclude that there exists
effective norfloxacin transport across the bilayer at physiological pH and salt concentrations.
Comparing the two measurements taken in PBS, we also observe a larger drop in ∆I in the
right scatter plot compared to the left scatter plot. We can explain this when we look at the
timespan that lies between the two measurement points for ∆I1 and ∆I2, which are given
inset. Approximately 14 seconds lie between the two measurement points in the scatter plot
on the left, which shows the smaller gap. In contrast to that, approximately 18 seconds lie
between the two measurement points in the scatter plot on the right, which displays the larger
gap between ∆I1 and ∆I2. The larger gap between ∆I1 and ∆I2 hence stems from the fact that
more autofluorescing drug molecules could diffuse across the bilayer in the additional time,
lowering ∆I2, as expected.
Figure 4.9C shows two representative scatter plots obtained for the fluoroquinolone drug
ciprofloxacin. Again, we observe a substantial decrease in ∆I between the two time points,
visualising the passive transport of this drug across the bilayer in the PBS environment. Note
that the ∆I scale is different in these scatter plots compared to the measurements taken for
norfloxacin. This is due to the fact that the ciprofloxacin measurements were obtained on a
different optical setup which required different gain and exposure settings.
Additional scatter plots with technical repeats for all measurements are shown in Appendix
Figures B.2 to B.5.
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Fig. 4.9. Representative scatter plots of permeability measurements. Every scatter point
represents a single vesicle measurement. The dark scatter points are taken at the first
measurement position at t ≈ 0 s, just after the vesicles encountered the drug. The coloured
scatter points are vesicle measurements taken at the second position, after the vesicles have
been exposed to the drug for the time given inset. (A) Norfloxacin measurement in acetic
acid buffer at pH 5. The dark and the coloured scatter points overlap, indicating that there
is no substantial drug perfusion into the vesicle in the given time frame. In the left scatter
plot, the field of view was moved to a position later in the chip that corresponds to a drug
exposure of the vesicles of over 40 seconds. (B) Norfloxacin measurements in PBS and
at a physiological pH level. The gap in ∆I between the two measurement positions reveal
that substantial transport occurred between the two measurement time points. The gap
between ∆I1 and ∆I2 is larger for the scatter plot on the right, where 18 seconds have passed
between the two measurement points, compared to 14 seconds for the scatter plot on the
left. (C) Ciprofloxacin measurements in PBS and at physiological pH level. The gap in ∆I,
again, reveals substantial transport via passive diffusion. Note that the ∆I levels in these
measurements are marginally different from the norfloxacin measurements, as they were
obtained on a different optical setup which required different gain settings.
The observed transport behaviour for the drugs at pH 5 and pH 7.4 is as we expect and is
a result of the charge state of the molecules in the different chemical environments. The
majority of norfloxacin molecules are positively charged at pH 5 whereas the proportion of
uncharged molecules is highest at pH 7.4 [153, 180, 181]. Lipid membranes are generally
regarded as largely impermeable to ions and highly charged molecules, since these cannot
cross the hydrocarbon section of the lipid bilayer easily. In nature, these transport processes
are governed by transmembrane proteins such as porins or ion channels [15]. The observed
behaviour is therefore perfectly in line with what the theory predicts.
The histograms showing the permeability coefficients of all the norfloxacin and ciprofloxacin
experiments performed in PBS are given in Figure 4.10. The total number of liposomes
for the norfloxacin histogram is 1620 and results in an overall average permeability co-
efficient of 4.13 ± 0.05 × 10−6 cm/s (mean ± std. error of mean) and a median value of
3.57 × 10−6 cm/s. The values were obtained from 12 experiments in 5 technical repeats.
The mean (± std. error of mean) permeability coefficient obtained for ciprofloxacin is
4.99 ± 0.07 × 10−6 cm/s and the median value is 4.83 × 10−6 cm/s. The values are ob-
tained from 4 experiments (4 technical repeats) and a total of 960 vesicles. For the pH 5
measurement, five experiments on two technical repeats were performed. An experiment is
defined as a continuously acquired dataset measured from one batch of liposomes produced
on the microfluidic device. As described above, up to four experiments were performed
on one microfluidic device, by restarting the liposome production after completion of one
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measurement. Each set of experiments performed on an individual device is defined as a
technical repeat.
Fig. 4.10. Histograms of the permeability coefficients for norfloxacin (N = 1620) and
ciprofloxacin (N = 960). The mean ± std. error of mean, as well as the median values are
noted. The permeability of ciprofloxacin is significantly higher than the permeability of
norfloxacin (two sample t-test, p < 0.001). The values for norfloxacin were obtained in 12
experiments performed on 5 different microfluidic chips (5 technical repeats). The values for
ciprofloxacin were obtained in 4 experiments on 4 different microfluidic chips.
The value obtained from the transport measurements matches the values previously obtained
in our group using the established electroformation liposome production technique. Pu-
rushothaman et al. measured the permeability coefficient of norfloxacin through PGPC lipo-
somes (30:70 ratio) in a 5 mM phosphate buffer solution at pH 7.0 to be 4.3 ± 0.2× 10−6cm/s
[98]. The main advantages of the on-chip OLA technique over electroformation are the high-
throughput liposome production and its compatibility with physiological salt concentrations.
The higher liposome production efficiency allows us to perform tests on 1620 liposomes here
compared to the 138 liposomes in previous experiments using electroformation. Due to the
greater efficiency of vesicle formation under these conditions and the correspondingly higher
number of data points, we can provide a more precise estimate of the permeability coefficient
than before, with the standard error of the mean lowered by over an order of magnitude
compared to the results previously reported [98] using electroformed vesicles. Furthermore,
the possibility of producing liposomes at physiological salt concentrations allows us to mimic
the natural environment of a bacterial cell more closely. Any possible remaining traces of
solvent (1-octanol, poloxamer P-188) do not seem to alter the transport properties of the
membrane, as seen by the similarity to the previously acquired result.
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Fig. 4.11. Chemical structures of norfloxacin and ciprofloxacin. Norfloxacin carries an ethyl
group at the N-1 position, whereas ciprofloxacin has a cyclopropyl group at this position.
The higher permeability coefficient of ciprofloxacin compared with norfloxacin is to be
expected based on the chemical structures of the respective molecules, drawn in Figure 4.11.
We see that norfloxacin carries an ethyl group at the N-1 position, where ciprofloxacin has
a cyclopropyl group. This functional group increases the lipophilicity of the compound as
compared to the corresponding ethyl group in norfloxacin, and therefore results in a higher
permeability coefficient [153].
According to the DrugBank database, calculated partition coefficient (log P) values for
norfloxacin lie between -0.47 and -0.92, while experiments show a log P of -1.03 [182]. For
ciprofloxacin, the calculated log P values lie between -0.57 and -0.81 with an experimental
value of 0.28 [182]. A positive partition coefficient indicates a larger lipophilicity of a
compound, whereas a more negative partition coefficient suggests a higher hydrophilicity.
The higher permeability coefficient we obtained for ciprofloxacin is therefore also in line
with the experimental and predicted partition coefficients of the two drugs.
Overall, our experiments demonstrated that our fluorescence-based assay can be effectively
used for the measurement of fluoroquinolone permeability. In the next section, we will
discuss the use of the platform with fluorescently labelled compounds.
4.5 Fluorescently Labelled Drug Molecules
4.5.1 Motivation
Aside from a few individual exceptions, the only other class of antibiotics aside from fluoro-
quinolones that expresses intrinsic fluorescence in the UV, is the tetracycline family [183].
In its current form, the setup can therefore only be used to obtain the permeabilities of these
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two classes of antibiotic molecules. Although it should be noted that there are applications in
other fields of drug discovery such as in chemotherapy where a number of compounds show
intrinsic fluorescence [184]. Further, as we demonstrated in [153], permeabilities within the
same group of antibiotics can span orders of magnitude, and hence this technique allows
us to study the effect of specific functional groups on lipid permeability. For instance, we
showed that a tertiary amine within a quinolone’s piperazine group significantly enhances
membrane permeability compared to secondary amines at the same position and were able to
quantify this using the microfluidic assay [153].
One seemingly obvious possibility to expand the technique is by using fluorescent derivates
of drug molecules, which have found much attention in biomedical research recently [183].
The limited number of fluorescent drugs that are available to date have been used successfully
in numerous studies and helped us gain a deeper insight into various aspects of the drugs,
such as their mode of action, localisation or biological targets [183–187].
However, a major concern when working with fluorescently tagged molecules is the influence
of the fluorophore on target binding and membrane permeation. Recently, Stone et al.
reported a procedure to fluorescently tag drug molecules using an azide-handle which links
the drug molecule and the fluorophore. This handle is placed at a position that is believed
not to inhibit the binding of the drug to the intracellular target, thereby maintaining the
tagged-molecule’s antimicrobial activity [188]. Stone et al. furthermore used 7-nitrobenz-2-
oxa-1,3-diazol-4-yl (NBD) to tag the drug molecules. This fluorophore has a low molecular
weight compared to other fluorescent tags commonly used and is therefore expected to
influence the membrane and cytosol permeation of the drug in bacterial cells to a lesser
extent [188].
Importantly for us, Stone et al. synthesised an NBD-tagged version of ciprofloxacin. Al-
though the new fluorescent version required higher minimal inhibitory concentrations (MIC)
than the native form of the drug, the developers concluded that it could be used for bacterial
penetration and efflux studies [188]. The fluorescent version of ciprofloxacin provides the
opportunity for us to directly compare the permeabilities of the native version of the drug
to the fluorescent derivate. Using our assay, we should be able to characterise and quantify
the influence of the fluorophore on drug permeability - knowledge of which is important for
the interpretation of studies using fluorescently tagged antibiotics. The developers of the
NBD-ciprofloxacin supplied us with a stock of the said drug, which we investigated with our
microfluidic permeability assay.
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4.5.2 Results and Discussion
We conducted the experiment following the same experimental procedure as we did for
the native ciprofloxacin. The IA, OA and LO phases were identical to the experiments
above. To obtain the drug solute, we diluted a NBD-ciprofloxacin stock (10 mM in DMSO)
with IA buffer to a final concentration of 100 µM. Due to the stronger fluorescence of the
NBD-tag compared to the native autofluorescence, we were able to work with lower drug
concentrations compared to the 2 mM drug concentrations we used in the experiments above.
The microfluidic device was operated on the same commercial epifluorescence microscope
(Nikon TE 2000U) as the native ciprofloxacin measurements.
To our surprise, exposing the vesicles to the NBD-ciprofloxacin did not yield the typical
images we observed in our assay using autofluorescence. Instead, we saw a bright ring
appear around the vesicles, as shown in Figure 4.12. We have not seen such a fluorescent ring
appear, using native fluoroquinolones, excited in the UV. The ring around the vesicle using
NBD-ciprofloxacin is already formed at the first measurement position, immediately after
exposure to the drug. We furthermore observed that if we flushed octanol droplets through
the chip, the droplets increase drastically in fluorescence.
Fig. 4.12. PGPC vesicles exposed to NBD-ciprofloxacin. (A) Two vesicles in different
parts of the channel. The vesicle in the upper ROI is recorded immediately after exposure
to the drug. The GUV in the bottom ROI has been exposed to the drug for approximately
12 seconds. The fluorescence is induced by excitation at λex = 460 nm. A fluorescent ring
around the GUV starts to form as soon it is exposed to the drug. (B) Microfluidic chip at
lower magnification. A bright octanol droplet as well as two GUVs are indicated by arrows.
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These observations led us to believe that the fluorescence of the NBD-ciprofloxacin is
dependent on the chemical environment and increases when it changes from an aqueous
phase to an organic phase. To validate this, we measured the fluorescence of 50 µM NBD-
ciprofloxacin samples in a fluorimeter (slit size 5 µm, Varian Eclipse), both in millipore water
and in 1-octanol. The emission spectra of the two samples upon excitation at 460 nm and at
360 mm are shown in Figure 4.13A and 4.13B, respectively. We see that the fluorescence of
NBD increases more than 12-fold when it is dissolved in an organic compound, compared
to when it is dissolved in water. Indeed, this behaviour of NBD is known and has been
investigated in the past. NBD is a so called solvatochromic dye. These fluorophores
exhibit strong shifts in their emission spectra as a function of environment hydration and
polarity [189], which explains our observation.
Fig. 4.13. Emission spectra of NBD-ciprofloxacin in different chemical environments and
different excitation wavelengths. (A) Emission spectra upon excitation at 460 nm. NBD-
ciprofloxacin yields a more than 12-fold higher fluorescence when it is dissolved in octanol
compared to water. (B) Emission spectra of NBD-ciprofloxacin upon excitation in the UV. A
similar 12-fold increase in fluorescence in the organic environment can be observed. A small
peak stemming from the natural autofluorescence of the drug can be observed at 440 nm in
an aqueous environment. (C) Native ciprofloxacin shows comparable emission spectra in the
two solvents.
As we see in Figure 4.13B, the NBD-ciprofloxacin mainly emits at the fluorophore’s emission
wavelength at λem ~530 nm, even if it is excited in the UV. Furthermore, the drug also main-
tains the 12-fold increase in fluorescence when it is excited at this wavelength. Interestingly,
we do observe a small emission peak at λ ~440 nm, the autofluorescence wavelength, in an
aqueous environment for NBD-ciprofloxacin. However, it is not clear if this peak stems from
the labelled drug, or remaining ciprofloxacin that did not conjugate to the dye.
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We furthermore measured the fluorescence of native ciprofloxacin (100 µM, slit size 5 nm)
in water and octanol, shown in Figure 4.13C. As we see, the native ciprofloxacin shows
comparable fluorescence emission in the two solvents.
The fluorescent ring appearing around the vesicles made it impossible for us to analyse
the obtained video data with the previously developed MATLAB routine. Our code is
capable of automatically detecting GUVs that appear dark on a bright background, as shown
in Figure 4.7. However, due to the bright ring around the vesicles, these were either not
identified as GUVs at all, or detected with an incorrect radius. Instead, we therefore extracted
the necessary parameters (GUV radius, speed and intensity values) of 38 vesicles manually
from the videos using the imaging software ImageJ.
A scatter plot generated from the manually extracted data is shown in Figure 4.14A. The
scatter plot has the same general appearance as the scatter plots for our measurements on
unlabelled fluoroquinolones. Again, we obtain two bands of scatter points for the two
measurement positions, and a linear dependence of ∆I on the radius R. However, we notice
that the scatter points for ∆I2 show values of around 0 or are even negative for small radii.
Since we obtain ∆I from ∆I = Iout−IinIout , negative ∆I values appear when the vesicle fluorescence
(Iin) is higher than that of the background (Iout). This is a result of the measurement technique
and the strong contribution of the fluorescent ring. As we laid out in Section 4.3.4, we do
not perform a confocal measurement in our setup. The Iin we obtain is the signal stemming
from the fluorescent molecules along the optical axis, so the sum of the NBD-ciprofloxacin
inside and outside of the GUV, as well as in the hydrocarbon layer of the membrane. Unlike
in our previous measurements, the enhanced fluorescence of the NBD-ciprofloxacin in the
hydrocarbon layer contributes substantially to the Iin value explaining the negative values.
Fig. 4.14. (A) Scatter plot of NBD-ciprofloxacin experiment. The dark data points show
the ∆I1 measurements taken at the t0 time point. The red points visualise ∆I2 taken after the
time given inset (B) Histogram of obtained permeability coefficients. The average (mean ±
standard error) permeability coefficient of NBD-ciprofloxacin is 4.9 ± 0.2 × 10−6 cm/s.
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We proceeded to calculate the permeability coefficient of the NBD-ciprofoxacin as before,
using Equation 4.14. The histogram of the measued values is shown in Figure 4.14B.
We obtained a mean ± standard error of 4.9 ± 0.2 × 10−6 cm/s and a median value of
5.0× 10−6 cm/s. These values are very close to the ones we obtained for native ciprofloxacin.
Given in Table 4.1, we obtained a mean ± standard error of 4.99 ± 0.07 × 10−6 cm/s and a
median of 4.8 × 10−6 cm/s for the latter.
Table 4.1. Permeability coefficients of NBD-ciprofloxacin and native ciprofloxacin obtained
with the permeability platform.
NBD- Ciprofloxacin (N=38) Ciprofloxacin (N=960)
Mean ± S.E. 4.9 ± 0.2 × 10−6 cm/s 4.99 ± 0.07 × 10−6 cm/s
Median 5.0 × 10−6 cm/s 4.8 × 10−6 cm/s
The close permeability values are a very promising result. They indicate that the NBD
label does, in fact, not alter the transport properties to an extent that it drastically changes
the permeability coefficient. A low influence of the NBD fluorophore on the transport
properties is also claimed by the developpers of the NBD-ciprofloxacin [188]. However,
the solvatochromic behaviour of the NBD label is a potential source of error that must be
accounted for and further investigated. The permeability coefficient, was obtained under the
assumption that the fluorescent ring is fully developed at the t0 measurement position and
does not change its intenstiy over time. If this assumption holds true, the change in vesicle
intensity that we observe is indeed only due to the fluorescing drug that diffused across the
membrane into the inside of the GUV. However, if the fluorescence of the membrane is not
fully saturated at the t0 time point, the increase in signal from the membrane adds to that
of the diffusing drug leading to the overestimation of the fluorescent signal at the second
measurement position. The elevated fluorescence at the second measurement position would
in return lead to an overestimation of the permeability coefficient.
All in all, our experiments with the NBD-labelled ciprofloxacin show very promising, albeit
preliminary results. The permeability coefficient we obtained with the tagged molecule
is very close to what we measured for the native version. However, our experiments also
revealed that in addition to potential effects of the fluorescent label on the transport properties,
one also has to be concerned about the sensitivity of the fluorophore to environmental changes.
More experiments are necessary to determine definitely whether or not the NBD label affects
the transport properties of the drug. Potential next experiments should be performed using
fluorescent tags that do not express solvatochromic behaviour in order to ensure that our
measurement was not skewed by the fluorescence properties of the NBD-ciprofloxacin. A
change in optical technique could further improve our understanding of the fluorescent label
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on the transport. By introducing confocal detection, for instance, the fluorescence of a slice
in the centre of the vesicle could be viewed without the effects of the fluorescent membrane.
4.6 Conclusion
In this chapter, we presented an integrated microfluidic platform for quantifying drug perme-
ation across biomimetic membranes. We combined an on-chip liposome formation technique
OLA with a downstream T-junction for the controlled exposure of liposomes to a drug solute.
Norfloxacin and ciprofloxacin transport through biomimetic PGPC (1:3 ratio) liposomes was
measured at physiological pH and salt concentrations. The measurements yielded perme-
ability coefficients of 4.13 ± 0.05 × 10−6 cm/s (mean ± std. error of mean) with a median
value of 3.57 × 10−6 cm/s for norfloxacin and 4.99 ± 0.07 × 10−6 cm/s (mean ± std. error
of mean) and a median value of 4.8 × 10−6 cm/s for ciprofloxacin. These values are in good
agreement with previous measurements by Purushothaman et al. who obtained a permeability
coefficient of 4.3 ± 0.2 × 10−6 cm/s for norfloxacin in a similar lipid mixture [98, 153]. We
produced PGPC (1:3) liposomes to mimic the anionic charge density typically associated
with bacterial membranes [69, 177–179], and used this as a model system to quantify passive
drug transport through the lipid bilayer component of the Gram-negative cell envelope.
Since our method directly quantifies the permeability coefficient of the drug across the specific
membrane of interest, our technique offers an alternative to traditional drug transport assays
such as octanol-partition coefficients, or the parallel artificial membrane permeability assay
(PAMPA) which suffer from multiple drawbacks [164, 190]. Thanks to the microfluidic
character of our method, we require only very small reagent volumes in the microliter
range for our measurements [191]. Specifically, we only require approximately 70 µg
of each fluoroquinoline drug for each run of the microfluidic chip. Another advantage
of the integrated on-chip technique presented here over previously published optofluidic
permeability assays lies in the benefits of controlling liposome formation with OLA. OLA
allows the formation of large numbers of liposomes with physiological salt concentrations
and with complex lipid mixtures. Other techniques such as electroformation suffer from very
low yields in this environment [23], or in the case of other microfluidic techniques, require
extensive procedures to remove oil remnants associated with the production [56]. Moreover,
OLA allows for the efficient encapsulation of desired solutes inside the vesicles upon
production [56, 69]. This makes it an interesting technique for biosensor-based approaches
to detect drug molecules. The encapsulation approach has successfully been performed by
Kuhn et al. to measure tetracycline transport across lipid bilayers [163]. However, their
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experiments were performed using populations of small unilamellar vesicles (SUVs) of
under 200 nm in radius, whereas we can work with GUVs and analyse drug transport on the
single vesicle level. We will present such an encapsulation approach to measure membrane
permeability in the next chapter.
We performed transport studies on an NBD-labelled derivative of ciprofloxacin and compared
the permeability coefficient we obtained to that of the native version of the drug. We measured
a permeability coefficient for NBD-ciprofloxacin (mean ± S.E.) of 4.9 ± 0.2 × 10−6 cm/s
which lies within the error of the value we obtained previously for the unlabelled ciprofloxacin.
However, we also found that our measurements were affected by the solvatochromic be-
haviour of the NBD-label. This dye increases its fluorescence drastically in the hydrocarbon
phase of the bilayer, leading to the formation of a fluorescent ring around the vesicles. More
studies are necessary to conclude wether or not these fluorescence properties skew the ob-
tained permeability coefficients to higher numbers. For future permeability studies with
labelled molecules, it is advisable to use other, environmentally non-sensitive, fluorophores.
Furthermore, the introduction of a different imaging technique, such as confocal detection
could provide better means to study the permeation of fluorescently labelled compounds.
The microfluidic platform presented here is not bound to a specific form of visualisation such
as fluorescence. Since the optics and the microfluidics are decoupled from one another, the
platform can be combined with different approaches of label-free drug visualisation, which
is a field in its own right with various different methods published [192–195]. In Chapter 6,
we will explore other forms to visualise solute molecules in order to study non-fluorescent
molecules in the future.
While passive diffusion across lipids is an important element in bacterial drug uptake, it is
known that porin-mediated uptake plays a crucial role in drug permeation across the outer
membrane [20, 21]. Mutations of membrane proteins have furthermore been associated with
antibiotic resistance [21, 196]. The incorporation of these protein channels into liposomal
membranes is an attractive target for the study of drug uptake [20]. However, to integrate
this with on-chip liposome formation requires the development of on-chip protein recon-
stitution techniques, which are still pending. The successful insertion of the pore forming
toxin α-hemolysin into the membrane of OLA generated liposomes [56] suggests that the
microfluidic platform can be extended to form and study more complex lipid compositions
and even proteoliposomes on chip, potentially offering an alternative to current reconstitution
techniques [197].

Chapter 5
Towards Ion Transport through DNA
Nanopores 1
5.1 Motivation
After quantifying the transport of small antibiotic molecules across lipid membranes in the
previous chapter, we will turn to a different kind of membrane transport in the following
sections. In the work presented below, we will use microfluidic tools to investigate the
transport of ions, specifically, if novel DNA nanostructures are capable of forming channels
for hydrogen ions (protons) to cross the membrane.
As we discussed before, lipid membranes are generally considered to be impermeable to
charged molecules and ions [4]. We provided an illustration of this in the previous chapter,
when we showed that norfloxacin molecules cannot penetrate the membrane in their charged
form. In nature, charged molecules and ions cross biomembranes either via facilitated
diffusion or active transporters. Salts typically cross the membrane via bilayer spanning
proteins called ion channels [4, 21, 15]. Cells use these transporter proteins to regulate the flux
of ions into and out of the cell and maintain their salt homeostasis [4]. The precise balance
of salts is crucial for the survival of the cell and is highly regulated. The malfunction of these
processes can give rise to a number of diseases, which are called channelopathies [19, 198].
One example of a well-known channelopathy is cystic fibrosis (CF). Patients with this disease
suffer from an abnormal production of mucus, which leads to further complications in other
1Elements of this chapter have previously been published in Al Nahas et al., Lab Chip, 2019, 19, 837-
844 [69]
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organs, typically the lung and the pancreas [199]. However, it has been shown that the
underlying cause of CF is the mutation of a regulator gene, leading to an altered expression of
epithelial chloride channels [199, 200]. In other diseases, different ion channels are affected.
Patients of Dravet’s syndrome, for instance, carry a mutation that leads to the development
of dysfunctional sodium channels [201]. This disease manifests itself via severe epilepsy and
seizures [202]. For many channelophaties there exists no cure to date [203]. Ion channels
for salts like sodium or chloride are therefore an interesting field of study with important
medical implications.
Ion channels do not only exist for physiological salts like sodium, potassium or chloride, but
also for protons. Postulated in 1972, proton channels were found in 1982 by voltage-clamp
measurements on snail neurons [204–206]. However they are also present in the human
body [204, 207]. The role of proton channels has been a topic of intensive debate in the
scientific literature. Based on the findings that proton channels are highly selective and
regulated by pH gradients [208], DeCoursey et al. argue that their main functions are the
modulation of the membrane potential, regulation of internal and external pH and osmotic
balancing [209]. In the human body, malfunctions of proton channels are believed to be
linked to neurological diseases and cancer [207].
However, channel proteins are not the only mechanism of facilitated diffusion for protons
and other ions. Other ways for ions to cross the membrane include using ionophores.
Ionophores are typically lipid soluble molecules that bind to the ion on one side of the
bilayer, carry it across the bilayer and release it on the other side [210]. Ionophores that carry
protons are termed protonophores. They can, for instance, effectively short circuit the proton
pump mechanism in cells. One example of a protonophore is the small organic molecule
indole [211]. It has been shown to stop bacterial cell division by dissipating the membrane
potential [212]. The membrane dissipating property of protonophores makes them potential
candidates for novel antimicrobial agents. In fact, some protonophores are being tested for
the treatment of methicillin-resistant Staphylococcus aureus [213].
Other intensively studied channel proteins are proton pumps. These transmembrane proteins
are active systems and regulate the proton flux across membranes against a chemical gradient,
typically requiring an energy source like ATP to do so [4, 214]. An example for a proton
pump is the H+/K+-ATPase system, which is found in cells of the inner stomach lining. This
pump uses ATP to actively pumps cytoplasmic hydronium into the intestine, thereby lowering
the pH of the stomach contents [214]. However, proton pumps can also generate ATP from
existing proton gradients. A prominent example of this is found in the cell respiration process
of eukaryotes. The mitochondria inside these cells contain a double membrane that separate
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the mitochondria’s inside, called the mitochondrial matrix, from the cytosol. Within the
mitochondria, there exists a proton gradient between the mitochondrial matrix and the inner
membrane. This proton gradient gives rise to a proton-motive force. The protons flowing
back into the mitochondrial matrix drive the transmembrane protein ATP synthase which
catalyses the generation of ATP [215, 216].
The examples we listed above show that electrochemical proton gradients across lipid
membranes play an important role in biological systems. Furthermore, they exemplify
that the modulation of ion gradients across the membrane has many potential applications,
especially in the field of medicine. As a crucial element of natural cell membranes, ion
channels are also of interest to other fields of science, such as synthetic biology. This field
aims to (re)create biological systems via the synthesis or assembly of artificial or natural
components [217].
One interesting approach that is used in synthetic biology for the de novo assembly of
biological structures is DNA nanotechnology [218]. First conceptualised by Nadrian Seeman
in the early 1980s, DNA nanotechnology enables the design and assembly of nanoscale
structures using DNA as building material [219]. Several techniques are summarised under
the term DNA nanotechnology and almost all of them make use of the strict Watson-Crick
base pairing rules of DNA to assemble the structures [220]. The structure of DNA and
the base pairing rules are depicted in Figure 5.1A. The backbone of the DNA molecule
consists of two single strands which are connected by pairs of nucleotide bases to form a
double helix [220]. The four nucleotide bases are adenine, thymine, guanine and cytosine.
Importantly, adenine binds to thymine and guanine to cytosine. Two single strands of DNA
hence need to possess complementary base sequences to bind together [4]. A prominent
technique that exploits this property of DNA for the construction of arbitrary shapes is called
DNA origami [221]. Schematically shown in Figure 5.1B, DNA origami uses short single
DNA strands, called “staple” strands, to fold a long single DNA strand, called a “scaffold”
strand, into the desired structure [221, 222].
DNA origami structures in solid state nanopores have been presented by Bell et al. in
2012 [223]. Shortly after, Langecker et al. successfully inserted a DNA origami nanopore
into a lipid bilayer and showed that it can act as a membrane channel [224]. In the following
years, bilayer-spanning DNA pores have been presented by several other groups [225, 226].
In 2015, Göpfrich et al. introduced a DNA structure with dimensions comparable to those of
naturally occurring ion channels [227]. The nanopore used by Langecker et al. was assembled
via DNA origami and required a kilobase long scaffold and ≈200 staple strands [224]. In
contrast to that, the DNA pore by Göpfrich et al. was a so called non-scaffolded DNA
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structure, where the scaffold strand is omitted and the short single DNA strands bind directly
to each other to form the nanopore. The advantage of non-scaffolded structures is a greatly
simplified assembly process compared to classical DNA origami. In our studies below, we
used a modification of the non-scaffolded DNA pore [227], which was presented by Ohmann
et al. in 2018 [121].
Fig. 5.1. (A) Structure of the DNA molecule. Two single strands of a phosphate-sugar
backbone are connected via nucleotide base pairs. The base pairing follows strict rules with
adenine only pairing with thymine and guanine binding to cytosine. (B) A target structure
like a smiley face can be assembled via DNA origami. The technique makes use of the strict
base pairing rules according to which two single DNA strands bind together if they possess
complementary base sequences. Short single DNA strands called staple strands can therefore
be used to fold a long single DNA strand called a scaffold strand into the desired shape.
Images adapted from [9] and [222].
In the following sections we will explore proton transport into GUVs using DNA nanopores
as channels. Before we discuss our own experiments, we will first briefly present the
DNA nanostructure that we use in our experiments, followed by the introduction of a new
microfluidic perfusion platform which we use to carry out our measurements.
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5.2 DNA Nanostructures
5.2.1 Nanopore Design
The nanopore we use for the experiments is a non-scaffolded DNA structure designed by
A. Ohmann [228]. The pore consists of eight single DNA strands which assemble into four
interconnected DNA duplexes. Similar to the square packing of four cylinders, the DNA
duplexes have an opening at the centre point of the structure, as seen in Figure 5.2A. The
entire structure has a length of approximately 13.1 nm and a width of 5 nm. The hole in
the middle of the structure is approximately 0.8 nm in diameter [228]. The DNA structure
can furthermore be functionalised with up to two fluorescent labels as well as up to two
cholesterol anchors. The cholesterol anchors are consciously placed in the middle section
of the DNA structure so that the pore effectively spans the entire bilayer if both cholesterol
anchors are inserted in the membrane [228]. The strand layout is depicted in Figure 5.2B.
The DNA sequence of the individual strands is given in Appendix C1. A schematic of the
bilayer inserted DNA pore can be seen in Figure 5.2C. Both cholesterol tags are necessary
for the DNA pore to effectively insert into the membrane. DNA structures with only one
cholesterol tag merely attach to the membrane but do not orient themselves in such a way
that they span through the bilayer [228]. DNA pores without any cholesterol anchors neither
insert into, nor attach onto the lipid membrane [229].
Fig. 5.2. (A) Side and top view of the DNA structure. The structure is made up of four
double helix bundles linked together. The height of the structure is approximately 13 nm. It
features two cholesterol anchors shown in red. Similar to four cylinders in a square packing,
the structure has an opening in the middle spanning approximately 0.8 nm. (B) Layout of the
strand design. The pore is made up of eight single DNA strands which bind together to form
the structure. (C) Proposed position of the DNA pore inserted into a lipid bilayer. Image
adapted from [121] and [228].
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The pore design, depicted in Figure 5.2, has shown to promote lipid flipping between the
two leaflets, when inserted into a bilayer [121]. Furthermore, it has been used to investigate
the aggregation of cholesterol-tagged DNA structures [230]. Most importantly though,
electrophysiological measurements with the DNA pore inserted into a lipid bilayer have
successfully shown ion translocation through the pore [228].
5.2.2 Electrophysiological Measurements
The electrophysiological measurements on the DNA pores have been performed by A. Ohmann
[228] using black lipid membranes (BLM), a technique which found widespread use in the
investigation of ion channels and other transmembrane proteins [160]. The experimental
setup for the black lipid membranes (BLM) is schematically depicted in Figure 5.3A. Two
aqueous reservoirs are separated by a small aperture, which is covered by a lipid bilayer
[160, 231]. The size of the aperture can range from several microns to millimetres [160].
Other methods such as pipette aspiration work in a similar fashion, however, here a bilayer is
formed at the tip of a micro or nano pipette [231]. A voltage is applied across the bilayer
via two electrodes that are immersed in the liquid reservoirs and the resulting current trace
recorded. After the DNA structures are applied to one side of the aperture, the insertion
of these structure into the bilayer, as seen in Figure 5.3B, leads to a distinct jump in ion
conductance [232]. Interestingly, the current traces of the DNA pores also express short,
discrete drops in conductance, resembling the gating of naturally occurring ion channels [4].
Göpfrich et al. explain this behaviour with the flipping of the DNA pore from a complete
spanning of the bilayer to a mere attachment of the pore to the membrane. While the pore
spans the entire bilayer, ions can be conducted through the membrane, whereas the conduc-
tance drops once the DNA pore is no longer in this configuration [227]. An example current
trace showing both the insertion of the DNA structure into the membrane, as well as the
gating-like behaviour of the pore is shown in Figure 5.3C.
In the experiments below, we want to use microfluidically assembled GUVs and fluorescent
ion tracers instead of electrophysiological methods to show the translocation of ions through
the nanopore. While we do not apply a constant electric potential in these experiments, we
should be aware of the fact that electric fields are still present in this system. Concentration
differences of ions between the inside and outside of the membrane give rise to electrochemi-
cal gradients and therefore an electric potential [4]. Nevertheless, the optical detection of ion
transport into GUVs is a different approach to previous methods and can therefore provide
further evidence for the function of DNA nanopores.
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Fig. 5.3. Electrophysiological experiments conducted on a DNA nanopores. (A) Schematic
of Black Lipid Membrane (BLM) experimental setup. Two aqueous reservoirs are separated
by an aperture, which is sealed by a lipid bilayer. A voltage is applied via two electrodes
immersed in the aqueous reservoirs and the resulting current recorded. (B) Schematic of
aperture with DNA pore inserted into the lipid bilayer. (C) Example current trace showing a
discrete jump in current as the DNA pore inserts into the membrane, and a drop, as the DNA
pore returns to a low-conducting state. Short drops in conductance resemble gating as also
observed in natural ion channels [4]. It is believed that the conducting behaviour is linked to
the arrangement of the DNA pore in the membrane and the high conducting state reached
when the pore is configured such that it fully spans the bilayer. Images (B) and (C) adapted
from [228].
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5.3.1 The Need for a Different Microfluidic Assay
As discussed above, the DNA pore has been successfully used for a number of experimental
studies, including electrophysiology [228] and scramblase experiments on lipid vesicles [121].
A result of these experiments was the observation that the DNA pores suffer from low
insertion efficiency in GUV membranes. This behaviour has also been observed by other
groups working with DNA origami pores [233]. For instance, Langecker et al. report that
voltage pulses were necessary for pore insertion in their electrophysiology experiments [224].
The high activation barrier likely stems from the significant rearrangement of the lipid
bilayer that is necessary to insert the negatively charged pore in it [233]. Established
protocols to insert the DNA pores in GUVs therefore require incubation periods of 1 hour or
more [121, 228].
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Attempts to use the permeability platform from Chapter 4 in conjunction with DNA pores
to study sodium transport were trialled by K. Jahnke [229]. In his experiments, K. Jahnke
encapsulated DNA pores inside OLA GUVs and mixed them with a sodium solution at the
T-junction. Visualisation of the sodium occurred via a fluorescent sodium indicator [234].
However, he was ultimately not able to observe transport of the ions into the GUVs. He
attributed this to the short period of time that the vesicles were incubated with the DNA pores.
After production, the vesicles in the permeability platform typically reach the T-junction
in less than 5 minutes, much shorter than the incubation times used by Ohmann et al. in
their successful experiments [121]. Furthermore, his experiments were impeded by the low
fluorescence signal and photo bleaching of the sodium indicator [229].
The investigation of the ion transport through DNA nanopores therefore requires a platform
that allows us to incubate the GUVs with the nanostructures for time scales of hours. Another
prerequisite is the use of very photo stable ion indicators, to avoid the issues of photo
bleaching.
In 2019, Al Nahas et al. presented a microfluidic perfusion platform that allows the on-chip
formation of GUVs with OLA and their subsequent immobilisation using vesicle traps. The
trapped vesicles can be perfused with a substance of interest and observed over time scales
of many hours. In their original publication, Al Nahas et al. perfused trapped GUVs for
time scales of up to 10 hours which can even be extended if needed [69]. Furthermore, the
microfluidic protocol uses the fluorescent dye HPTS. HPTS is not just a fluorescent pH
indicator [235], it is also a dye known for its high photo stability. For instance, HPTS is
the basis for several “super-photoacids” [236] that are used in ultrasensitive fluorescence
spectroscopy.
The assay therefore fulfils the requirements we set to the experiments in respect to photo
stability and incubation time of the vesicles. In the following section we will explain the
principle of the perfusion assay, before we discuss how we will use the platform to test for
proton transport through DNA nanopores.
5.3.2 Principle of the Perfusion Assay
Microfluidic Chip Design
The working principle of the chip is illustrated in Figure 5.4. The chip features a two level
design. The OLA junction for vesicles production as well as the perfusion part, which
features the vesicle traps, are located on the bottom layer. This bottom layer is drawn in blue
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in Figure 5.4. In contrast to the design that we have used previously, the OLA part does not
feed the GUVs directly into the perfusion part. Although the OLA junction and the perfusion
part are both located on the bottom layer, they are not directly connected. Instead, the two
are coupled via a second-level connector chip located on top of the first PDMS chip. The
second-level connector is indicated in red in Figure 5.4.
Fig. 5.4. Principle of the microfluidic perfusion platform. The microfluidic device has a
two-level design. The bottom layer, drawn in blue, features the OLA design, as well as a
perfusion design consisting of 8 chambers with 372 vesicle traps each. The OLA part and
the trapping part are connected by a second-level connector chip, drawn in red. The chip
is operated in a two-step process. The first step consists of the production and trapping of
vesicles. The liposomes are produced at the OLA junction. From there, the vesicles travel
upwards into the second-level connector chip via a vertical channel. From the connector
chip, the vesicles enter the perfusion part of the chip, by applying suction via outlet A. The
octanol droplets, which are present in the fluid stream as a by-product of liposome formation,
remain in the connector chip due to their lower density compared to the water-filled GUVs.
The octanol droplets leave the chip via outlet B, while the GUVs are immobilised in the
vesicle traps located in the perfusion chambers. After a sufficient number of vesicles has
been trapped, the GUVs are perfused with a substance of interest in a second step. For this,
outlet B is blocked and the substance is flushed in via the perfusion inlets. The interaction
with the immobilised vesicle can be observed in the trapping chamber. Image modified
from [69].
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Al Nahas et al. filled the perfusion chambers with a trap design that has previously been
presented by Kazayama et al. [237]. A schematic of the trap design is shown in Figure 5.5A.
The traps have a semicircle shape with a gap in the middle. The basket-like design allows for
the effective immobilisation of the vesicle once it has entered the trap. The gap between the
two trap components is necessary to allow sufficient liquid flow through the centre of the
trap to let a vesicle move into a trap. The traps are optimised to capture vesicles of diameters
20-25 µm, which we can obtain with OLA. Figure 5.5B shows an image obtained from a
fluorescence microscope featuring immobilised vesicles with the HPTS dye encapsulated
inside the GUVs.
Fig. 5.5. (A) Schematic of trap design. The basket-shaped vesicle traps are designed such
that vesicles of diameters ranging between 20 – 25 µm are immobilised in them. The spacing
of the traps is approximately 26 µm, whereas the gap size between the two trap components
measures approximately 5 µm. The values are optimised such that the vesicles cannot squeeze
through the gap, but enough flow is present to allow vesicles to enter the trap. (B) Image of
the perfusion chamber with immobilised GUVs in the traps. The fluorescent dye HPTS is
encapsulated inside the vesicles (λex = 488 nm). Images adapted from [69].
5.3.3 Chip Operation
The operation of the microfluidic device consists of two steps. In the first step, the vesicle
traps are filled with GUVs. Vesicle production occurs in the OLA part of the microfluidic
device. This happens in a similar fashion to that described in Chapter 3 using pressure
driven Fluigent pumps. After production at the OLA junction, the vesicles flow downstream
and enter a hole which was punched into the microfluidic chip at the end of the channel.
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The punch serves as a vertical channel and allows the vesicles to flow upward into the
connector chip. Among other functions, which are explained in more detail below, the
connector chip serves as a reservoir for the GUVs. From the connector chip, the GUVs
can enter the perfusion/trapping part of the microfluidic device. This part of the chip is
likewise connected to the connector chip via punches serving as vertical channels for the
GUVs. Suction is applied via outlet A using a flow-driven syringe pump (neMESYS, Cetoni
GmbH). This forces the vesicles down into the perfusion part of the chip which is made
up of 8 perfusion chambers containing 372 vesicle traps each. After a sufficient number of
GUVs have been trapped (in our case we aimed for approximately 80% of the traps filled),
the vesicle production is stopped and the syringe pump is disconnected from outlet A. This
marks the beginning of the second step of the experimental protocol.
In the second step, the vesicles are flushed with a substance of interest via the perfusion inlets.
However, before perfusion of the trapping chamber is started, the second-level outlet B is
blocked. This is achieved by setting a microfluidic switch that is connected to this outlet to
the “closed” mode. The switch system (2-Switch, Fluigent SA, France) has two states. In
the “open” state, the switch allows a fluid stream to pass through unhindered. In the “closed”
state, the switch effectively blocks all fluid streams. The blocking of outlet B ensures that
the substance entering through the perfusion inlets in fact continues to flow into the trapping
chambers and does not flow upwards into the connector chip towards that exit. The perfusion
flows are again controlled using a pressure-driven Fluigent pump. There exist four different
perfusion inlets. The channel of each perfusion inlet bifurcates and flushes two chambers
and the trapped vesicles within them. Up to four different substances can hence be tested on
the same batch of vesicles, by using a different solution in each individual perfusion inlet.
After the perfusion has been initiated, the interaction between the solute and the immobilised
vesicles can be observed in the trapping chambers [69].
Note that we used two versions of the microfluidic chip in the experiments below. They are
identical in basic design and operation procedure. However, one design features 8 chambers
with 372 vesicle traps each, whereas the second design features 8 chambers with 744 traps.
In the first design, the flow from one perfusion inlet bifurcates and perfuses two trapping
chambers, while each trapping chamber has a separate perfusion inlet in the second design.
Schematics of both chip designs can be found in Appendix C.6.
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5.3.4 Advantages of the Two-Level Design
As indicated above, the use of a second-level connector chip has several advantages associated
with it. One of the advantages is its use as reservoir from which the vesicles are drawn to fill
the traps. This eliminates the need to extract the liposomes off chip and reintroduce them
into a different device [69]. The connector chip approach furthermore simplifies the device
fabrication, as the OLA junction must be treated with PVA in order to enable GUV formation.
However, Al Nahas et al. found that PVA treatment can render the traps dysfunctional,
if coating materials such as PVA solidify between the trapping microstructures [69]. By
separating the perfusion part and the OLA part and linking them together with a separate
connector chip later, the PVA treatment of the OLA section can be performed without PVA
entering the trapping and perfusion system. Lastly, the use of a second-layer connector
chip is also an effective way to separate the GUV population from the octanol droplets,
which are present in the fluid streams as a by-product of vesicle formation with OLA [56].
Schematically drawn in Figure 5.6, the microfluidic device uses the density-based approach
for GUV purification, which we already discussed in the previous chapter. As we see in
Figure 5.6, both GUVs and octanol droplets enter the connector chip after generation at the
OLA junction. However, when suction is applied via outlet A, only the water-filled GUVs
are driven down into the trapping chambers, whereas the low-density octanol droplets remain
in the top-level connector chip and leave the chip via outlet B.
Fig. 5.6. Separation of GUVs and octanol droplets in second-level connector chip. GUVs
as well as octanol droplets enter the connector chip via a 750 µm punch which serves as
a vertical channel. By applying suction from the bottom-level outlet, the GUVs are pulled
down into the chamber containing the vesicle traps, where the GUVs are immobilised. Due
to the lower density of the octanol droplets compared to the water-filled GUVs, the droplets
remain in the connector chip and flow towards a second outlet located on the connector chip.
Image from [69].
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5.3.5 Data Acquisition and Image Processing
The microfluidic chip is run on an epifluorescence microscope (Olympus IX 73) equipped
with an EMCCD camera (Evolve 512, Photometrics), an LED light source (wLS LED,
Q-Imaging) and a programmable piezo stage (ProScan III, Prior Scientific Instruments, UK).
The chambers are imaged using a 10× objective (UPLFLN, Olympus). This setup allows for
the systematic scanning of the perfusion chambers to observe the trapped vesicles using the
microscope’s epifluorescence capabilities.
Fig. 5.7. Array of trapped vesicles, exemplifying the drop in fluorescence upon perfusion
with a 5 µM solution of the pore forming peptide CecB. After approximately 60 minutes
of exposure to the peptide, the dye begins to leak out from the vesicles, lowering their
fluorescence intensity. The average normalised intensity of the trapped vesicles is drawn in
the graph below. Scale bar 50 µm. Image from [69].
As stated before, Al Nahas et al. designed the platform for testing the efficacy of antimicrobial
peptides. Pore forming peptides can be designed to specifically target bacterial membranes
where they accumulate and lead to cell lysis [69]. The perfusion platform allows for the
investigation of this behaviour of peptides. For this purpose, Al Nahas et al. encapsulate the
fluorescent dye HPTS inside the vesicles upon production. When the peptides are flushed
in via the perfusion inlets, they lead to the disintegration of the vesicle membrane causing
leakage of the dye and ultimately bursting of the vesicle. An array of such trapped vesicles
with the fluorescent dye inside can be seen in Figure 5.7. As the vesicles are perfused with
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the peptide Cecropin B (CecB), they gradually lose their internal fluorescence. The drop
in vesicle fluorescence that is associated with this process is recorded and analysed. The
tracking of large numbers of vesicles in such a way provide a good metric to evaluate and
compare the efficacy of antimicrobial peptides [69].
In the next section, we will discuss how we use the microfluidic perfusion assay to assess
whether or not DNA nanopores can mediate proton transport across vesicle membranes.
5.4 Measurement of Proton Flux
5.4.1 Experimental Procedure
Upon production, we encapsulate the fluorescent and photo stable dye HPTS inside the
vesicles. Using the perfusion platform, we fill the vesicle traps with the generated GUVs,
as described above. The platform features four perfusion inlets, each of which flushes two
trapping chambers. We can therefore perform both the DNA pore experiments and the control
experiments on the same batch of vesicles. We perfuse half of the chambers with the DNA
structure and flush the other half of the chambers with a buffer control void of the DNA
pores. In a second perfusion step, we change the perfusion solute and expose the trapped
vesicles to a solution of low pH. As we know, the pH is defined as the negative decadic
logarithm of the proton concentration of a solution: pH =− log10(c(H+)). Furthermore, we
know that acids, with a low pH value, serve as proton donors [238]. We therefore obtain a
concentration difference in protons between the vesicles outside, which is perfused by a low
pH solution, and the vesicle’s inside which encapsulates buffer of a higher pH. Proton flux
across the membrane manifests itself via a pH shift inside the vesicles.
Under the assumption that the lipid bilayer provides an effective barrier for the protons, we
only expect to see a shift in pH in the vesicles that have been incubated with the DNA pores,
as the protons can use these as channels to cross the membrane. The control group would
maintain the pH gradient or decrease at a much lower rate due to diminutive leakage of ions.
As we will see later, protons represent a special case of ion movement across membranes
and proton leakage plays a much larger role than we initially anticipated. However, for the
design of the experiment we assumed that passive proton permeation through the bilayer is
small compared to potential movement through DNA pores.
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We make use of the properties of the HPTS dye which is encapsulated inside the GUVs to
assess the flux of protons across the bilayer. This is possible because HPTS is a fluorescent
pH indicator. A pH drop in a solution containing HPTS is associated with a decrease in
fluorescence intensity [235, 239]. We confirmed this by measuring the fluorescence of a PBS
buffer with 50 µM HPTS in a range from pH 5.9 to pH 7.4, shown in Figure 5.8. We can
see that a drop of pH from 7.4 to 5.9 results in an approximately linear, 9-fold decrease in
the fluorescence of HPTS. For the measurement, the pH of the buffer solution was adjusted
by adding small amounts of hydrochloric acid (37%) to the solution and confirmed using a
digital pH meter (Hanna Instruments, UK). The fluorescence signals were obtained using
a fluorimeter (Eclipse, Varian; slit size 5 nm) and are the peak emission values (λem range
500–600 nm) upon excitation at λem = 488 nm.
Fig. 5.8. (A) Chemical Structure of HPTS. (B) Fluorescence intensity curve for HPTS. The
x-axis shows pH value of the solution, the y-axis the fluorescence intensity. The fluorescence
of a 50 µM HPTS solution is highest for neutral pH and decreases for more acidic pH levels.
At pH 5.9 the fluorescence intensity decreased to approximately 10% of the fluorescence
at neutral levels (pH 7.4). The single data points are the peak emissions of individual
measurements with λex = 488 nm and an emission range from 500 – 650 nm.
This property of HPTS allows us to perform the proton transport experiments using the
tools that were developed by Al Nahas et al. for the study of antimicrobial peptides. In the
case of perfusion with peptides, a drop in fluorescence is the results of dye leakage due to
peptide-induced membrane poration. In our experiments, we perfuse the vesicles with a low
pH solution (pH 5.9) instead of peptides. A drop in fluorescence indicates a pH shift inside
the vesicle as a result of proton flux.
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5.4.2 Materials and Methods
Chip Fabrication and Preparation
The microfluidic chips were made of polydimethylsiloxane (PDMS) following the protocol
presented in Sections 2.4.2 and 4.4.2. The silicon master chip was designed and fabricated by
K. Al Nahas as previously described [69]. Note that we used two versions of the perfusion
assay design, both of which can be found in Appendix section C.6. The two chip designs are
identical in operating principle, but differ in the amount of vesicle traps per chamber. One
design contains 372 vesicle traps per chamber, whereas the second design features enlarged
perfusion chambers that hold 744 vesicle traps each. We performed one experiment on the
version with the smaller perfusion chambers and two experiments using the chip with 744
vesicle traps.
The first level of the microfluidic chip was plasma bonded (100 W, 10 s exposure, 25 sccm,
plasma oven from Diener Electric, Germany) onto a PDMS coated glass slide (76 mm ×
39 mm and 1 mm thickness). The OLA junction of that chip was then PVA coated using a
5% PVA solution as described in section 2.4.2 using a Fluigent pump and baked in the oven
at 120°C for 15 minutes. The connector chip was PVA coated by hand by spreading 10 µL
of PVA (10 mg/mL) on the open channels using a pipette tip. The connector chip was then
likewise baked in the oven for 1 hour at 60°C. After both, the first layer chip and connector
chip have been PVA coated and cured in the oven, the connector chip is plasma bonded on
top of the first layer such that it bridges the vertical channels from the OLA and the perfusion
part.
Solution Composition
The DNA strands were sourced from Integrated DNA Technology (IDT) and assembled
according to an established folding protocol [228] given in Appendix C.2. Folding occurred
in TE20 buffer (10 mM Tris, pH 8.0, 0.1 mM EDTA) containing an additional 20 mM MgCl2,
which is necessary for the stability of the DNA structure. The folding process yielded a
1 µM stock of DNA structures which we diluted with the basic OLA stock solution to a final
concentration of 50 nM. We validated the correct folding of the DNA structures prior to our
experiments via gel electrophoresis. An example of this is given in Appendix Figure C.1.
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We formed the GUVs using the same standard stock solution we also used in our drug
transport experiments. The basic stock consisted of 200 mM sucrose and 15% v/v glycerol in
PBS buffer (pH 7.4). The IA phase was made up of the base stock but contained an additional
50 µM HPTS dye. As before, the OA was made up of the base stock with 50 mg/mL P-188.
The LO phase consisted of 4 mg/mL DOPC in 1-octanol.
The DNA perfusion solute was similarly made up of the base stock, but contained an
additional 20 mM MgCl2 and 50 nM of the DNA pores. The buffer control was identical to
the DNA perfusion solute but contained 50 nM of the folding buffer without the DNA pores.
Using the separate perfusion chambers, we always performed experiments on both the DNA
pores and a buffer control on the same chip.
The low pH buffer to which we exposed the vesicles in the second perfusion step was
similarly made up of the base stock with 20 mM MgCl2. However, we lowered the pH of this
solute to 5.9 by adding HCl (37%) to the solution. The pH of all solutions was checked and
adjusted before every experiment using a digital pH meter (Hanna Instruments, UK). The
low pH solution furthermore contained either 5 µM or 20 µM of HPTS as a fluorescent tracer.
The slight background fluorescence marks the arrival of the low pH solution in the trapping
chamber.
The exact solutions for all experiments are again listed in detail in Appendix C.4. All
solutions were obtained from Sigma Aldrich, unless stated otherwise.
Pressure Control and Vesicle Perfusion
We formed and trapped GUVs using the perfusion assay as described in section 5.3.3. A
detailed description of the experimental protocol including the necessary pressures and flow
rates is given in Appendix section C.5.
The procedure for the two perfusion steps is depicted in Figure 5.9. In the first perfusion step,
we flush the chambers with the DNA pore solution and a control solution, respectively. In the
second perfusion step, we flush the chambers with a PBS solution that is adjusted to pH 5.9.
Importantly, when we switch to the second perfusion step, we do not remove the tubing that
is connected to the microfluidic device. Instead we exchange the vial carrying the fluid in the
Fluiwell system. This allows us to change the perfusion liquid without unplugging the tubing
from the microfluidic device. However, at this moment, the tubing that connects the fluid
reservoir to the microfluidic chip is still filled with the DNA pore/buffer solution from the
first perfusion step. The low pH solution does not arrive in the perfusion chamber until all the
remaining DNA pore solution present in the tubing is pushed through the microfluidic chip.
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Fig. 5.9. Procedure of chip perfusion. (A) In the first perfusion step, we perfuse half of the
chambers with the DNA pores and the other half with a buffer control solution. (B) The vials
with the DNA/control are exchanged for vials containing the low pH solution. The tubing
connecting the fluid reservoir to the chip is still filled with the initial DNA/control solutions
which continues to be perfused through the chip. (C) The second perfusion step begins once
all the remaining DNA/control solution has been flushed through and the low pH solution
reaches the chambers with the immobilised vesicles. Since the low pH solution contains a
small amount of fluorescence tracer, its arrival in the perfusion chambers is marked with a
slight increase in background fluorescence.
We found the method shown in Figure 5.9 to be the only feasible way to change the perfusion
liquid. Unplugging of the tubes causes movement of the liquid in the microfluidic chip and
this perturbance is severe enough to flush out the vesicles from their traps. Furthermore,
removal and reinsertion of tubing into the microfluidic chip can introduce air bubbles which
disturb the flow patterns in the chip and can lead to heterogeneous perfusion of the chambers.
We always applied the same pressure for the first (DNA/buffer) and second (low pH) perfusion
step. In total we conducted 3 experiments. Perfusion in the first two experiments occurred
at 10 mbar and 8 mbar per chamber, respectively. The third experiment was perfused at
4 mbar. The effective perfusion times that resulted from these pressures are given in Table 5.1.
We reduced the perfusion pressure with every experiment, as we observed that the higher
perfusion rates caused the flushing out of vesicles from the traps, reducing the overall vesicle
count. The small amount of HPTS that we added to the low pH solution allows us to
determine the time point at which all remaining DNA solution from the tubing has been
pushed through the chip and the low pH solution hits the vesicles. This moment is indicated
by a slight increase of background fluorescence. After arrival of the low pH solution we
observed the fluorescence of the vesicles in the individual chambers for another 400 minutes.
Note that within the individual experiments there are differences in the exact time point
when the low pH solution arrives in the different chambers. The spread increases for
the experiments with lower perfusion pressures. We observed the largest difference in
Experiment 3, where the difference between the first and the last arrival of the low pH
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solution was 100 minutes. The reason for the spread in arrival time is due to small differences
in fluidic resistance in the different channels, which we attribute to variations in tubing length
or the connection to the microfluidic chip. We tried to minimise this by using tubing with the
same 5 cm length for all perfusion chambers. However, we cannot rule out the possibility of
a partial blockage of one of the perfusion channels. Partial blockage would lead to an overall
lower flow rate in the perfusion chamber that is fed by this particular channel. This might
have been the case in one perfusion chamber in Experiment 3, leading to the late arrival time.
Table 5.1. Solution composition for confocal micrographs of OLA and electroformed
vesicles.
Experiment Perfusion 1DNA pores/buffer control
Perfusion 2
pH 5.9 solution
Experiment 1 250 - 260 min 400 min
Experiment 2 240 - 300 min 400 min
Experiment 3 300 - 400 min 400 min
Data Acquisiton and Analysis
After switching the vials for the low pH solution, we started image acquisition. The mi-
crofluidic chip was operated on an epifluorescence microscope (Olympus IX 73) equipped
with an EMCCD camera (Evolve 512, Photometrics), an LED light source (wLS LED,
Q-Imaging) and a programmable piezo stage (ProScan III, Prior Scientific Instruments, UK).
The chambers were imaged using a 10x objective (UPLFLN, Olympus). We programmed
the piezo stage to systematically scan the perfusion chambers. Experiment 1 featured 40
recording positions; each position was recorded once every 30 seconds. Experiments 2 and 3,
which were run on a device with larger perfusion chambers, featured 64 recording positions,
each of which was recorded once every minute.
The intensity values of the individual vesicles were extracted using a python routine2. The
basic algorithm is depicted in Figure 5.10. The script identifies the vesicles in the input video
file and assigns unique labels to the individual vesicles. The intensity value of a 4×4 pixel
box around the vesicle’s centre is then averaged and extracted.
We smoothed the extracted intensity data with a Savitzky–Golay filter. Furthermore, we
excluded vesicles that burst or escape the traps from the data. Burst or escaped vesicles
manifest themselves via a sudden drop in fluorescence, rather than a steady decay. Finally,
2The python routine used for the data analysis was developed by M. Fletcher.
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we excluded all vesicles in chambers that show an inhomogeneous background profile, which
indicated unsteady perfusion with the low pH solution. An image of the desired background
profile is shown in Figure 5.11 of the next section where we discuss the background signal in
more detail.
Fig. 5.10. Python routine to extract the vesicle intensity data. The video data is first smoothed
and the vesicles are identified based on an intensity threshold. Subsequently, the location
of the centre points and the maximum intensity values are used to assign a label to each
individual vesicle. The intensity value of a 4x4 pixel box around the vesicle’s centre is then
averaged and extracted.
5.4.3 Results and Discussion
Overall, we conducted three experiments. Every experiment was run on an individual
microfluidic device in which we perfused half of the chambers with the DNA pore solution
and the other half with a buffer control. In Figure 5.11, we show typical intensity traces of two
vesicles as well as of the background over the entire length of the experiment. Figure 5.11A
shows the intensity and background curves of a vesicle incubated with the DNA pore, while
Figure 5.11B shows the curves of a vesicle which was perfused with the buffer control.
The left curve in Figure 5.11A shows the intensity trace of the background signal over the
entire length of the experiment. This curve provides us with information on the perfusion
state and the pH environment in the chamber. In the first 400 minutes, the intensity signal is
low while the trapping chamber is being perfused with the DNA pore solution which does
not contain any fluorescent HPTS tracer. After 400 minutes, the low pH solution containing
5 µM HPTS as fluorescent tracer arrives in the chamber. At this time point, we observe
an increase in background fluorescence. Interestingly, the intensity curve does not have a
sigmoidal shape which Al Nahas et al. observed when the chamber was homogeneously
filled with the solution [69], but a peak that drops off again and equilibrates at a value that
lies between the maximum fluorescence and the baseline when no fluorescent tracer was
present. We believe that our chambers are also homogeneously filled, and the distinct shape
of the background fluorescence results from the pH dependent fluorescence of the HPTS
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Fig. 5.11. Example intensity traces of vesicles and background. (A) Fluorescent traces
from a chamber perfused with the DNA pore. The left curve shows the background signal
in the perfusion chamber. The background goes through three individual phases. During
the perfusion with the DNA pore or the buffer control, the BG signal is low, as no HPTS
is present in the background. After about 400 minutes, the low pH solution arrives in the
perfusion chamber, indicated by a spike in fluorescence signal. The pH inside the chamber
goes through a transition phase. The fluorescence initially overshoots, as the pH adjusts, since
HPTS shows stronger fluorescence at neutral pH values. In the third phase, the background
remains steady, indicating a constant pH in the chamber. The right graph shows the intensity
of a GUV overlaid with the background. Both intensities are normalised to the fluorescence
of the vesicle before low pH arrival. During the perfusion of the chamber with the DNA
pores, the fluorescent signal is constant. As the low pH solution arrives in the chamber,
the inside fluorescence begins to decrease. The pH transition period coincides with a steep
decline in fluorescence intensity, which tapers off after the pH in the chamber has fully
adjusted. (B) Example traces from chamber perfused with buffer control. The background
and the vesicle intensity go through similar phases as the vesicle that was perfused with the
DNA pore. The low pH solution arrives earlier in this chamber, after roughly 300 minutes.
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tracer. We observe the mixing of the low pH solution (pH 5.9) with the solution present in
the perfusion chamber (pH 7.4). The pH in the perfusion chamber undergoes a transition
which we can observe because the fluorescence of the HPTS tracer is higher at neutral pH
than at acidic levels. Once the pH shift in the chamber to a value of pH 5.9 is complete, the
background stays steady at one fluorescence level. The pH transition times necessary for the
adjustment of the lie between 20 and 40 minutes in the different experiments. These time
scales are typical for the perfusion assay and similar to the times that Al Nahas et al. require
for the filling of the perfusion chambers in their experiments on antimicrobial peptides [69].
The right-hand side graph in Figure 5.11A shows the same background signal overlaid with
the intensity trace of a vesicle in the chamber. We see that the fluorescence intensity of
the GUV remains constant during the perfusion with the DNA pore and then expresses a
two-stage decay in fluorescence with a steep, initial decay which then suddenly tapers off.
The dashed lines indicate the two critical time points we identified before: the arrival of the
low pH solution and the complete shift of pH in the perfusion chamber. The decrease in
vesicle fluorescence begins with the arrival of the low pH solution, while the shift from the
fast fluorescence decay to the slower decay matches the time point of pH equilibration in the
outside chamber.
In Figure 5.11B, we look at the signal for a vesicle that has been perfused with a buffer control.
From the background signal, we can again identify the two critical time points. The arrival
of the low pH solution occurs after 300 minutes of perfusion with buffer. Approximately 30
minutes later, the pH in the perfusion chamber has adjusted to a pH 5.9 level. Surprisingly,
the intensity trace of the vesicle that has been perfused with the control looks similar to the
vesicle that has been perfused with the DNA pore. Again, we observe a steep, initial decay in
fluorescence, which coincides with the pH transition in the chamber, followed by a steady
decrease at a lower rate, once the pH in the chamber has adjusted.
In order to compare the intensity traces of the entire set of trapped vesicles, we created
heatmaps which display the behaviour of all vesicles that were perfused with the same
substance (DNA pore/buffer) in a single experiment. In the heatmaps, shown in Figure 5.12,
every horizontal line originating from the y-axis shows the normalised intensity of the
encapsulated HPTS in an individual vesicle. The intensity values are colour coded with the
maximum value displayed in red and a complete loss of fluorescence shown in blue. The
intensity traces are sorted by the time point the fluorescence decreases below 50% of the
initial intensity. The x-axis denotes the time of exposure to the low pH solution. Note that the
t0 time point of the heat maps is set to the arrival of the low pH solution which is identified
by the python code. We do not depict the perfusion step with the DNA pores/buffer control
in the heatmaps.
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Fig. 5.12. Heatmaps of the perfusion experiments. The time of exposure to the low pH
solution is given on the x-axis, the individual vesicle on the y-axis. Every horizontal line
depicts the intensity decay curve of a single vesicle. The normalised vesicle intensities are
colour coded with the maximum intensity depicted in bright red and a complete loss of
fluorescence in dark blue. The vesicles are sorted by the time point at which the intensity
drops to 50% of the initial value. Subfigure A, B and C show the results of experiments 1, 2
and 3, respectively. The respective number of vesicles is given inset.
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The same fluorescence data as for the heatmaps is used in Figure 5.13. However, here we
do not show the data of the individual vesicles, but a mean ± std. dev of all the vesicles in a
single experiment over time. In each of the plots, the average intensity of the vesicles that
were incubated with the DNA pore is shown in red and the buffer control is shown in blue.
The decay traces give us a more quantitative view of what is shown in the heatmaps.
Fig. 5.13. Fluorescence decay curves of the different experiments. The solid line displays the
mean intensity of all vesicles in the respective experiments. The shadowed region indicates
the standard deviation. The vesicles incubated with the DNA pores are shown in red, the
buffer control group is shown in blue. All experiments show a rapid increase in fluorescence
to about 75% of the initial fluorescence in the first 30 minutes. After the initial, quick decay,
the decrease continues for both sets of vesicles, albeit at a slower rate. Overall the vesicles
incubated with the DNA pore show a slightly faster decay than the control group, however,
this behaviour is most substantial in the first experiment.
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Looking at the heatmaps of Experiment 1 in Figure 5.12A, we see an immediate shift
from dark red to bright red within the first few minutes of the experiment in both vesicle
populations. This decrease represents the initial drop in vesicle intensity during the pH
transition period in the chamber. Initially, the decrease in both groups occurs in almost the
same time period. From Figure 5.13A, we can see that a drop to 75% of the initial intensity
occurs within 19 minutes in the pore-incubated vesicles and 20 minutes for the control group.
After this time span, the intensity traces of the two vesicle populations noticeably diverge.
After 50 minutes of exposure to the low pH solution, the vesicles with the DNA pores show
an average fluorescence intensity of 53% ± 14% of the initial value, compared to 61% ± 11%
of the control. This divergence can also be seen in the heat map, as we see a substantially
faster shift from red to blue in the DNA vesicles than in the control. After the initial fast
decrease in fluorescence, both groups steadily decay in fluorescence until the end of the
experiment, albeit not at a rate as high as in the first 50 minutes of the experiment.
In Experiments 2 and 3 we similarly see the fast, initial decay for both the vesicles incubated
with the pore and the control group. In Experiment 2, the drop to 75% of the initial
fluorescence occurs within 26 minutes for the pore-incubated vesicles and 29 minutes for
the control. In Experiment 3 these numbers are 33 minutes and 40 minutes, respectively. As
in Experiment 1, the fast decay in Experiment 3 continues for the DNA-incubated vesicles,
while it tapers off for the control group. Figure 5.13C shows us that after 50 minutes, the
mean fluorescence (mean ± std. dev.) in the DNA incubated vesicle dropped to 65% ± 10%
of the initial value, compared to 71% ± 11% in the control. Interestingly, we do not see
such a pronounced divergence of the decay traces in Experiment 2, although the overall
fluorescence decay is larger for the vesicles that were incubated with DNA pores here as
well.
Overall, the total mean intensity decay in Experiments 2 and 3 is not as strong as in Experi-
ment 1. The overall fluorescence (mean ± std. dev.) in the latter drops to 18% ± 16% and
23% ± 18% for the pore-incubated and control group, respectively. The DNA-incubated and
control vesicles in Experiment 2 decay to a value of 37% ± 20% and 40% ± 19% after 400
minutes, respectively. These values are 32% ± 14% and 34 ± 13% for the DNA and control
vesicles in Experiment 3.
The number of vesicles we were able to trap and observe throughout the entire length of the
experiment differed between the technical repeats. In Experiment 1, we were able to trap 96
vesicles that were incubated with the DNA pore and 55 vesicles for the buffer control. In
Experiments 2 these numbers were 183 for the DNA pore and 328 for the control, as well as
177 and 380, respectively for Experiment 3. The lower number of vesicles in Experiment 1
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is due to the reason that we used the chip design with fewer vesicle traps compared to the
chip in Experiments 2 and 3. In addition, not all vesicle traps were filled when we switched
to the perfusion step and some vesicles escaped from the traps or burst, which we also
excluded. Furthermore, we disregarded all vesicles in perfusion chambers that did not show
a homogeneous background signal, as shown in Figure 5.11, reducing the overall number of
vesicles again.
The fact that the initial drop in vesicle fluorescence coincides with the transition period that
we identified in the background signal suggests that the intravesicular pH drops alongside
the pH in the chamber. There is no substantial time delay between the arrival of the low pH
solution and the drop in vesicle fluorescence, as we see in Figure 5.11. The protons seem to
flow across the membrane and change the intravesicular pH as they arrive in the perfusion
chamber. This is despite the fact that PBS buffer is encapsulated inside the GUVs, which
should slow down a shift in pH due to its buffering capacity. The fast shift in pH suggests a
low permeability barrier of the membrane to protons. We expected such a behaviour for the
vesicles that were incubated with the DNA pore, since the protons can use these as channels.
However, since we see a similar drop in pH in the vesicles that were incubated with a buffer
solution, we must conclude the pure lipid bilayer of these vesicles likewise does not provide
an effective barrier to the protons.
It is interesting that after the initial drop in fluorescence which coincides with the pH transition
in the chamber, the fluorescence of the GUVs continues to decline. This indicates that the
pH transition inside the vesicles is not complete after the initial drop in fluorescence and
seemingly contradicts the observation of the fast proton transport that we witnessed during
the first few minutes of the experiment. The continued decline in fluorescence over the time
scale of hundreds of minutes suggest that the bilayer is indeed an effective barrier for the
protons; the opposite conclusion that we drew from the first few minutes of the experiment.
We compared the steady decay that followed the initial drop in fluorescence, since the latter
seems to be rate limited by the pH transition in the perfusion chamber. For this, we fitted
an exponential function of the form y = a× exp(−bt) to the decay of the final 350 minutes
of every vesicle in the respective experiments. An example trace with the corresponding
exponential fit is shown in Figure 5.14. Histograms of the decay parameter b are shown in
Figure 5.15 for the vesicles incubated with the DNA pore, as well as for the buffer control.
The median values are given inset. Note that outliers > 0.02 min−1 are not shown in the
histograms, but are included in the calculation of the median.
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Fig. 5.14. Example trace of exponential decay trace. The displayed decay trace is a vesicle
incubated with the DNA pore from Experiment 3. The normalised intensity of the vesicle is
shown in red. An exponential trace is fitted to the secondary decay for the final 350 minutes
of the experiment.
Fig. 5.15. Exponential decay parameters fitted to the steady state decay for the last 350 min-
utes of every experiment. The decay rates of the vesicles incubated with the DNA pore are
shown in red, the control group in blue. The median value is given inset.
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In line with our previous observations, Experiment 1 not only shows the greatest absolute
rate constant, and hence the fastest decay, but also the greatest spread in decay parameters.
However, there is remarkably little difference between the rate constants of vesicles that
have been incubated with the DNA pore, compared to the control group. The median decay
parameter of both sets of vesicles is 0.0031 min−1. Compared to Experiment 1, the absolute
decay rates are smaller in Experiments 2 and 3, in line with the smaller overall decay we see
for these experiments in the heatmaps and decay traces. Like before, the decay parameters
are similar for the DNA incubated vesicles and the control group. In Experiment 2 the median
values are 0.0020 min−1 for the DNA incubated vesicles, and 0.0016 min−1 for the buffer
control. These values are 0.0018 min−1 and 0.0019 min−1 for Experiment 3, respectively.
The analysis above shows that, overall, we cannot observe a notable enhancement of proton
flux in the set of vesicles that have been incubated with the DNA pore, compared to the
control group. This is somewhat surprising, considering the pH gradient between the bilayer
and the size of the nanopore. In Appedix C.6, we perform a theoretical calculation, according
to which a single DNA pore can mediate sufficient proton transport to equlibrate the pH
within several minutes. Effects like the previously discussed low insertion efficiency of the
pore as well as the possibility of the flushing away of the DNA pores can be explanations
for this discreptancy. However, the most crucial cause for our inability to see enhanced
transport is the passive permeation of the protons through the bilayer itself. We designed
the experiment under the assumption that the bilayer provides an effective barrier for the
protons. In that case, even a small enhancement of ion flux due to the DNA pore would
accumulate over the entire span of the experiment and show a noticeable effect. Instead, we
see a seemingly two-step process of pH adjustment of the vesicles irrespective of whether
DNA pore are present or not. An initial drop in fluorescence of the vesicles coincides with
the pH transition in the perfusion chamber, which suggests fast proton transport across
the membrane. However, after the initial acidification, we observe a steady decrease in
fluorescence over the remaining time span of hours, which suggests slow proton permeation.
The review of the literature on the membrane permeation of protons reveals that this transport
process is indeed a non-trivial and highly debated phenomenon. There exist conflicting num-
bers on the actual membrane permeability coefficient of protons. Measurements range from
10−4 to 10−12 cm/s [159, 240–243]. Early measurements of proton permeability through
lipid membranes were conducted by the group of David Deamer who have consistently found
permeability values in the order of 10−4 – 10−5 cm/s [159, 241, 242]. This is surprising,
as the permeabilities of other ions like potassium and sodium lie in the order of 10−12 to
10−14 cm/s [15, 241, 244]. We can put these numbers into perspective, when we compare
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them to the permeability values we obtained for the passive diffusion of fluoroquinolones in
the previous chapter. For the transport processes that occurred over time scales of tens of
seconds, we obtained permeability values of 10−6 cm/s. The proton permeability coefficients
measured by Deamer et al. lie two orders of magnitude above that, implying transport in the
time scales of hundreds of milliseconds. Following this analogy, the transport of sodium and
other ions occurs in the time scale of hundreds of hours, a number which is consistent with
the observations by Hauser et al. [244].
The permeability coefficients measured by Deamer et al. have been questioned by other
groups, due to their severe physiological implications [240]. For instance, it was argued that
the high passive proton permeability can collapse the electrochemical H+/OH− gradient
that drive the proton motive force that is necessary for processes like the synthesis of ATP
which we discussed earlier in this chapter [240, 241]. Nozaki and Tanford measured the
permeability values of H+ ions to be in the order of 10−12 cm/s [240], while Gutknecht
and Walther obtained 10−9 cm/s in a 1981 study [245]. In a later publication, Gutknecht
reported various other values ranging from 10−5 to 10−7 [241, 243]. It turns out that the
permeability values obtained depended strongly on the conditions in which the measurements
were performed. A 1987 review concluded that proton permeability measurements only
provide useful comparative information if they are obtained under the same conditions [241].
The same review also concluded that the high permeability values measured in vesicle
systems or with black lipid membranes do not contradict the existence of proton gradients
across membranes in biological systems. For instance, it has been shown that the proton
conductance of mitochondrial membranes is in the order of 10−6 S/cm2, similar to that of
other ions [241]. However, because the concentration gradients of protons in this system is
typically six orders of magnitude lower than that of other ions, the membrane function is not
impeded by the high intrinsic membrane permeability [241].
Irrespective of the exact value for the permeability coefficient, most researchers agree that
proton permeability is abnormally high compared to that of other ions and that protons have
a unique mechanism via which they cross the bilayer [241, 243]. Two main theories are
discussed in the literature. According to one model, proton permeation occurs along transient
hydrogen-bonded chains. These chains act as “water wires” [243] and allow protons to
cross the membrane similar to electrical conductance in an electrical wire [241]. The second
model explains the unusually high proton permeability with the presence of contaminants
that act as a protonophore. Gutknecht et al. have argued that even oxidized lipids can act as
protonophores increasing proton permeability drastically [241, 243].
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The large range of proton permeability and the strong dependence on the chemical environ-
ment could explain the biexponential shape that we see in our fluorescence decay curves.
The environment of the experiment could be such that there initially exists a large proton flux
across the membrane which then decreases. For instance, the fast, initial flow could be driven
by the Nernst potential that arises due to the concentration difference of ions between the two
sides of the membrane. The pH difference of 1.5 gives rise to a voltage of -88.5 mV [238], to
which we have to add a potential of -14.5 mV stemming from the concentration difference in
HPTS [246]. The initial high flux of protons could equalise the electrical potential difference
which in return decreases the driving force for the protons. After the depletion of the electric
potential, different transport mechanisms dominate the system.
Another effect that could lead to the distinct biexponential decay curve is the movement of
counter ions. There exist several publications on cells where the external drop of pH leads
to an intracellular pH profile of the distinct shape we also observe [247, 248]. An initial
internal acidification originated from fast proton or undissociated acid transport across the
membrane. A slower, passive efflux of anions then continues to lower the internal pH. In our
case, (protonated) phosphate ions could passively diffuse out of the vesicle. The leakage of
buffer ions can change the equilibrium reaction inside the vesicle and over prolonged periods
of time lead to a lower pH inside the vesicle than outside [247].
Finally, it is possible that the subsequent drop in fluorescence is due to bleaching of the
HPTS dye. We think this explanation is unlikely though, as Al Nahas et al. performed a
bleaching control on HPTS encapsulated vesicles with the same exposure settings and did
not observe any bleaching of the dye over the time span of at least 10 hours [69]. Similarly,
the fluorescence trace shown in Figure 5.11 shows no sign of substantial bleaching in the
400 minutes before the arrival of the low pH solution. Studies on the solvent dependence of
HPTS confirm that this stability also extends to the molecule in acidic environments [249].
Finally, we must conclude that we were not able to observe enhanced ion flux mediated by
DNA nanpores in our microfluidic system. However, our assay allowed us to witness the
anomaly of proton permeation through lipid bilayers and is a potential tool to study this
phenomenon in more detail in future studies.
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5.5 Conclusion
In this chapter we investigated the transport of hydrogen ions through GUV membranes. We
introduced a DNA nanopore that can insert into lipid bilayers and has shown ion conductance
in electrophysiological measurements. Using a novel microfluidic perfusion assay, we
compared the proton flux across GUV membranes that were incubated with the DNA pore
to untreated vesicle membranes. We exposed the two populations of vesicles to a low pH
solution and compared the decay of the fluorescent pH indicator HPTS that is encapsulated
inside the vesicles. The fluorescence intensity of the pH indicator decreases with lower pH
and is therefore a readout of the proton concentration inside the GUVs. The fluorescence
decay curves revealed a distinct biexponential shape with a steep initial decay that is followed
by a slower decrease. We found this decay curve for both, the vesicles that were incubated
with the DNA pores and the control group. On average, the vesicles with the DNA pore
showed a steeper initial decline as well as a greater overall decrease in fluorescence. However,
the means of the different decay curves all lie within the standard deviation of each other.
Moreover, we also observed that the steep decay coincides with the pH transition in the
perfusion chamber in which the vesicles are trapped. We can therefore not rule out that the
steeper initial decrease is an artifact stemming from the different filling of the perfusion
chamber with the low pH solution. The analysis of the exponential decay that follows the
initial drop in fluorescence revealed similar decay rates for both sets of vesicles over the final
350 minutes of the experiment. Due to the passive diffusion of protons across the membrane,
any potentially transport enhancing effect of the DNA pore is therefore not detectable with
the current experimental procedure.
However, a series of experiments are possible that could clarify the behavior of the proton
transport we observed. One measure to enhance the informative value of the assay in
future experiments would be adding the same concentration of HPTS as we have inside the
vesicles to the low pH solution with which we perfuse the vesicles. In the way we currently
designed the experiment, the HPTS in the low pH solution only serves as a tracer to signal
the arrival of the pH 5.9 solution in the chamber. By having the same concentration of
HPTS in the background, we can use this signal as chip internal calibration, to determine
which fluorescence intensity corresponds to that pH value. This would be an effective way
to assess to which extent the initial drop in pH we observe equalises the proton gradient.
Other possible experiments involve the use of ionophores such as valinomycin. Other groups
have used this compound to modulate the membrane potential and study its effect on proton
permeability [250]. It would be interesting to include valinomycin in our experiments and
verify whether or not the steep decline of the biexpoential curve is indeed linked to the
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Nernst potential that arises from the pH gradient. Furthermore, it would also be interesting
to perfuse the vesicles with a known protonophore such as indole in order to have a side-
by-side comparison of the proton flux across untreated GUV membranes, vesicles that have
been incubated with a DNA pore and the proton transport in presence of an established
protonophore.
Our experiments revealed that hydrogen ions are not the ideal choice of ions to study the
flux through DNA nanopores due to their abnormally high passive permeation. Ions such
as sodium or potassium might be more suited, as no substantial passive transport of these
ions should occur over the time scales of the experiment. Any transport we observe in
vesicles that are incubated with DNA pores would therefore most likely be conducted via the
pore. However, as noted above, any fluorescent tracer used in the perfusion assay must be
highly photo stable, in order to avoid severe photo bleaching over the long time scales of the
experiment. Advances in the development of such indicators for other ions could open up the
possibilities for further experiments in this direction.
Chapter 6
Towards a Deep UV Absorbance Assay
to Determine Membrane Permeability
6.1 Motivation
In the previous chapters, we relied on the molecule’s autofluorescence, or fluorescent indica-
tors such as HPTS to visualise the molecule/ion whose transport we want to study. In this
chapter we will look into a new potential way to expand the scope of our assay. One advan-
tage of our microfluidic platform is the fact that it is not bound to fluorescent readouts but
can be combined with other optical sensing mechanisms. By using a different optical effect
to visualise the molecule of interest, we can improve our assay and obtain the permeability
of compounds that we were unable to measure before.
The development of label-free methods to investigate membrane permeability and other
membrane-molecule interactions is a field in its own right and several different methods
have been published in the past [251]. For instance, Zeng et al. used a non-linear optical
phenomenon called second-harmonic generation (SHG) to study the transport of Machalite
green across E.coli membranes [192]. In this technique, two incident photons interact
with the target molecule to create a second order polarisation in its assembly. Via an
intermediate virtual state, the two photons are then converted into a single photon which
can be detected. Since the resulting photon has double the initial frequency, the effect used
for this imaging technique is also called frequency doubling [252, 253]. Other groups used
confocal Raman spectroscopy to study drug-membrane interactions and the permeability of
anti-inflammatory drugs [195, 251]. Raman spectroscopy relies on the inelastic scattering
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of light in a medium to identify a molecule. An incident photon is absorbed and lifts an
electron to a higher virtual energy state. As the electron returns to a lower energy state,
it emits a photon. However, the electron does not return to the ground energy level, but
to an excited state that corresponds to different vibrational and rotational modes of the
molecule. This leads to a shift in the emission spectrum which can be recorded and used to
study the molecule [195, 251]. There are also non-optical methods being developed to study
molecule-membrane interactions. Ghatkesar et al. for instance developed a micro-cantilever
assay that allows for the investigation of peptide adsorption to liposome membranes [254].
In their assay, lipid vesicles are immobilised on an oscillating cantilever and exposed to the
peptide melittin. As the peptides insert into the membrane, the resonance frequency of the
cantilever changes. The group exploits the change in resonance frequency to obtain the mass
of inserted peptides and measure other micromechanical changes in the membrane [254].
A disadvantage of many of the label-free methods above is the fact that they cannot be coupled
with microfluidic techniques or require extensive equipment such as pulsed femtosecond
lasers to function. We want to maintain the microfluidic character of our permeability assay,
as it offers advantages such as the precise control over the chemical environment, small
reagent volumes and single vesicle resolution. For this reason, we opted for the use of
a different technique to expand our assay. In the work below, we exploit the absorbance
property of a molecule to visualise the transport through a vesicle membrane and determine
its permeability coefficient. However, we will not conduct our experiments with visible
light, but use ultraviolet (UV) radiation instead. As we will see below, we use light with a
wavelength of 280 nm in the new optical setup. Electromagnetic radiation with wavelengths
from 100 – 280 nm is defined as UV-C radiation by the International Organisation of
Standardisation (ISO). UV-C radiation is commonly also called hard UV or deep UV [255],
which is why we refer to the technique developed in this chapter as the Deep UV Absorbance
Assay, or simply Absorbance Assay. The advantage of using UV radiation instead of visible
light for the absorbance setup is the fact that many organic molecules show an absorbance
peak in this part of the electromagnetic spectrum [256, 257]. A transport assay using the
UV absorbance can therefore expand the scope of our transport studies to molecules we
were unable to investigate previously, due to their lack of autofluorescence or fluorescent
indicators.
Beer-Lambert’s law describes the relationship of a molecule’s absorbance to its concentration
along a given optical path length [258–260]. The principle of this interaction is shown in
Figure 6.1. Light with an initial intensity I0 is attenuated as it traverses a medium containing
the absorbing substance. The absorbance A is described by the product A = ε× c×L where
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L is the optical path length and c is the molar concentration of the absorbing substance. ε is a
material property called the molar attenuation or extinction coefficient. Multi-component sys-
tems, or several absorbing layers in series behave additively, so we obtain ∑Ni=1 = εi× ci×Li.
The absorbance of the light is likewise described by the equation A = log10(
IT
I0
) with the
transmitted intensity IT and the incident intensity I0.
Fig. 6.1. Schematic explaining Beer-Lambert’s law. Light with an incident intensity I0 is
attenuated as it traverses a medium containing an absorbing substance with concentration c
and attenuation coefficient ε . The Absorbance A is described by the logarithm of the ratio of
incident and transmitted intensities I0 and IT .
Beer-Lambert’s law is used in interpreting data from UV-Vis spectrophotometers and other
techniques to determine the concentration of a target compound [261]. Moreover, it is also
used in medical imaging techniques like computed tomography (CT) to identify specific
tissues [262].
In the following sections, we will show how we can use it in conjunction with our microfluidic
techniques to measure the permeability coefficient of molecules traversing lipid membranes.
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6.2 Design of Experiment
6.2.1 Fleroxacin as a Model Antibiotic
As before, we will use an antibiotic of the fluoroquinolone family as a model drug to test our
assay. In this chapter, we will work with the antibiotic fleroxacin, whose chemical structure is
depicted in Figure 6.2A. The advantage of this molecule is the fact that we can image it both
using absorbance and autofluorescence. As we see in Figure 6.2B, the molecule expresses
an absorbance peak at λ = 286 nm, but also a smaller peak at 340 nm. The latter can be
used in our permeability assay in Chapter 4 to include autofluorescence. The absorbance
maxima overlaps with the emission wavelength of our deep UV light source whose emission
peak is stated as 275 – 285 nm by the manufacturer. These properties make fleroxacin an
ideal candidate for our purpose, as we can compare the permeability value we obtain with
our new technique as well as with the established technique. In Figure 6.2C, we show the
calibration curve of fleroxacin showing that the absorbance at 280 nm scales linearly with
the concentration, in line with Beer-Lambert’s law. The absorbance spectrum, as well as
the calibration curves were obtained in a NanoDrop UV-Vis Spectrometer (NanoDrop 2000,
Thermo Scientific, UK) in a 5 mM acetic acid buffer.
Fig. 6.2. (A) Chemical structure of fleroxacin. (B) Absorbance spectrum of 10 mM fleroxacin
in a 5 mM acetic acid buffer. The absorbance peak at λ ≈ 286 nm is exploited for the
visualisation of the drug in the new optical setup. (C) Calibration curve showing the linear
scaling of the absorbance in the relevant concentration range.
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6.2.2 Optical Setup and Flow Control
We conducted the studies presented in this chapter before we developed the integrated vesicle
production and permeability testing microfluidic platform introduced in Chapter 4. For this
reason, we did not use our own microfluidic chip design for the experiments below. Instead,
we used the original chip design presented by Cama et al. in 2014 that our own permeability
platform is based on. We ran the old chip design with our altered optical train, suitable for
absorbance measurements.
The optical setup is depicted in Figure 6.3A. An ultraviolet LED (M280L3, Thorlabs,
Germany) generates light of 280 nm which is collimated and evenly illuminates a PDMS chip
bonded to a PDMS coated quartz cover slip (Type 2, UQG Optics, UK). The signal passing
through the chip is detected by a 40× UV objective (0.5 N.A. LMU- 40X-UVB, Thorlabs).
Any autofluorescence is filtered out by a 280 nm bandpass filter (280/10 nm BrightLine
single-band bandpass filter, Semrock). The signal is then focused into an EMCCD camera
(Evolve 512 Delta, Photometrics). The camera is controlled using the open source software
µ-Manager 1.4 [166]. Video recordings occurred at EM gain 25, bin 2 and 10 ms exposure
time. All involved lenses and optics are either made of quartz or UV grade fused silica
(Thorlabs, Germany).
The microfluidic chip design is shown in Figure 6.3B. The fluid flows are similar to that in our
own permeability platform. Two channels, one containing lipid vesicles and one containing a
drug solute, meet at a two-way T-junction where the flows mix equally. The field of view of
the camera is set to an observation point indicated by the red box in Figure 6.3B that allows
the recording of vesicles passing through two different parts of the channel. The liposomes
in the different parts of the channel have been exposed to the drug for different amounts
of time and therefore have different amounts of drug molecules within them. Comparison
of the intensity levels of the vesicles allows the calculation of the permeability coefficient.
Yet, the visualisation of the drug transport is achieved by a completely different principle
as before. Instead of emitting light and therefore appearing bright, the drug absorbs the
incoming wavelength in this assay and appears dark. The vesicles on the other hand are
initially bright as they do not have absorbing drug molecules within them. The T-junction
that shows the difference in transmitted light between the vesicles and the drug solute is
shown inset in Figure 6.3B. The GUVs grow darker as the drug diffuses across the membrane.
By comparing the transmitted light intensity of the vesicles at two different time points, the
membrane’s permeability to the drug of interest can be determined. We present a diffusion
model that allows for the calculation of the permeability coefficient from the transmitted
light intensities in Section 6.2.3.
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Fig. 6.3. Schematic of the absorbance assay. (A) Optical train of the setup. Light from a
deep-UV LED is collimated and evenly illuminates a microfluidic chip on a quartz cover
slip. The signal passes through a deep-UV transparent objective. Fluorescence artefacts
are filtered out by a 280 nm bandpass filter and the signal is then focused into an EMCCD
camera. (B) Design of the microfluidic chip. Two flows, one containing lipid vesicles, one
containing a drug solute, equally mix at the junction. The flow containing the drug solute is
dark as the drug molecules absorb the UV light, whereas the flow containing the vesicles
remains bright. As the drug molecules diffuse across the membrane, the vesicles get darker
due to the higher concentration of absorbing drug molecules within them. By analysing the
light intensity of the vesicles at distinct time points, indicated by red boxes, the speed of drug
transport across the membrane can be determined. Image modified from [37].
The fluid flow in the chip is driven by a neMESYS syringe pump (Cetoni GmbH, Germany)
with a 250 µL Duran Borosilicate glass syringe (ILS, Germany) that is connected to the outlet
of the microfluidic chip via an Upchurch 1520 G tubing with an inner diameter of 0.03”.
Two pipette tips, one containing 40 µL of the drug solute and one containing 40 µL of the
vesicle solution are placed into the inlet chambers of the microfluidic chip and serve as fluid
reservoirs. Initial suction of 30 µL/h is applied for 30 minutes via the syringe pump. Over
the time period of 20 minutes, the flow rate is reduced stepwise to 3 µL/h. After the flows
settle, the field of view is set to the measurement position and image acquisition started.
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6.2.3 Beer-Lambert Law and Diffusion Model
As mentioned above, the attenuation of light passing through a material is described by
Beer-Lambert’s law [258]. We can combine the diffusion model from Chapter 4 with this
law to produce a model for the membrane’s permeability based on the UV absorbance of the
drug molecules within a vesicle. According to Beer-Lambert’s law, the absorbance A of a
material sample is directly proportional to the path length of the light travelling through a
material, as well as to the individual concentrations of the attenuating substances [258].
A =
N
∑
i=1
εi× ci×Li (6.1)
Where εi is the attenuation coefficient, ci the molar concentration of the substance and Li the
path length of the travelled light.
Furthermore, the overall absorbance is described by the equation
A = log10
(
I0
IT
)
(6.2)
with I0 the incident intensity and IT the transmitted intensity.
In order to determine the permeability coefficient, we require three measurements of the
transmitted intensity, which we depict in Figure 6.4.
The first measurement is that of the background intensity IBG, which has to be measured
when no vesicle is present in the microfluidic channel.
ABG = log10
(
I0
IBG
)
= εdrug× cout×L+X (6.3)
→ cout =
log10
(
I0
IBG
)
−X
εdrug×L (6.4)
Where εdrug×cout×L is the absorbance of the drug solute in the channel. Unknown elements
such as the absorbance of the quartz cover slip and the rest of the PDMS are contained in the
variable X and will later cancel out.
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Fig. 6.4. Illustration of the intensity values that have to be obtained in order to determine
the drug concentration inside the vesicles. The background intensity IBG is measured when
no vesicle is present in the channel. The transmitted intensity values of the vesicles IVesicle
have to be taken at two distinct time points. The microfluidic channel has a height of L and
is filled with a drug solute of concentration cout and attenuation coefficient εdrug. The drug
concentration in the inside of the vesicle at a given time point t is cin.
The other two transmitted intensities are that of the vesicle IVesicle. The intensity must
be measured at two distinct time points. We will call the intensity measurement at these
time points I1 and I2. As in our previous diffusion model, we perform the first intensity
measurement of a vesicle I1 immediately after mixing with the drug solute (time point t1)
and the second measurement I2 after several seconds when the vesicle appears in the field of
view again (time point t2).
A1 = log10
(
I0
I1
)
= εdrug× c1×2R+ εdrug× cout× (L−2R)+X (6.5)
→ c1 =
log10
(
I0
I1
)
− εdrug× cout× (L−2R)−X
2R× εdrug (6.6)
A2 = log10
(
I0
I2
)
= εdrug× c2×2R+ εdrug× cout× (L−2R)+X (6.7)
→ c2 =
log10
(
I0
I2
)
− εdrug× cout× (L−2R)−X
2R× εdrug (6.8)
The summands εdrug×c1×2R and εdrug×c2×2R express the absorbance of the drug within
the vesicle at the time points t1 and t2, respectively. The absorbance of the drug solute
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surrounding the vesicle in the channel is expressed by εdrug× cout× (L−2R). The unknown
parameters are again substituted for X .
We can assume that c(t1 = 0) = 0, as the initial concentration of drug within the vesicle is
zero. We can then solve Equation 6.5 for the unknown parameter X .
X = log10
(
I0
I1
)
− εdrug× cout× (L−2R) (6.9)
Inserting Equation 6.9 into Equation 6.4 gives us for cout
cout =
log10
(
I0
IBG
)
− log10
(
I0
I1
)
2R× εdrug =
log10(I1)− log10(IBG)
2R× εdrug (6.10)
We remember from our permeability model in Chapter 4 that
P =− R
3t
× ln
(
cout− cin(t)
cout
)
(6.11)
For c(t) in Equation 6.11, we can assume that c(t) = c2− c1 and receive from inserting
Equation 6.6 and Equation 6.8
c(t) = c2− c1 =
log10
(
I0
I2
)
− log10
(
I0
I1
)
2R× εdrug =
log10(I1)− log10(I2)
2R× εdrug (6.12)
The expressions for cout and c1− c2 can now be inserted into Equation 6.11. For the
expression in the brackets we receive
cout + c1− c2
cout
= 1− c2− c1
cout
=
log10(I1)−log10(I2)
2R×εdrug
log10(I1)−log10(IBG)
2R×εdrug
(6.13)
⇔ cout + c1− c2
cout
= 1− log10(I1)− log10(I2)
log10(I1)− log10(IBG)
(6.14)
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For our final formula of the permeability coefficient we get
P =− R
3t
ln
(
1− log10(I1)− log10(I2)
log10(I1)− log10(IBG)
)
(6.15)
The diffusion model in the absorbance assay therefore requires the same parameters that we
needed to calculate the permeability coefficient using autofluorescence. These are intensities
I1 and I2 of a vesicle at two time points, the background intensity IBG, as well as the vesicles
radius R and the time t between the two measurement points.
6.3 Validation Experiments
6.3.1 Materials and Methods
Microfluidic Chip Design and Fabrication
The microfluidic chips were made of polydimethylsiloxane (PDMS) following the protocol
presented in Sections 2.4.2 and 4.4.2. The silicon master chip was designed by J. Cama as
previously described [37]. The design of the microfluidic chip is depicted in the Appendix
Figure D.1.
Since standard glass coverslips are not transparent to UV radiation at 280 nm, we used quartz
cover slips (Type 2, UQG Optics, UK) for our experiments in the absorbance assay. For
the purpose of reusability, we coated the quartz cover slips with a thin PDMS layer as we
described in Section 2.4.2. The microfluidic chip was then bonded onto the PDMS layer,
rather than to the glass itself. This way the PDMS chip could be removed from the cover slip
and the quartz slide reused.
Solution Composition
The vesicles were obtained via the electroformation method, according to the protocol we
presented in Section 3.1.1. The lipid suspensions consisted of 80 µL DPhPC lipid (1,2-
diphytanoyl-sn-glycero-3-phosphocholine, 5 mg/mL in chloroform) and were prepared in a 5
mM acetic acid, 200 mM sucrose buffer at pH 5. After electroformation, the vesicles were
stored in an Eppendorf tube and used within one week.
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The drug solute was prepared by dissolving fleroxacin powder (Sigma Aldrich, USA) in
the same pH 5 acetic acid buffer (200 mM sucrose, 5 mM acetic acid) as used for vesicle
formation. The drug concentration in the drug solute used for the absorbance setup was
8 mM, which leads to an overall concentration of 4 mM in the channel, if we assume equal
mixing with the vesicle flow. The pH value of the buffer was adjusted using a digital pH
meter (Hana Instruments, UK) by adding several µL of KOH (10 %) and HCl (10 %).
All chemicals were obtained from Sigma-Aldrich unless stated otherwise.
MATLAB Analysis Routine
After the system has been setup as described above, the field of view is moved to a recording
position and image acquisition started using µManager. Frames are recorded at 100 fps and
stored on external hard drives. After the data acquisition, the videos are analysed using a
MATLAB routine. Among other values, this script extracts the area, the major and minor
axis lengths, the weighted centroid and the intensity values of the vesicles passing through
the channel for every frame. Based on the extracted data, the permeability values according
to the model above are calculated.
Due to the low signal-to-noise ratio (SNR), intensive image processing has to be performed
to reliably detect vesicles passing through the channel. The processing consists of 4 steps,
illustrated in Figure 6.5. First, an image of the background is taken without vesicles being
present in the channels. This background image is subtracted from each frame of the video.
Vesicles that are present in the channel therefore appear much clearer than in the original
image, similar to a dark field image. In a next step, a contrast enhancement algorithm from
the MATLAB Image Processing Toolbox is used to further enhance the contrast of the image.
Third, the enhanced image is converted into a binary image. A binary image is necessary
in order to specify which pixel shows part of a vesicle and which pixel shows background.
In this script, pixels with the value 1 show part of the vesicle, pixels with the value 0 show
the background. The 1-pixels thus define the contour of the vesicle and we can use this
information to extract the vesicle’s properties that we are interested in, such as the area or
the intensity values. Yet, before these properties can be extracted, several filters have to be
applied to the binary image in the final step of image processing.
Two filters are applied to remove isolated noise pixels. Using the bwmorph(‘clean’) and the
bwmorph(‘fill’) functions, false positive and false negative pixels are removed, respectively.
In the binary image, false positive pixels are fields in the picture matrix with the value of 1
that are surrounded by fields with a value of 0. Similarly, false negatives are fields with a
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value of 0 that are surrounded by fields of the value 1. Next, the bwmorph(‘majority’) filter
is used to smoothen the edges of the vesicle. It sets a pixel to 1 if five or more pixels in its
3-by-3 neighbourhood are 1. Finally, the bwareaopen function is used to eliminate small
objects from the image that show the value of 1 that consist of less than 30 pixels. These are
usually bright specs of lipid aggregates that otherwise would be detected as a vesicle.
Fig. 6.5. Four step image processing to detect vesicles: First, a background image is
subtracted from the acquired frames. Next, a contrast enhancing algorithm is applied to the
images in order to increase the vesicle’s contour. In a third step, the image is converted into a
binary image. Finally, several filters are applied to the black-white image in order to remove
noise pixels and remove false positives.
6.3.2 Results and Discussion
Scatter plots of our measurements are depicted in Figure 6.6. The x-axis displays the vesicle
radius and the y-axis the transmitted intensity, normalised to the background intensity. Every
scatter point represents a single vesicle measurement. The dark scatter points were obtained
at the time point t1 ≈ 0 s, just after the vesicle entered the mixing channel. The coloured data
points show the vesicle intensity after the time given inset.
As we did for our permeability assay in Chapter 4, we did not compare the intensity levels of
one and the same vesicle at the two time points. Instead, we fitted a linear function to the
scatter points we obtained for I1 as a function of the radius. For every measurement at the
second recording position (red scatter points), we recalculated the corresponding I1 value
according to the function.
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The gap between the dark scatter points and the coloured points visualise the drug transport
from the outside into the inside of the vesicle. Initially, the vesicle is bright on a dark
background, represented by a high intensity to background ratio I1IBG . As the light absorbing
drug molecules permeate through the membrane, the transmitted intensity decreases and the
vesicle appears darker. The intensity ratio at the second measurement position I2IBG is therefore
closer to the baseline. Calculation of the permeability coefficient according to the diffusion
model above reveals a permeability value of 14.4 ± 2.1 × 10−6 cm/s (mean ± standard error,
N = 29) for fleroxacin at pH 5 through DPhPC vesicle membranes.
Fig. 6.6. Scatter plots of two fleroxacin experiments using the absorbance assay. The y-
axis shows the intensity value of the vesicle normalised to the background intensity. The
two graphs show the results of two individual experiments with the same drug. Every
scatter point represents an individual vesicle measurement. The dark data points are taken
at t1 ≈ 0 s. A linear function is fitted through these points and shown as solid line. The
individual measurement points at t2 are depicted in red. The time difference between the two
measurement points, as well as the number of vesicles is shown in the top left corner.
The easiest way to assess the results we obtained from the absorbance assay is to directly
compare them to a measurement we performed under the same conditions using the autoflu-
orescence imaging mode. We performed such measurements on fleroxacin in a previous
publication [153]. Two scatter plots of these permeability measurements are shown in Fig-
ure 6.7. It should be noted that the concentration of the drug solute in the autofluorescence
measurements was 2 mM, instead of the 8 mM we use in the absorbance assay. All other
chemical parameters between the experiments, such as the buffer or the lipid type were
identical.
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We can interpret the scatter plots shown in Figure 6.7 in a similar manner to the scatter plots
we discussed in Chapter 4, as they follow the same imaging principle. If we remember, in
the autofluorescence assay, we normalised the intensity inside the vesicle Iin to the intensity
of the outside Iout in order to obtain ∆I = Iout−IinIout . The ∆I value for the vesicles was obtained
at two time points. The dark scatter points were measured just after the vesicle encountered
the drug solute (t1 ≈ 0 s) and the coloured data points after the time difference given inset.
The permeability coefficient could then be calculated according to Equation 4.14. Our mea-
surements in 2015 yielded a permeability value of 4.1 ± 0.2 × 10−6 cm/s (mean ± standard
error, N = 283) [153]. In Table 6.1, we compare that value to the permeability coefficient we
obtained with the absorbance assay.
Fig. 6.7. Scatter plots of fleroxacin measurements using the autofluorescence assay. We
calculate the y-axis value according to the formula ∆I = Iout−IinIout . The radius is given in the
x-axis. Every scatter point represents an individual vesicle measurement. The dark data
points are taken at t1 ≈0 s. A linear function is fitted through these points and shown as solid
line. The individual measurement points at t2 are depicted in green. The time difference
between the two measurement points, as well as the number of vesicles is shown in the top
left corner. The downward shift in ∆I results from an increase in autofluorescence within the
vesicles, as the drug diffuses across the membrane. Image modified from [153].
Table 6.1. Permeability coefficient (mean ± standard error) of fleroxacin measured at pH 5
with the respective setups in 10−6 cm/s
Autofluoresence Assay Absorbance Assay
4.1 ± 0.2 14.4 ± 2.1
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The most evident difference when comparing the scatter plots obtained with the two tech-
niques is the difference in the number of lipid vesicles in the experiments. While we detected
a total of 283 vesicles with the two experiments conducted with the autofluorescence assay,
this number is only 29 for our two experiments using absorbance. Even though the vesicle
yield of the electroformation technique can vary from batch to batch, such a large deviance
is unusual. It is in fact highly likely that more vesicles were present in the absorbance
experiment, but we were not able to detect these. The reason for this is most likely the
difference in signal to noise ratio (SNR) between the two assays. In the autofluorescence
assay, the drug molecule itself emits the fluorescent signal we measure. Elements of the
chip where no drug is present therefore appear dark in the image with a strong contrast to
the fluorescing drug. The signal intensities of the vesicles and the background typically lie
60% - 100% apart, making it easy to detect the vesicles in the autofluorescence assay. In the
absorbance assay, on the other hand, we measure the intensity of transmitted light from the
UV LED. The mechanism that provides contrast is the difference in absorbance of the UV
rays, which, however, is a very small effect. The signal of a vesicle often lies only 10% - 20%
above that of the background level. As the drug permeates into the vesicle, that difference
decreases even more, making it hard to detect the vesicles.
The low signal to noise ratio of the absorbance assay is also the reason why we used a
drug concentration of 8 mM fleroxacin in these experiments, compared to 2 mM when
relying on autofluorescence. As we discussed above, the absorbance is described as the
product of the optical path length L, the attenuation coefficient ε and the concentration c.
Since the path length is limited by the chip geometry (channel height) and the attenuation
coefficient is a material constant, the only way for us to improve the signal to noise ratio
was by increasing the drug concentration. The high drug concentration also forced us to
conduct the experiments at pH 5, instead of at neutral pH levels. This is due to the fact
that fluoroquinolones such as fleroxacin show their lowest aquesous solubility at neutral pH
levels [181]. We were therefore only able to increase the fleroxacin concentration to 8 mM
by usinga pH 5 acetic acid buffer.
Our optical resolution was further impeded by the available hardware suitable for deep UV
measurements. Our autofluorescence setup is equipped with a 60× water immersion objective
(UPLSAPO Olympus) with a numerical aperture (N.A.) of 1.2, whereas the absorbance
setup uses a 0.5 N.A. air objective (LMU-40×-UVB, Thorlabs). The water immersion
objective captures more light and enables finer specimen resolution than the air objective,
but is not suitable for the deep UV experiments, due to the low UV transmittance of its
constituent borosilicate glass. Furthermore, the EMCCD camera used for our experiments is
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not optimised for use in the deep UV. According to the manufacturer, the quantum efficiency
of the optical sensor lies between 50% - 95% in the optical range. This values drops to below
10% in the deep UV, further reducing our signal to noise ratio.
Finally, it is obvious from Table 4 that we obtain slightly different values for the permeability
coefficient with the two setups. The value (mean ± S.E.) acquired with the autofluorescence
assay is 4.1 ± 0.2 × 10−6 cm/s, whereas the permeability coefficient acquired with the
absorbance assay is 14.4 ± 2.1 × 10−6 cm/s. This is a factor of 3.5 between the values.
We explain this difference with the limiting factors of the absorbance measurement listed
above: low SNR, lower optical resolution and a low number of vesicles. Another factor that
might have contributed to the higher permeability value we observe in the absorbance assay
is the higher drug concentration in these experiments. While the absolute concentration is
accounted for in the diffusion model and should not influence the measured permeability
coefficient, the vesicles might experience a higher osmotic pressure, which could alter the
membrane tension and enhance the observed molecule flux through the membrane.
After discussing the differences between the two optical assays, we briefly want to comment
on the fact that we were able to observe membrane permeation at pH 5 for fleroxacin in this
chapter, while we did not observe norfloxacin permeation at pH 5 in Chapter 4 over the time
scale of 40 seconds. The reason for this can be found in the chemical structure of the two
compounds. As we see marked blue in Figure 6.7, fleroxacin carries two additional fluorine
atoms, compared to norfloxacin. One fluoride atom is attached to the aromatic ring while the
other is connected to an ethyl group. Furthermore, we see that both molecules have an amine
in their piperazin-1-yl group. However, in norfloxacin, this amine is secondary, while it is
a tertiary amine in fleroxacin. The secondary amine of norfloxacin is marked in red in the
figure below.
Fig. 6.8. Chemical structures of fleroxacin and norfloxacin. The two additional fluoride
atoms of fleroxacin are marked in blue. The secondary amine in the norfloxacin molecule is
marked in red.
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In our 2015 publication, we showed that the secondary amine is responsible for the decreased
lipophilicity of norfloxacin compared to fleroxacin [153, 263]. This manifests itself in
the comparatively reduced permeability coefficient of norfloxacin, which lies one to two
orders of magnitude below that of fleroxacin, depending on the pH [153]. The difference in
lipophilicity between the compounds is also expressed in their respective octanol partition
coefficients. According to the DrugBank database, calculated log P values for norfloxacin lie
between 0.47 and -0.92, while experiments show a log P of -1.03 [182]. For fleroxacin, the
calculated log P values lie between 0.3 and 1.12 with an experimental value of 0.24 [182].
For a detailed analysis of the permeability coefficients of the different compounds, we
refer to our 2015 publication, where we measured and compare the permeability value of
four fluoroquinolone antibiotics over a pH range from pH 5 – 7 using the autofluorescence
assay [153].
Our results show that permeability measurements using the molecule’s absorbance property
are possible and could be a potential alternative for the label-free measurement of membrane
transport. However, our validation experiments showed a significant difference in the
obtained permeability coefficient compared to measurements using autofluorescence, which
we attribute to the low signal to noise ratio, as well as to the lower optical resolution and
number of vesicles in the absorbance measurements.
6.4 Conclusion
In this chapter, we investigated whether or not exploiting a molecule’s absorbance property
in the deep UV is a viable alternative to autofluorescence for the label-free measurement
of membrane permeability. We developed a new optical setup and combined it with an
established T-junction microfluidic chip assay, where we can expose electroformed vesicles
to a drug solute, or a different molecule of interest, in a controlled manner. Furthermore,
we derived a diffusion model from Beer-Lambert’s law that allows for the calculation of the
permeability coefficient.
We performed validation experiments on the new absorbance assay and measured the perme-
ability coefficient of the fluoroquinolone drug fleroxacin through DPhPC lipid membranes.
We compared these results with previous measurements that we performed with an estab-
lished technique using autofluorescence. The permeability coefficient we obtained with the
new method lies 3.5× above the value we measured previously. We attribute this disagree-
ment in the values to the low signal to noise ratio and lower optical resolution of the UV-C
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grade components that are necessary in the absorbance assay, compared to the assay based
on autofluorescence.
Our experiments show that it is indeed possible to use the UV absorbance of a molecule as a
tool to measure membrane permeation. However, our studies also reveal that the low signal to
noise ratio of the absorbance method hinders us from achieving the same degree of sensitivity
in our measurements that we were able to obtain using a molecules autofluorescence. In
order to truly expand the scope of the possible molecule’s that can be measured with the
absorbance technique, the issue of low signal to noise must be addressed in future studies.
The two elements that make up the absorbance assay can be broken down into the optics part
and the microfluidics part. Both areas have potential to improve the signal to noise ratio of
the assay.
As we pointed out above, the deep UV radiation forced us to use a fused silica objective
(LMU-40×-UVB, Thorlabs) that is capable of transmitting the 280 nm light. However, this
objective features a lower numerical aperture, as well as a lower magnification (0.5 N.A.,
40× magnification) compared to the autofluorescence setup (1.2 N.A., 60× magnification)
leading to a substantially decreased image quality and overall signal in the absorbance setup.
Future modification of the absorbance setup should therefore include a higher N.A. and
higher magnification objective. A possible example is the Zeiss Ultrafluar series of objectives.
These objectives use quartz lenses and are therefore able to transmit deep UV light. An
objective with a 100×magnification and a numerical aperture of N.A. 1.25 is available which
should provide better specimen resolution and enhanced signal, compared to the objective
used by us. Further enhancement of the signal and image quality could also be provided by a
different camera. While the EMCCD camera used by us (Evolve 512 Delta, Photometrics,
UK) only has a quantum yield of 10% at wavelengths of 280 nm, there exist cameras such as
the Prime 95B UV (Photometrics, UK) which are optimised for use between 250-310 nm
and have a quantum yield of up to 80% in this range.
A look at the equation of the absorbance A=∑Ni=1 = εi×ci×Li can help us identify potential
changes of the microfluidic design that could lead to a stronger absorbance contrast and
hence a better signal to noise ratio. From the equation above, we see that the absorbance A
scales directly with the optical path length L. Running the assay with larger vesicles would
increase the relevant path length and therefore directly enhance the absorbance contrast
between a GUV and the background. The microfluidic channels currently have a height of
40 µm, which also sets the upper boundary for the size of the GUVs. The redesign of the
microfluidic chip with a larger channel height would allow us to perform the experiment
with larger vesicles and obtain a better contrast. In our work with the permeability assay
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presented in Chapter 4, we aimed to produce vesicles between ∅ 20-30 µm. However, in
these experiments we observed that is possible to form GUVs with diameters of up to 60 µm,
with the OLA permeability platform. The combination of this microfluidic chip with the
absorbance assay might thus provide a possibility to enhance the absorbance contrast by up
to 50%.
The other elements contributing to the absorbance are the molar attenuation coefficient and
the drug concentration. Both the aqueous solubility (determining the maximal possible drug
concentration) and the attenuation coefficient ε are material properties of the compound.
We used fleroxacin in our studies presented here, as it shows both autofluorescence upon
excitation at λ = 340 nm, as well as an absorbance peak λ = 280 nm and can therefore
be measured with both the absorbance, and the autofluorescence assays. However, we did
not screen and compare the absorbance of fleroxacin to that of other compounds. It is
likely that other antibiotics with an absorbance peak in the range of our Deep UV LED,
such as rifampicin, isoniazid, or pyrazinamide [264] have a greater attenuation coefficient
and thus show a stronger overall absorbance. In future studies the antibiotic classes that
the afore mentioned compounds belong to (rifamycins, hydrazides or pyrazine derivatives)
could systematically be screened in order to determine whether they express a stronger UV
absorbance than fluoroquinolones, and correspondingly whether they are more promising
candidates for the absorbance assay.

Chapter 7
Summary and Outlook
The aim of this thesis was to use microfluidics for the investigation of passive transport
processes through lipid membranes. We used the lipid bilayer of giant unilamellar vesicles
as model for biological cell membranes. These membranes consist of a single lipid bilayer
of a well-defined lipid composition and, unlike natural cell membranes, do not contain any
membrane proteins. They therefore provide an ideal system for the isolated study of passive
transport processes.
A novel microfluidic method called Octanol-Assisted Liposome Assembly (OLA) was the
primary source of GUVs in our studies. Presented in 2016, this method has great potential for
the study of membrane transport processes. Other microfluidic methods to generate GUVs
on chip use alkanes or fatty acids as carrier phase for the lipid. In many cases, the vesicles
made with these methods contain residual solvent in the membrane which has to be removed
from the GUV in a subsequent washing step [54]. In contrast to that, OLA used the aliphatic
alcohol 1-octanol as carrier phase for the lipids. The developers of the OLA technique have
found that the use of octanol diminished the need for a second washing step, as the octanol
separates from the GUV automatically due to a combination of surface tension minimisation
as well as shear forces from the fluid flow and PDMS channel wall [56]. This property of
OLA makes it an ideal candidate to be incorporated into microfluidic transport platforms to
measure membrane permeability.
Before turning to microfluidic transport studies on the GUVs, we wanted to gain a better
understanding of the properties of the GUVs made with the novel OLA technique. For this
purpose, we compared vesicles generated with OLA to those obtained using the established
electroformation method. Using confocal microscopy, we showed that OLA vesicles are
highly homogeneous and have a very narrow size distribution upon production. Furthermore,
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we observed the absence of any multivesicular or multilamellar vesicles among the OLA
vesicles. We also tested the unilamellarity of the OLA vesicles quantitatively via a dithionite
bleaching assay. In this assay, the membrane impermeable anion sodium dithionite is added
to a population of vesicles labelled with the fluorophore NBD. While the inner leaflet
remains unaffected, the dithionite reduces and quenches the fluorophore in the outer leaflet
of the membrane [120]. A drop to in vesicle fluorescence to half of the initial value, like
we observed it for the OLA vesicles, therefore quantitatively shows a lamellar structure
consisting of a single lipid bilayer.
Previous research has shown that the lipid headgroup has substantial influence on the prop-
erties of the membrane [124, 150]. It is therefore important to know the precise lipid
composition of the vesicles when conducting biophysical studies. However, there exists
evidence suggesting that different lipid types have a different affinity to octanol [123]. We
wanted to rule out the possibility of a demixing of the lipids in the Lipid-Octanol (LO) phase
in OLA and tested whether or not the lipid mixture we add to the octanol translates directly
into the lipid composition of the GUVs. For this purpose, we combined the lipids DOPC,
DOPG and DOPE in the mixing ratios 1:3, 3:1 and 1:1 each. One of the lipid components
in every binary lipid mixture was doped with a fluorescent tracer. From the scaling of the
fluorescence intensity between the generated liposomes, we were able to show that the GUVs
indeed maintain the lipid composition we add to the octanol. However, we were unable to
form stable GUVs made from the DOPE-DOPG mixture in the 1:3 ratio, which we attribute
to the high charge density as well as to the lipid polymorphism which makes it energetically
unfavourable for PE lipids to form lamellar structures [126].
Next, we compared the lateral diffusion coefficient of DOPC and POPC vesicles obtained
with electroformation and OLA by means of fluorescence recovery after photobleaching
(FRAP). The lateral diffusion coefficient is an important biophysical property of membranes
and the lateral mobility of lipids and proteins has been found to be rate limiting for many
cellular processes [148–150]. Our results showed quantitatively similar lateral diffusion
coefficients for vesicles obtained with the two techniques. Importantly, we found that the
presence of the Poloxamer P-188, which is necessary for the formation of vesicles with
OLA, does not affect the lateral lipid mobility. This finding is in line with other studies that
have not found the alteration of membrane properties due to the presence of P-188 [81, 82].
Among the tested vesicles were also GUVs that had an octanol pocket attached to them.
These vesicles were not subjected to enough shear force within the microfluidic chip for the
octanol pocket to separate from it. Interestingly, we found no difference in lateral diffusion
between the vesicles with and without visible octanol pocket. Similar results have been found
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by Karamdad et al. who used a different microfluidic method to form vesicles and likewise
found no difference in the mechanical properties between vesicles with and without residue
solvent attached to them [52].
After the investigating of the membrane properties of OLA vesicles, we turned to the devel-
opment of a microfluidic platform that enables the measurement of membrane permeability
coefficients. We combined the OLA technique with a T-junction design that allows for the
controlled exposure of GUVs to a substance of interest [37, 68]. The interaction between
the vesicle and the target molecule can be observed as the vesicles flows along a microflu-
idic channel, engulfed in the solute. The microfluidic chip is operated on a custom-built
epifluorescence setup that allows the excitation of the molecule whose transport is to be
studied with a target wavelength. We performed permeation studies on vesicles made from a
DOPC-DOPG lipid mixture on the fluoroquinolones norfloxacin and ciprofloxacin, exploiting
the autofluorescence these antibiotics show upon excitation in the UV (λex = 350 nm). As the
autofluorescing drug diffuses across the lipid membrane, the vesicles increase in brightness
over time. By measuring the intensity of the vesicles at two well-defined time points, we can
calculate the permeability coefficient of the respective drug to the vesicle membrane.
We measured a median permeability coefficient of 3.57 × 10−6 cm/s for norfloxacin and
4.83× 10−6 cm/s for ciprofloxacin in a PBS buffer at pH 7.4, respectively. These values agree
with the partition coefficients of the drugs, as well as previous studies on lipid vesicles [68, 98].
In addition to the permeability value at pH 7.4, we showed that norfloxacin does not permeate
the PGPC membrane over a time period of 40 seconds in an acidic pH 5 environment.
The reason for this is the fact that at pH 5, the zwitterionic norfloxacin molecules are
predominantly in their charged form which cannot easily permeate the hydrocarbon layer
of the membrane [37]. Importantly, the pH 5 measurements revealed that the observed
membrane permeability is indeed due to passive diffusion and does not stem from leakage
caused by shear or other forms of mechanical stress on the membrane.
The presented microfluidic platform is an advancement to previous liposome-based perme-
ability assays, due to its incorporation of the OLA technique. OLA allows for the reliable
liposome formation in a wide range of buffers and at salt concentrations that prove difficult
for other methods of GUV formation [56, 23]. Vesicle formation is furthermore possible with
various lipid types, as we showed in our analysis of the lipid mixtures. Another advantage
of the technique is its ability to effectively encapsulate substances inside the vesicles. By
encapsulating fluorescent tracers or other biomarkers, compounds can be studied that do not
express fluorescence themselves [69].
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We used the capability of OLA to encapsulate substance inside the vesicles in the study of
proton flux through vesicle membranes [121, 228]. Charged molecules and ions typically
do not cross lipid membranes via passive diffusion. Instead, their transport is mediated via
transmembrane proteins that span the lipid bilayer [4]. The recreation of such channel proteins
is an active field of research in disciplines like synthetic biology. One promising approach for
the creation of artificial ion channels is DNA nanotechnology. Using a DNA nanostructure
that has previously shown ion conductance in electrophysiological measurements [228], we
attempted to measure proton transport through the pore using microfluidics. We conducted
the measurements on a novel microfluidic platform that enables the GUV formation with
OLA and their subsequent capture on chip using vesicle traps [69]. The immobilised vesicles
can then be perfused with a substance of interest. Importantly, the vesicle are trapped in up to
eight separate perfusion chambers, which allowed us to expose vesicles created in identical
chemical environment to different substances.
We trapped DOPC vesicles and performed two perfusion steps on them. In the first perfusion
step, half of the perfusion chambers were flushed with the DNA nanopore, whereas the other
half was flushed with a simple buffer solution. In the second perfusion step, we exposed
all trapped vesicles to a low pH solution. Vesicle formation, as well as the first perfusion
step for all vesicles occurred at pH 7.4, the second perfusion step at pH 5.9. Importantly,
we encapsulated the fluorescent pH indicator HPTS inside the vesicles. HPTS is strongly
fluorescent at neutral pH, but the signal is effectively quenched at lower pH values [235].
Since the pH is defined as the negative decadic logarithm of the proton concentration, the
fluorescence is a direct readout of the number of protons inside the GUVs.
To our surprise, we observed a drop in fluorescence and therefore a significant proton
transport in both, the vesicles that were incubated with the DNA pore, as well as for the
control group. Moreover, the fluorescent traces of both sets of vesicles showed a similar,
distinct biexponential decay curve. Our analysis revealed that the initial drop in fluorescence,
to about 70% of the initial value, coincides with the pH shift inside the perfusion chamber.
This first decay is completed after approximately 20-40 minutes. After that, the vesicle
fluorescence exponentially decreases steadily at a lower rate until the observation was
terminated, 400 minutes after exposure to the low pH solution. Our analysis of the decay
parameters of the secondary decrease did not show significant differences between the
vesicles that were exposed to the DNA pore or the buffer solution.
It turns out that proton transport represents a special form of membrane transport, whose
mechanism is still an intensively debated topic [241, 243]. While lipid membranes provide
an effective barrier for the ions of basic salts, hydrogen ions (protons) are able to cross
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the membrane without the assistance of transmembrane proteins. Two main theories are
proposed to explain this anomaly. According to one model, proton permeation occurs along
transient hydrogen-bonded chains. These act similar to an electrical wire, which is why
they are termed “water wires” [241]. The second model explains the unusually high proton
permeability with the presence of contaminants that act as a protonophore and thereby
mediate the proton transport [243]. Furthermore, the proton permeability spans over a large
range of permeability values and depends strongly on the chemical environment [241]. It is
possible that this behavior of proton transport, as well as potential counter ion movement,
is responsible for the distinct biexponential shape we observe in our fluorescence decay
curves [247].
The high passive permeation impeded our capability to detect substantial enhancement of
proton flux through the DNA pore. Although overall we observed a slightly greater decrease
in fluorescence for the vesicles incubated with the DNA structures, we cannot rule out the
possibility that this is an artefact stemming from differences in perfusion speed between the
different experiments. Different ions such as sodium or potassium might be more suited to
assess the ion translocation through the DNA nanopores, as no substantial passive transport
of these ions should occur over our observation period. Advances in the development of
photo stable indicators for these ions could open up the possibility for further experiments in
this direction.
In a last series of experiments, we looked into a different optical method which can be
combined with our microfluidic transport assays. Instead of relying on autofluorescence or
fluorescent tracers to visualise the target molecules, we used Beer-Lambert’s law and exploit
the absorbance peak that many organic molecules express in the deep UV to visualise the
transport [256]. We designed and constructed an optical setup in which we collimated UV
light from a 280 nm light source and radiated it on a microfluidic T-junction chip. The deep
UV light is absorbed and therefore strongly attenuated by the target molecule. Because the
absorbance scales linearly with the concentration, the transmitted intensity can be used as
metric for the presence of the absorbing substance.
We conducted initial validation experiments on electroformed DPhPC vesicles on the flu-
oroquinolone antibiotic fleroxacin. This drug expresses both an absorbance peak at the
wavelength of our deep UV LED (λLED= 280 nm) and can also be imaged using its autofluo-
rescence upon excitation at 340 nm. The microfluidic chip design we used for the absorbance
experiments consists of a simple T-junction design. As before, a stream of GUVs encounters
and mixes with a stream of drug solute in the microfluidic chip. The vesicles in this assay
initially appear bright on a dark background, as no absorbing drug is present within the lipid
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vesicle initially. As the drug permeates through the membrane, the transmitted brightness
of the vesicles decreases. By comparing the transmitted intensities of GUVs at two distinct
time points, we can calculate the permeability coefficient.
Using the novel assay, we obtained a mean permeability coefficient (mean ± SE) for flerox-
acin molecules through DPhPC vesicle membranes of 14.4 ± 2.1 × 10−6 cm/s (N = 29) in a
5 mM acetic acid buffer at pH 5. In an earlier publication, we measured the drug permeability
in the same buffer using autofluorescence. In these experiments, we obtained a value of
4.1 ± 0.2 × 10−6 cm/s (N = 283). The two measurements hence differ by a factor of 3.5. We
attribute this deviation to two main factors. The first is the fact that we were bound to lower
resolution optics in the absorbance assay. We were not able to use the same objective in both
experiments. The 60× water immersion objective (N.A. 1.2) used for the autofluorescence
measurements does not transmit light in the deep UV. Therefore, we had to use a 40× air
objective (N.A. 0.5) made of fused silica to measure the transmitted deep UV rays. However,
due to its lower magnification and numeric aperture, this objective does not provide the
same degree of specimen resolution and captures less light than the objective used for the
autofluorescence assay. The second element impeding our measurements with the absorbance
assay was the low signal to noise ratio of this method. While the detected intensity contrast
between a vesicle and the background lies in the order of 60% – 100% in the autofluorescence
assay, this difference is only 10% – 20% in the absorbance assay. This is despite the fact
that we used a 4-fold higher drug concentration in the latter method. We also attribute the
low number of detected vesicles in the absorbance assay to its low signal to noise ratio. The
smaller number of data points further contributes to the deviation in measured permeability
coefficient. All in all, however, our measurements show that it is possible to determine
the membrane permeability exploiting a molecules absorbance property in the deep UV.
Yet, in order for the absorbance experiments to match the preciseness of our permeability
measurements based on autofluorescence, modifications of the setup are needed. Optical
hardware more suitable for measurements in the deep UV could be introduced. Further,
adjustments of the microfluidic chip design that increase absorbance contrast, such as the use
of larger GUVs, are possible.
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In this thesis, we worked on the development and validation of new microfluidic methods
to measure passive membrane permeation. The microfluidic OLA technique is an ideal
platform for this purpose, as it allows us to generate vesicles and perform transport mea-
surements in a wide range of chemical environments and at physiologically relevant pH
and salt concentrations. Due to their microfluidic characters, we only require small reagent
volumes in the platforms presented here. This makes our tools suitable for use in the early
stages of drug development, when only small quantities of compounds are available for
experimentation [69].
Another main advantage of OLA is its ability to encapsulate substances inside the vesicle
upon formation. This enables us to work with fluorescent tracers and biomarkers in our
transport studies. In our experiments on proton permeation, we already made use of this
property of the technique to encapsulate the pH indicator HPTS inside the GUVs. However,
fluorescent biosensors are available for a large number of other molecules. In recent years,
there has been particularly strong progress in the development of biosensors based on DNA
aptamers [265]. DNA aptamers are short, single DNA strands that selectively bind to a
target substance [266]. For example, an aptamer that is known to bind to the broad-spectrum
antibiotic kanamycin A, was used by Ma et al. for the development of fluorescent biosensors
to this drug [267]. The mechanism of the biosensor is schematically drawn in Figure 7.1.
Fig. 7.1. Mechanism of fluorescent aptamer biosensor for kanamycin A. Four aptamers
form a G-quadruplex (G4) structure which can bind to G4-sensitive dyes as well as the
antibiotic. If bound to the fluorescent dye Thioflavin T (ThT), the aptamers form a complex
that expresses a higher fluorescence than the unbound dye. The displacement of the dye with
kanamycin A therefore leads to a drop in fluorescence signal, an effect which can be used to
assess the presence of kanamycin molecules. Image from [267].
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In solution, four kanamycin aptamer strands associate into a G-quadruplex (G4) structure.
As such, both the antibiotic, as well as G4 sensitive dyes like Thioflavin T (ThT) can bind
to the structure. If bound to the aptamer, the Aptamer-ThT complex expresses a stronger
fluorescence than the unbound dye. The biosensor makes use of this effect, as well as of
the fact that the aptamer has a higher affinity to bind to kanamycin than to the dye. If
the Aptamer-ThT complex encounters a kanamycin molecule, its fluorescence is therefore
effectively “turned off”. It is likely that biosensors with such fluorescence properties can be
used with our microfluidic tools.
Another example of a highly debated transport process that can be explored with our tools is
that of free fatty acids (FFAs) permeation. Fatty acids are carboxylic acids with aliphatic
chain of different lengths. Examples of three fatty acids are shown in Figure 7.2.
Fig. 7.2. Three examples of fatty acid molecules. The name of the acid and the number of
carbon atoms are indicated.
Fatty acids are an important component in the human body and serve different structural,
functional or biological roles [268]. For instance, as we know from our discussion in
Chapter 1, they are a component of the lipids that make up the cell membrane [4]. However,
the elevated circulation and cellular uptake of FFAs is also linked to a number of diseases
such as diabetes, hypertension, atherosclerosis and non-alcoholic fatty liver disease [269].
Despite its severe medical implications, the process of membrane permeation is still not well
understood. While short chained FFAs with five carbon atoms or less seem to follow the
same diffusion mechanism as the small antibiotic molecules we investigated in this thesis,
medium and long chained FFAs with more than 6 carbon atoms, are believed to cross the
membrane via a flip-flop mechanism, as well as mediated by transporter proteins [157].
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Further elements of controversy are the magnitude of the transport rate and the rate-limiting
kinetic step of the transport [270].
Importantly, there exist fluorescent conjugates of the FFAs as well as fluorescent biomarkers
such as the Acrylodan labeled Intestinal Fatty Acid Binding Protein (ADIFAB) that serve
as indicators for FFAs [271]. Free fatty acids are therefore a promising candidate that we
can study with our microfluidic assays. A possible experiment could be, for instance, to
encapsulate the fluorescent biomarker ADIFAB inside GUVs using OLA and use it as a
readout for the transport of FFA molecules into the vesicles. Alternatively, the fluorescently
tagged version of the FFA molecules can be exposed to vesicle membranes directly using our
permeability platform. In the latter case, however, it would be necessary to also investigate
the effect of the fluorescent label on the transport properties of the molecule.
While the different mechanisms of passive diffusion are far from fully understood, a worth-
while aim for the further development of the microfluidic tools could be to enable the
investigation of facilitated diffusion or even active transport. It is a well-known fact that
many molecules do not cross cellular membranes via passive diffusion, but are mediated by
porins or active transporters [4, 272]. The expansion of the OLA technique for the on-chip
formation of proteoliposomes, could provide greater insight into the transport processes and
the interplay between these proteins and other membrane components.
Membrane transport is fundamental for all living cells. Gaining a better understanding of the
laws that govern membrane processes is not just important for the fields of drug discovery or
cell signalling, but across a wide range of biological and biophysical questions. The methods
presented in this thesis opens this field up to further investigation and provide a useful tool to
improve our knowledge of this fundamental aspect of cellular life.

References
[1] Howard Gest. The discovery of microorganisms by robert hooke and antoni van
leeuwenhoek, fellows of the royal society. Notes and records of the Royal Society of
London, 58(2):187–201, 2004.
[2] Paolo Mazzarello. A unifying concept: the history of cell theory. Nature Cell Biology,
1(1):E13–E15, 1999.
[3] Nina Parker, Mark Schneegurt, Anh-Hue Thi Tu, Philip Lister, and Brian M Forster.
Microbiology. OpenStax, 2016.
[4] Bruce Alberts, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and
Peter Walter. Molecular Biology of the Cell. Garland Science, 4th edition, 2002.
[5] Wilhelm Pfeffer. Osmotische Untersuchungen: Studien zur Zellmechanik. W. Engel-
mann, 1877.
[6] Thomas Heimburg. Thermal Biophysics of Membranes. John Wiley & Sons, 2008.
[7] Jonathan Lombard. Once upon a time the cell membranes: 175 years of cell boundary
research. Biology Direct, 9(1):32, 2014.
[8] Steven H Zeisel. A brief history of choline. Annals of Nutrition and Metabolism,
61(3):254–258, 2012.
[9] Mary Ann Clark, Matthew Douglas, and Jung Choi. Biology. OpenStax, 2nd edition,
2018.
[10] E Gorter and F Grendel. On bimolecular layers of lipoids on the chromocytes of the
blood. Journal of Experimental Medicine, 41(4):439–443, 1925.
[11] Gheorghe Benga. Structure and Properties of Cell Membranes: Volume I. CRC Press,
2018.
[12] David J Robertson. The ultrastructure of cell membranes and their derivatives. In
Biochemical Society Symposium, volume 16, pages 3–43, 1959.
[13] Jonathan S Singer and Garth L Nicolson. The fluid mosaic model of the structure of
cell membranes. Science, 175(4023):720–731, 1972.
156 References
[14] Garth L Nicolson. The fluid—mosaic model of membrane structure: Still rele-
vant to understanding the structure, function and dynamics of biological membranes
after more than 40 years. Biochimica et Biophysica Acta (BBA)-Biomembranes,
1838(6):1451–1466, 2014.
[15] Nicole J Yang and Marlon J Hinner. Getting across the cell membrane: an overview
for small molecules, peptides, and proteins. In Site-Specific Protein Labeling, pages
29–53. Springer, 2015.
[16] Abhirup Mandal, Vibhuti Agrahari, Varun Khurana, Dhananjay Pal, and Ashim K
Mitra. Transporter effects on cell permeability in drug delivery. Expert Opinion on
Drug Delivery, 14(3):385–401, 2017.
[17] Hannah Sunshine and M Luisa Iruela-Arispe. Membrane lipids and cell signaling.
Current Opinion in Lipidology, 28(5):408–413, 2017.
[18] Inchul Cho, Mark R Jackson, and Joe Swift. Roles of cross-membrane transport
and signaling in the maintenance of cellular homeostasis. Cellular and Molecular
Bioengineering, 9(2):234–246, 2016.
[19] Huseyin Demirbilek, Sonya Galcheva, Dogus Vuralli, Sara Al-Khawaga, and Khalid
Hussain. Ion transporters, channelopathies, and glucose disorders. International
Journal of Molecular Sciences, 20(10):2590, 2019.
[20] Anne H Delcour. Outer membrane permeability and antibiotic resistance. Biochimica
et Biophysica Acta (BBA)-Proteins and Proteomics, 1794(5):808–816, 2009.
[21] Jehangir Cama, Harsha Bajaj, Stefano Pagliara, Theresa Maier, Yvonne Braun, Math-
ias Winterhalter, and Ulrich F Keyser. Quantification of fluoroquinolone uptake
through the outer membrane channel ompf of escherichia coli. Journal of the Ameri-
can Chemical Society, 137(43):13836–13843, 2015.
[22] Demetri Psaltis, Stephen R Quake, and Changhuei Yang. Developing optofluidic
technology through the fusion of microfluidics and optics. Nature, 442(7101):381–
386, 2006.
[23] Dirk van Swaay and Andrew DeMello. Microfluidic methods for forming liposomes.
Lab Chip, 13(5):752–767, 2013.
[24] Abolfazl Akbarzadeh, Rogaie Rezaei-Sadabady, Soodabeh Davaran, Sang Woo Joo,
Nosratollah Zarghami, Younes Hanifehpour, Mohammad Samiei, Mohammad Kouhi,
and Kazem Nejati-Koshki. Liposome: classification, preparation, and applications.
Nanoscale Research Letters, 8(1):102, 2013.
[25] Alec D Bangham and RW Horne. Negative staining of phospholipids and their
structural modification by surface-active agents as observed in the electron microscope.
Journal of Molecular Biology, 8(5):660–668, 1964.
[26] David W Deamer. From “banghasomes” to liposomes: a memoir of alec bangham,
1921–2010. The FASEB Journal, 24(5):1308–1310, 2010.
References 157
[27] AD Bangham, Malcolm M Standish, and Jeff C Watkins. Diffusion of univalent
ions across the lamellae of swollen phospholipids. Journal of Molecular Biology,
13(1):238–252, 1965.
[28] AD Bangham, MM Standish, and G Weissmann. The action of steroids and streptolysin
s on the permeability of phospholipid structures to cations. Journal of Molecular
Biology, 13(1):253–259, 1965.
[29] Grazia Sessa and Gerald Weissmann. Phospholipid spherules (liposomes) as a model
for biological membranes. Journal of Lipid Research, 9(3):310–318, 1968.
[30] Rumiana Dimova. Giant vesicles and their use in assays for assessing membrane phase
state, curvature, mechanics, and electrical properties. Annual Review of Biophysics,
48:93–119, 2019.
[31] Mehmet E Solmaz, Roshni Biswas, Shalene Sankhagowit, James R Thompson,
Camilo A Mejia, Noah Malmstadt, and Michelle L Povinelli. Optical stretching
of giant unilamellar vesicles with an integrated dual-beam optical trap. Biomedical
Optics Express, 3(10):2419–2427, 2012.
[32] John P Reeves and Robert M Dowben. Formation and properties of thin-walled
phospholipid vesicles. Journal of Cellular Physiology, 73(1):49–60, 1969.
[33] Miglena I Angelova and Dimiter S Dimitrov. Liposome electroformation. Faraday
Discussions of the Chemical Society, 81:303–311, 1986.
[34] Omar Mertins, Nádya P da Silveira, Adriana R Pohlmann, André P Schröder, and
Carlos M Marques. Electroformation of giant vesicles from an inverse phase precursor.
Biophysical Journal, 96(7):2719–2726, 2009.
[35] Sarah L Veatch and Sarah L Keller. Seeing spots: complex phase behavior in sim-
ple membranes. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research,
1746(3):172–185, 2005.
[36] Hammad A Faizi, Shelli L Frey, Jan Steinkühler, Rumiana Dimova, and Petia M
Vlahovska. Bending rigidity of charged lipid bilayer membranes. Soft Matter,
15(29):6006–6013, 2019.
[37] J Cama, C Chimerel, S Pagliara, A Javer, and UF Keyser. A label-free microfluidic
assay to quantitatively study antibiotic diffusion through lipid membranes. Lab Chip,
14(13):2303–2308, 2014.
[38] Jonas Korlach, Petra Schwille, Watt W Webb, and Gerald W Feigenson. Character-
ization of lipid bilayer phases by confocal microscopy and fluorescence correlation
spectroscopy. Proceedings of the National Academy of Sciences, 96(15):8461–8466,
1999.
[39] Rumiana Dimova, Pasquale Stano, Carlos M Marques, and Peter Walde. Preparation
methods for giant unilamellar vesicles. In Rumiana Dimova and Carlos M Marques,
editors, The Giant Vesicle Book, chapter 1, pages 3–20. CRC Press, 2019.
158 References
[40] Marie Breton, Mooud Amirkavei, and Lluis M Mir. Optimization of the electroforma-
tion of giant unilamellar vesicles (guvs) with unsaturated phospholipids. The Journal
of Membrane Biology, 248(5):827–835, 2015.
[41] Jan Steinkühler, Philippe De Tillieux, Roland L Knorr, Reinhard Lipowsky, and
Rumiana Dimova. Charged giant unilamellar vesicles prepared by electroformation
exhibit nanotubes and transbilayer lipid asymmetry. Scientific Reports, 8(1):11838,
2018.
[42] Eda Baykal-Caglar, Ebrahim Hassan-Zadeh, Bahar Saremi, and Juyang Huang. Prepa-
ration of giant unilamellar vesicles from damp lipid film for better lipid compositional
uniformity. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1818(11):2598–
2604, 2012.
[43] M Gertrude Gutierrez, Shotaro Yoshida, Noah Malmstadt, and Shoji Takeuchi. Pho-
tolithographic patterned surface forms size-controlled lipid vesicles. APL Bioengi-
neering, 2(1):016104, 2018.
[44] Peter Walde, Katia Cosentino, Helen Engel, and Pasquale Stano. Giant vesicles:
preparations and applications. ChemBioChem, 11(7):848–865, 2010.
[45] Michel Wautelet. Scaling laws in the macro-, micro-and nanoworlds. European
Journal of Physics, 22(6):601, 2001.
[46] Jake J Abbott, Zoltan Nagy, Felix Beyeler, and Bradley J Nelson. Robotics in the
small, part i: microbotics. IEEE Robotics & Automation Magazine, 14(2):92–103,
2007.
[47] Edward M Purcell. Life at low reynolds number. American Journal of Physics,
45(1):3–11, 1977.
[48] David J Beebe, Glennys A Mensing, and Glenn M Walker. Physics and applications
of microfluidics in biology. Annual Review of Biomedical Engineering, 4(1):261–286,
2002.
[49] Eric K Sackmann, Anna L Fulton, and David J Beebe. The present and future role of
microfluidics in biomedical research. Nature, 507(7491):181–189, 2014.
[50] Dorothee Krafft, Sebastian Lopez-Castellanos, Rumiana Dimova, Ivan Ivanov, and
Kai Sundmacher. Compartments for synthetic cells: Osmotically assisted separation
of oil from double emulsions in microfluidic chip. ChemBioChem, 20(20):2604–2608,
2019.
[51] Shia-Yen Teh, Ruba Khnouf, Hugh Fan, and Abraham P Lee. Stable, biocompatible
lipid vesicle generation by solvent extraction-based droplet microfluidics. Biomicroflu-
idics, 5(4):044113, 2011.
[52] K Karamdad, RV Law, JM Seddon, NJ Brooks, and O Ces. Preparation and mechanical
characterisation of giant unilamellar vesicles by a microfluidic method. Lab Chip,
15(2):557–562, 2015.
References 159
[53] Sandro Matosevic and Brian M Paegel. Stepwise synthesis of giant unilamellar
vesicles on a microfluidic assembly line. Journal of the American Chemical Society,
133(9):2798–2800, 2011.
[54] Yung-Chieh Tan, Kanaka Hettiarachchi, Maria Siu, Yen-Ru Pan, and Abraham Phillip
Lee. Controlled microfluidic encapsulation of cells, proteins, and microbeads in lipid
vesicles. Journal of the American Chemical Society, 128(17):5656–5658, 2006.
[55] Antoine Vian, Valentine Favrod, and Esther Amstad. Reducing the shell thickness of
double emulsions using microfluidics. Microfluidics and Nanofluidics, 20(12):159,
2016.
[56] Siddharth Deshpande, Yaron Caspi, Anna EC Meijering, and Cees Dekker. Octanol-
assisted liposome assembly on chip. Nature Communications, 7:10447, 2016.
[57] Laura R Arriaga, Sujit S Datta, Shin-Hyun Kim, Esther Amstad, Thomas E Kodger,
Francisco Monroy, and David A Weitz. Ultrathin shell double emulsion templated giant
unilamellar lipid vesicles with controlled microdomain formation. Small, 10(5):950–
956, 2014.
[58] Justin L MacCallum and D Peter Tieleman. Structures of neat and hydrated 1-octanol
from computer simulations. Journal of the American Chemical Society, 124(50):15085–
15093, 2002.
[59] Andréas Manz, N Graber, and H áM Widmer. Miniaturized total chemical analysis
systems: a novel concept for chemical sensing. Sensors and Actuators B: Chemical,
1(1-6):244–248, 1990.
[60] Gina S Fiorini and Daniel T Chiu. Disposable microfluidic devices: fabrication,
function, and application. BioTechniques, 38(3):429–446, 2005.
[61] Younan Xia and George M Whitesides. Soft lithography. Annual Review of Materials
Science, 28(1):153–184, 1998.
[62] George M Whitesides, Emanuele Ostuni, Shuichi Takayama, Xingyu Jiang, and
Donald E Ingber. Soft lithography in biology and biochemistry. Annual Review of
Biomedical Engineering, 3(1):335–373, 2001.
[63] Yujie Ma, Julian Thiele, Loai Abdelmohsen, Jinge Xu, and Wilhelm TS Huck. Bio-
compatible macro-initiators controlling radical retention in microfluidic on-chip photo-
polymerization of water-in-oil emulsions. Chemical Communications, 50(1):112–114,
2014.
[64] Siddharth Deshpande and Cees Dekker. On-chip microfluidic production of cell-sized
liposomes. Nature Protocols, 13(5):856, 2018.
[65] Shohei Kaneda, Koichi Ono, Tatsuhiro Fukuba, Takahiko Nojima, Takatoki Yamamoto,
and Teruo Fujii. Modification of the glass surface property in pdms-glass hybrid
microfluidic devices. Analytical Sciences, 28(1):39–44, 2012.
160 References
[66] Tatiana Trantidou, Yuval Elani, Edward Parsons, and Oscar Ces. Hydrophilic surface
modification of pdms for droplet microfluidics using a simple, quick, and robust
method via pva deposition. Microsystems & Nanoengineering, 3:16091, 2017.
[67] JM Gohil and P Ray. Studies on oxalic acid as a crosslinker of polyvinyl alcohol.
Polymers and Polymer Composites, 17(7):403–410, 2009.
[68] Michael Schaich, Jehangir Cama, Kareem Al Nahas, Diana Sobota, Hannah Sleath,
Kevin Jahnke, Siddharth Deshpande, Cees Dekker, and Ulrich F Keyser. An integrated
microfluidic platform for quantifying drug permeation across biomimetic vesicle
membranes. Molecular Pharmaceutics, 2019.
[69] Kareem Al Nahas, Jehangir Cama, Michael Schaich, K Hammond, S Deshpande, Cees
Dekker, MG Ryadnov, and UF Keyser. A microfluidic platform for the characterisation
of membrane active antimicrobials. Lab Chip, 19(5):837–844, 2019.
[70] Siddharth Deshpande, Anthony Birnie, and Cees Dekker. On-chip density-based
purification of liposomes. Biomicrofluidics, 11(3):034106, 2017.
[71] Siddharth Deshpande, Willem Kasper Spoelstra, Marleen van Doorn, Jacob Kersse-
makers, and Cees Dekker. Mechanical division of cell-sized liposomes. ACS Nano,
12(3):2560–2568, 2018.
[72] Daniel J Estes and Michael Mayer. Giant liposomes in physiological buffer using elec-
troformation in a flow chamber. Biochimica et Biophysica Acta (BBA)-Biomembranes,
1712(2):152–160, 2005.
[73] Thomas H Vaughn, HR Suter, Lester G Lundsted, and Marc G Kramer. Properties of
some newly developed nonionic detergents. Journal of the American Oil Chemists’
Society, 28(7):294–299, 1951.
[74] Joseph G Moloughney and Noah Weisleder. Poloxamer 188 (p188) as a membrane re-
sealing reagent in biomedical applications. Recent Patents on Biotechnology, 6(3):200–
211, 2012.
[75] Irving R Schmolka. A review of block polymer surfactants. Journal of the American
Oil Chemists’ Society, 54(3):110–116, 1977.
[76] Françoise Bonneté. Macromolecular crystallization controlled by colloidal interac-
tions: the case of urate oxidase. In Marcello Rubens and Barsi Andreeta, editors,
Crystallization - Science and Technology, chapter 13, pages 349–378. InTech Open,
2012.
[77] Martin Emanuele and Balu Balasubramaniam. Differential effects of commercial-
grade and purified poloxamer 188 on renal function. Drugs in R&D, 14(2):73–83,
2014.
[78] Patricia Adams-Graves, Amos Kedar, Mabel Koshy, Martin Steinberg, Robert Veith,
Daniel Ward, Rebekah Crawford, Suzanne Edwards, James Bustrack, and Martin
Emanuele. Rheothrx (poloxamer 188) injection for the acute painful episode of sickle
cell disease: a pilot study. Blood, 90(5):2041–2046, 1997.
References 161
[79] Eugene P Orringer, James F Casella, Kenneth I Ataga, Mabel Koshy, Patricia Adams-
Graves, Lori Luchtman-Jones, Ted Wun, Masayo Watanabe, Frank Shafer, Abdullah
Kutlar, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of
sickle cell disease: a randomized controlled trial. Jama, 286(17):2099–2106, 2001.
[80] Raphael C Lee, L Philip River, Fu-Shih Pan, Li Ji, and Robert L Wollmann. Surfactant-
induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proceed-
ings of the National Academy of Sciences, 89(10):4524–4528, 1992.
[81] Stacey A Maskarinec, Jürgen Hannig, Raphael C Lee, and Ka Yee C Lee. Direct
observation of poloxamer 188 insertion into lipid monolayers. Biophysical Journal,
82(3):1453–1459, 2002.
[82] Colette Weingarten, Nereide S Santos Magalhaes, Adam Baszkin, Simon Benita,
and Monique Seiller. Interactions of a non-ionic aba copolymer surfactant with
phospholipid monolayers: possible relevance to emulsion stabilization. International
Journal of Pharmaceutics, 75(2-3):171–179, 1991.
[83] Chi-Yuan Cheng, Jia-Yu Wang, Ravinath Kausik, Ka Yee C Lee, and Songi Han.
Nature of interactions between peo-ppo-peo triblock copolymers and lipid mem-
branes:(ii) role of hydration dynamics revealed by dynamic nuclear polarization.
Biomacromolecules, 13(9):2624–2633, 2012.
[84] Goran T Vladisavljevic´, Ruqaya Al Nuumani, and Seyed Ali Nabavi. Microfluidic
production of multiple emulsions. Micromachines, 8(3):75, 2017.
[85] HW Tan, AR Abdul Aziz, and MK Aroua. Glycerol production and its applications as
a raw material: A review. Renewable and Sustainable Energy Reviews, 27:118–127,
2013.
[86] Kelly M Schultz and Eric M Furst. High-throughput rheology in a microfluidic device.
Lab Chip, 11(22):3802–3809, 2011.
[87] Evangelia Roumpea, Nina M Kovalchuk, Maxime Chinaud, Emilia Nowak, Mark JH
Simmons, and Panagiota Angeli. Experimental studies on droplet formation in a
flow-focusing microchannel in the presence of surfactants. Chemical Engineering
Science, 195:507–518, 2019.
[88] S ten Klooster, S Sahin, and K Schroën. Monodisperse droplet formation by spon-
taneous and interaction based mechanisms in partitioned edge microfluidic device.
Scientific Reports, 9(1):7820, 2019.
[89] Nian-Sheng Cheng. Formula for the viscosity of a glycerol- water mixture. Industrial
& Engineering Chemistry Research, 47(9):3285–3288, 2008.
[90] Bo-Bi Tzeng and Yung-Shin Sun. Design and fabrication of a microfluidic viscometer
based on electrofluidic circuits. Micromachines, 9(8):375, 2018.
[91] Agnieszka Nowacka, Stephane Douezan, L Wadsö, Daniel Topgaard, and Emma Sparr.
Small polar molecules like glycerol and urea can preserve the fluidity of lipid bilayers
under dry conditions. Soft Matter, 8(5):1482–1491, 2012.
162 References
[92] Abraham D Stroock, Stephan KW Dertinger, Armand Ajdari, Igor Mezic´, Howard A
Stone, and George M Whitesides. Chaotic mixer for microchannels. Science,
295(5555):647–651, 2002.
[93] Peter Westh. Unilamellar dmpc vesicles in aqueous glycerol: preferential interactions
and thermochemistry. Biophysical Journal, 84(1):341–349, 2003.
[94] Witold K Surewicz. Membrane actions of water-soluble fusogens: effect of dimethyl
sulfoxide, glycerol and sucrose on lipid bilayer order and fluidity. Chemistry and
Physics of Lipids, 34(4):363–372, 1984.
[95] Albert Leo, Corwin Hansch, and David Elkins. Partition coefficients and their uses.
Chemical Reviews, 71(6):525–616, 1971.
[96] Younggil Kwon. Handbook of essential pharmacokinetics, pharmacodynamics and
drug metabolism for industrial scientists. Springer Science & Business Media, 2001.
[97] Dong-Sun Lee, Hee-Jung Han, Kun Kim, Won-Bong Park, Jung-Kil Cho, and Jae-
Hyun Kim. Dissociation and complexation of fluoroquinolone analogues. Journal of
Pharmaceutical and Biomedical Analysis, 12(2):157–164, 1994.
[98] Sowmya Purushothaman, Jehangir Cama, and Ulrich F Keyser. Dependence of
norfloxacin diffusion across bilayers on lipid composition. Soft Matter, 12(7):2135–
2144, 2016.
[99] Gregor Cevc, Ida Berts, Stefan F Fischer, Joachim O Radler, and Bert Nickel. Nanos-
tructures in n-octanol equilibrated with additives and/or water. Langmuir, 34(21):6285–
6295, 2018.
[100] Bin Chen and J Ilja Siepmann. Microscopic structure and solvation in dry and wet
octanol. The Journal of Physical Chemistry B, 110(8):3555–3563, 2006.
[101] NP Franks, MH Abraham, and WR Lieb. Molecular organization of liquid n-octanol:
An x-ray diffraction analysis. Journal of Pharmaceutical Sciences, 82(5):466–470,
1993.
[102] Kaarlo Sakari Vahvaselkä, RITVA Serimaa, and Mika Torkkeli. Determination of
liquid structures of the primary alcohols methanol, ethanol, 1-propanol, 1-butanol and
1-octanol by x-ray scattering. Journal of Applied Crystallography, 28(2):189–195,
1995.
[103] Michael J Pringle, Kenneth B Brown, and Keith W Miller. Can the lipid theories
of anesthesia account for the cutoff in anesthetic potency in homologous series of
alcohols? Molecular Pharmacology, 19(1):49–55, 1981.
[104] Beate Griepernau, Simon Leis, Matthias F Schneider, Martin Sikor, Daniel Steppich,
and Rainer A Böckmann. 1-alkanols and membranes: a story of attraction. Biochimica
Et Biophysica Acta (BBA)-Biomembranes, 1768(11):2899–2913, 2007.
[105] JD Whitby. Alcohol in anaesthesia and surgical resuscitation. Anaesthesia, 35(5):502–
505, 1980.
References 163
[106] Andreas Missner and Peter Pohl. 110 years of the meyer–overton rule: predicting
membrane permeability of gases and other small compounds. ChemPhysChem, 10(9-
10):1405–1414, 2009.
[107] Marieke Kranenburg and Berend Smit. Phase behavior of model lipid bilayers. The
Journal of Physical Chemistry B, 109(14):6553–6563, 2005.
[108] Thomas Heimburg and Andrew D Jackson. The thermodynamics of general anesthesia.
Biophysical Journal, 92(9):3159–3165, 2007.
[109] Frank K Hui and Peter G Barton. Mesomorphic behaviour of some phospholipids
with aliphatic alcohols and other non-ionic substances. Biochimica et Biophysica Acta
(BBA)-Lipids and Lipid Metabolism, 296(3):510–517, 1973.
[110] AW Eliasz, D Chapman, and DF Ewing. Phospholipid phase transitions. effects of
n-alcohols, n-monocarboxylic acids, phenylalkyl alcohols and quatenary ammonium
compounds. Biochimica et Biophysica Acta (BBA)-Biomembranes, 448(2):220–233,
1976.
[111] Martyn W Hill. The effect of anaesthetic-like molecules on the phase transition
in smectic mesophases of dipalmitoyllecithin i. the normal alcohol up to c= 9 and
three inhalation anaesthetics. Biochimica et Biophysica Acta (BBA)-Biomembranes,
356(1):117–124, 1974.
[112] AG Lee. Interactions between anesthetics and lipid mixtures. normal alcohols. Bio-
chemistry, 15(11):2448–2454, 1976.
[113] Elizabeth L Godden, R Adron Harris, and Thomas V Dunwiddie. Correlation between
molecular volume and effects of n-alcohols on human neuronal nicotinic acetylcholine
receptors expressed in xenopus oocytes. Journal of Pharmacology and Experimental
Therapeutics, 296(3):716–722, 2001.
[114] Thomas H Aagaard, Mette N Kristensen, and Peter Westh. Packing properties of
1-alkanols and alkanes in a phospholipid membrane. Biophysical Chemistry, 119(1):61–
68, 2006.
[115] Helgi I Ingólfsson and Olaf S Andersen. Alcohol’s effects on lipid bilayer properties.
Biophysical Journal, 101(4):847–855, 2011.
[116] Lewen Yang and James T Kindt. Simulation study of the permeability of a model lipid
membrane at the fluid–solid phase transition. Langmuir, 31(7):2187–2195, 2015.
[117] Andreas Blicher, Katarzyna Wodzinska, Matthias Fidorra, Mathias Winterhalter, and
Thomas Heimburg. The temperature dependence of lipid membrane permeability, its
quantized nature, and the influence of anesthetics. Biophysical Journal, 96(11):4581–
4591, 2009.
[118] Michael Schaich, Diana Sobota, Hannah Sleath, Jehangir Cama, and Ulrich F
Keyser. Characterization of lipid composition and diffusivity in ola generated vesicles.
Biochimica et Biophysica Acta (BBA)-Biomembranes, page 183359, 2020.
164 References
[119] Su Li, Peichi Hu, and Noah Malmstadt. Confocal imaging to quantify passive transport
across biomimetic lipid membranes. Analytical Chemistry, 82(18):7766–7771, 2010.
[120] Jonathan C McIntyre and Richard G Sleight. Fluorescence assay for phospholipid
membrane asymmetry. Biochemistry, 30(51):11819–11827, 1991.
[121] Alexander Ohmann, Chen-Yu Li, Christopher Maffeo, Kareem Al Nahas, Kevin N
Baumann, Kerstin Göpfrich, Jejoong Yoo, Ulrich F Keyser, and Aleksei Aksimentiev.
A synthetic enzyme built from dna flips 10 7 lipids per second in biological membranes.
Nature Communications, 9(1):2426, 2018.
[122] Elizabeth S Rowe, Fengli Zhang, Tina Wu Leung, James S Parr, and Peter T Guy.
Thermodynamics of membrane partitioning for a series of n-alcohols determined by
titration calorimetry: role of hydrophobic effects. Biochemistry, 37(8):2430–2440,
1998.
[123] Robert S Cantor. Bilayer partition coefficients of alkanols: predicted effects of varying
lipid composition. The Journal of Physical Chemistry B, 105(31):7550–7553, 2001.
[124] Kui Yang and Xianlin Han. Lipidomics: techniques, applications, and outcomes
related to biomedical sciences. Trends in Biochemical Sciences, 41(11):954–969,
2016.
[125] Paul A Beales, Barbara Ciani, and Alexa J Cleasby. Nature’s lessons in design:
nanomachines to scaffold, remodel and shape membrane compartments. Physical
Chemistry Chemical Physics, 17(24):15489–15507, 2015.
[126] Vadim A Frolov, Anna V Shnyrova, and Joshua Zimmerberg. Lipid polymorphisms
and membrane shape. Cold Spring Harbor Perspectives in Biology, 3(11):a004747,
2011.
[127] Els van den Brink-van der Laan, J Antoinette Killian, and Ben de Kruijff. Nonbilayer
lipids affect peripheral and integral membrane proteins via changes in the lateral
pressure profile. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1666(1-2):275–
288, 2004.
[128] Ben de Kruijff. Lipid polymorphism and biomembrane function. Current Opinion in
Chemical Biology, 1(4):564–569, 1997.
[129] Philippe F Devaux. Static and dynamic lipid asymmetry in cell membranes. Biochem-
istry, 30(5):1163–1173, 1991.
[130] Ana Tari and Leaf Huang. Structure and function relationship of phosphatidylglycerol
in the stabilization of phosphatidylethanolamine bilayer. Biochemistry, 28(19):7708–
7712, 1989.
[131] Krzysztof Murzyn, Tomasz Róg, and Marta Pasenkiewicz-Gierula.
Phosphatidylethanolamine-phosphatidylglycerol bilayer as a model of the in-
ner bacterial membrane. Biophysical Journal, 88(2):1091–1103, 2005.
References 165
[132] Wei Zhao, Tomasz Róg, Andrey A Gurtovenko, Ilpo Vattulainen, and Mikko Karttunen.
Atomic-scale structure and electrostatics of anionic palmitoyloleoylphosphatidylglyc-
erol lipid bilayers with na+ counterions. Biophysical Journal, 92(4):1114–1124,
2007.
[133] Paulo FF Almeida, Winchil LC Vaz, and TE Thompson. Lateral diffusion in the liquid
phases of dimyristoylphosphatidylcholine/cholesterol lipid bilayers: a free volume
analysis. Biochemistry, 31(29):6739–6747, 1992.
[134] Begona Ugarte-Uribe, Kushal Kumar Das, and Ana J. Garcia-Saez. Lipid and protein
mobility in giant unilamellar vesicles. In Rumiana Dimova and Carlos M Marques,
editors, The Giant Vesicle Book, chapter 21, pages 455–471. CRC Press, 2019.
[135] Eric AJ Reits and Jacques J Neefjes. From fixed to frap: measuring protein mobility
and activity in living cells. Nature Cell Biology, 3(6):E145–E147, 2001.
[136] Anne K Kenworthy. Fluorescence recovery after photobleaching studies of lipid rafts.
In Lipid Rafts, pages 179–192. Springer, 2007.
[137] Daniel Axelrod, DE Koppel, J Schlessinger, Elliot Elson, and Watt W Webb. Mo-
bility measurement by analysis of fluorescence photobleaching recovery kinetics.
Biophysical Journal, 16(9):1055–1069, 1976.
[138] DM Soumpasis. Theoretical analysis of fluorescence photobleaching recovery experi-
ments. Biophysical Journal, 41(1):95–97, 1983.
[139] Yun Chen, B Christoffer Lagerholm, Bing Yang, and Ken Jacobson. Methods to
measure the lateral diffusion of membrane lipids and proteins. Methods, 39(2):147–
153, 2006.
[140] Jean-François Tocanne, Laurence Dupou-Cézanne, and André Lopez. Lateral diffusion
of lipids in model and natural membranes. Progress in Lipid Research, 33(3):203–237,
1994.
[141] Lin Guo, Jia Yi Har, Jagadish Sankaran, Yimian Hong, Balakrishnan Kannan, and
Thorsten Wohland. Molecular diffusion measurement in lipid bilayers over wide
concentration ranges: a comparative study. ChemPhysChem, 9(5):721–728, 2008.
[142] Radek Machánˇ, Yong Hwee Foo, and Thorsten Wohland. On the equivalence of
fcs and frap: simultaneous lipid membrane measurements. Biophysical Journal,
111(1):152–161, 2016.
[143] Andrey Filippov, Greger Orädd, and Göran Lindblom. Influence of cholesterol and
water content on phospholipid lateral diffusion in bilayers. Langmuir, 19(16):6397–
6400, 2003.
[144] Frédéric Pincet, Vladimir Adrien, Rong Yang, Jérôme Delacotte, James E Rothman,
Wladimir Urbach, and David Tareste. Frap to characterize molecular diffusion and
interaction in various membrane environments. PLoS One, 11(7):e0158457, 2016.
166 References
[145] Greger Orädd, Göran Wikander, Göran Lindblom, and Lennart B-Å Johansson. Ef-
fect of glycerol on the translational and rotational motions in lipid bilayers studied
by pulsed-field gradient 1 h nmr, epr and time-resolved fluorescence spectroscopy.
Journal of the Chemical Society, Faraday Transactions, 90(2):305–309, 1994.
[146] Peter Jönsson, Magnus P Jonsson, Jonas O Tegenfeldt, and Fredrik Höök. A method
improving the accuracy of fluorescence recovery after photobleaching analysis. Bio-
physical Journal, 95(11):5334–5348, 2008.
[147] Simona Rifici, Giovanna D’Angelo, Cristina Crupi, Caterina Branca, Valeria Conti Ni-
bali, Carmelo Corsaro, and Ulderico Wanderlingh. Influence of alcohols on the
lateral diffusion in phospholipid membranes. The Journal of Physical Chemistry B,
120(7):1285–1290, 2016.
[148] Anna L Duncan, Tyler Reddy, Heidi Koldsø, Jean Hélie, Philip W Fowler, Matthieu
Chavent, and Mark SP Sansom. Protein crowding and lipid complexity influence the
nanoscale dynamic organization of ion channels in cell membranes. Scientific Reports,
7(1):16647, 2017.
[149] Fen Zhang, Greta M Lee, and Ken Jacobson. Protein lateral mobility as a reflection of
membrane microstructure. Bioessays, 15(9):579–588, 1993.
[150] Ken Jacobson, Ping Liu, and B Christoffer Lagerholm. The lateral organization and
mobility of plasma membrane components. Cell, 177(4):806–819, 2019.
[151] WD Stein. The molecular basis of diffusion across cell membranes. The movement of
molecules across cell membranes, pages 65–125, 1967.
[152] Begona Ugarte-Uribe, Ana J. Garcia-Saez, and Mireille M.A.E. Claessens. Membrane
permeability measurements. In Rumiana Dimova and Carlos M Marques, editors, The
Giant Vesicle Book, chapter 20, pages 437–451. CRC Press, 2019.
[153] Jehangir Cama, Michael Schaich, Kareem Al Nahas, Silvia Hernández-Ainsa, Stefano
Pagliara, and Ulrich F Keyser. Direct optofluidic measurement of the lipid permeability
of fluoroquinolones. Scientific Reports, 6:32824, 2016.
[154] Massimiliano Pio Di Cagno, Fabrizio Clarelli, Jon Vabeno, Christina Lesley,
Sokar Darsim Rahman, Jennifer Cauzzo, Erica Franceschinis, Nicola Realdon, and
Paul C Stein. Experimental determination of drug diffusion coefficients in unstirred
aqueous environments by temporally resolved concentration measurements. Molecular
Pharmaceutics, 15(4):1488–1494, 2018.
[155] AM Kleinfeld. Lipid phase fatty acid flip-flop, is it fast enough for cellular transport?
The Journal of membrane biology, 175(2):79–86, 2000.
[156] JA Hamilton. Transport of fatty acids across membranes by the diffusion mechanism.
Prostaglandins, Leukotrienes and Essential Fatty Acids, 60(5-6):291–297, 1999.
[157] Frits Kamp and James A Hamilton. How fatty acids of different chain length enter
and leave cells by free diffusion. Prostaglandins, Leukotrienes and Essential Fatty
Acids, 75(3):149–159, 2006.
References 167
[158] H Ti Tien and A Louise Diana. Bimolecular lipid membranes: a review and a summary
of some recent studies. Chemistry and Physics of Lipids, 2(1):55–101, 1968.
[159] John Gutknecht and DC Tosteson. Diffusion of weak acids across lipid bilayer mem-
branes: effects of chemical reactions in the unstirred layers. Science, 182(4118):1258–
1261, 1973.
[160] Mathias Winterhalter. Black lipid membranes. Current Opinion in Colloid & Interface
Science, 5(3-4):250–255, 2000.
[161] John Gutknecht, MA Bisson, and FC Tosteson. Diffusion of carbon dioxide through
lipid bilayer membranes. effects of carbonic anhydrase, bicarbonate, and unstirred
layers. The Journal of General Physiology, 69(6):779, 1977.
[162] Manfred Kansy, Frank Senner, and Klaus Gubernator. Physicochemical high through-
put screening: parallel artificial membrane permeation assay in the description of
passive absorption processes. Journal of Medicinal Chemistry, 41(7):1007–1010,
1998.
[163] Phillip Kuhn, Klaus Eyer, Steffen Allner, Dario Lombardi, and Petra S Dittrich. A
microfluidic vesicle screening platform: monitoring the lipid membrane permeability
of tetracyclines. Analytical Chemistry, 83(23):8877–8885, 2011.
[164] D Galinis-Luciani, L Nguyen, and M Yazdanian. Is pampa a useful tool for discovery?
Journal of Pharmaceutical Sciences, 96(11):2886–2892, 2007.
[165] Yang Jun Kang and Sung Yang. Fluidic low pass filter for hydrodynamic flow
stabilization in microfluidic environments. Lab Chip, 12(10):1881–1889, 2012.
[166] Arthur D Edelstein, Mark A Tsuchida, Nenad Amodaj, Henry Pinkard, Ronald D
Vale, and Nico Stuurman. Advanced methods of microscope control using µmanager
software. Journal of Biological Methods, 1(2):E10, 2014.
[167] Maryn McKenna. Antibiotic resistance: the last resort. Nature News, 499(7459):394,
2013.
[168] European Centre for Disease Prevention and Control. Surveillance of antimicrobial
resistance in europe 2016. Annual Report of the European Antimicrobial Resistance
Surveillance Network (EARS-Net), 2017.
[169] Jessica MA Blair, Mark A Webber, Alison J Baylay, David O Ogbolu, and Laura JV
Piddock. Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiol-
ogy, 13(1):42–51, 2015.
[170] Lynn L Silver. A gestalt approach to gram-negative entry. Bioorganic & Medicinal
Chemistry, 24(24):6379–6389, 2016.
[171] Jean-Marie Pagès, Chloë E James, and Mathias Winterhalter. The porin and the
permeating antibiotic: a selective diffusion barrier in gram-negative bacteria. Nature
Reviews Microbiology, 6(12):893–903, 2008.
168 References
[172] David A Six, Thomas Krucker, and Jennifer A Leeds. Advances and challenges in
bacterial compound accumulation assays for drug discovery. Current Opinion in
Chemical Biology, 44:9–15, 2018.
[173] Mariano Andrea Scorciapino, Silvia Acosta-Gutierrez, Dehbia Benkerrou, Tommaso
D’Agostino, Giuliano Malloci, Susruta Samanta, Igor Bodrenko, and Matteo Cecca-
relli. Rationalizing the permeation of polar antibiotics into gram-negative bacteria.
Journal of Physics: Condensed Matter, 29(11):113001, 2017.
[174] Imrich Barák and Katarína Muchová. The role of lipid domains in bacterial cell
processes. International Journal of Molecular Sciences, 14(2):4050–4065, 2013.
[175] Susanne F Fenz and Kheya Sengupta. Giant vesicles as cell models. Integrative
Biology, 4(9):982–995, 2012.
[176] Hannah Stein, Susann Spindler, Navid Bonakdar, Chun Wang, and Vahid Sandogh-
dar. Production of isolated giant unilamellar vesicles under high salt concentrations.
Frontiers in Physiology, 8:63, 2017.
[177] Maxim G Ryadnov, Galina V Mukamolova, Ayman S Hawrani, James Spencer, and
Roscoe Platt. Re coil: an antimicrobial peptide regulator. Angewandte Chemie
International Edition, 48(51):9676–9679, 2009.
[178] Anthony G Vecchiarelli, Min Li, Michiyo Mizuuchi, and Kiyoshi Mizuuchi. Differ-
ential affinities of mind and mine to anionic phospholipid influence min patterning
dynamics in vitro. Molecular Microbiology, 93(3):453–463, 2014.
[179] Paulina D Rakowska, Haibo Jiang, Santanu Ray, Alice Pyne, Baptiste Lamarre,
Matthew Carr, Peter J Judge, Jascindra Ravi, Ulla IM Gerling, Beate Koksch, et al.
Nanoscale imaging reveals laterally expanding antimicrobial pores in lipid bilayers.
Proceedings of the National Academy of Sciences, 110(22):8918–8923, 2013.
[180] H Nikaido and DG Thanassi. Penetration of lipophilic agents with multiple protonation
sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrobial
Agents and Chemotherapy, 37(7):1393, 1993.
[181] Valentina Uivarosi. Metal complexes of quinolone antibiotics and their applications:
an update. Molecules, 18(9):11153–11197, 2013.
[182] David S Wishart, Yannick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R
Grant, Tanvir Sajed, Daniel Johnson, Carin Li, Zinat Sayeeda, et al. Drugbank
5.0: a major update to the drugbank database for 2018. Nucleic Acids Research,
46(D1):D1074–D1082, 2018.
[183] M Rhia L Stone, Mark S Butler, Wanida Phetsang, Matthew A Cooper, and Mark AT
Blaskovich. Fluorescent antibiotics: new research tools to fight antibiotic resistance.
Trends in Biotechnology, 36(5):523–536, 2018.
[184] Sunil Shah, Anjali Chandra, Amanjot Kaur, Nirupama Sabnis, Andras Lacko, Zyg-
munt Gryczynski, Rafal Fudala, and Ignacy Gryczynski. Fluorescence properties of
doxorubicin in pbs buffer and pva films. Journal of Photochemistry and Photobiology
B: Biology, 170:65–69, 2017.
References 169
[185] Anas Allam, Laure Maigre, Julia Vergalli, Estelle Dumont, Bertrand Cinquin,
Rodolphe Alves de Sousa, Jelena Pajovic, Elizabeth Pinet, Nikaia Smith, Jean-Philippe
Herbeuval, et al. Microspectrofluorimetry to dissect the permeation of ceftazidime in
gram-negative bacteria. Scientific Reports, 7(1):986, 2017.
[186] Kittichoat Tiyanont, Thierry Doan, Michael B Lazarus, Xiao Fang, David Z Rudner,
and Suzanne Walker. Imaging peptidoglycan biosynthesis in bacillus subtilis with fluo-
rescent antibiotics. Proceedings of the National Academy of Sciences, 103(29):11033–
11038, 2006.
[187] Kamilia Abdelraouf, Kai-Tai Chang, Taijun Yin, Ming Hu, and Vincent H Tam.
Uptake of polymyxin b into renal cells. Antimicrobial Agents and Chemotherapy,
58(7):4200–4202, 2014.
[188] M Rhia L Stone, Muriel Masi, Wanida Phetsang, Jean-Marie Pagès, Matthew A
Cooper, and Mark AT Blaskovich. Fluoroquinolone-derived fluorescent probes for
studies of bacterial penetration and efflux. MedChemComm, 10(6):901–906, 2019.
[189] Alexander P Demchenko, Yves Mély, Guy Duportail, and Andrey S Klymchenko.
Monitoring biophysical properties of lipid membranes by environment-sensitive fluo-
rescent probes. Biophysical Journal, 96(9):3461–3470, 2009.
[190] Alex Avdeef, Stefanie Bendels, Li Di, Bernard Faller, Manfred Kansy, Kiyohiko
Sugano, and Yukinori Yamauchi. Pampa—critical factors for better predictions of
absorption. Journal of Pharmaceutical Sciences, 96(11):2893–2909, 2007.
[191] Aaron M Streets and Yanyi Huang. Chip in a lab: Microfluidics for next generation
life science research. Biomicrofluidics, 7(1):011302, 2013.
[192] Jia Zeng, Heather M Eckenrode, Susan M Dounce, and Hai-Lung Dai. Time-resolved
molecular transport across living cell membranes. Biophysical Journal, 104(1):139–
145, 2013.
[193] Trang T Nguyen, Kelvin Rembert, and John C Conboy. Label-free detection of drug-
membrane association using ultraviolet- visible sum-frequency generation. Journal of
the American Chemical Society, 131(4):1401–1403, 2009.
[194] José B A Custódio, Leonor M Almeida, and Vitor MC Madeira. A reliable and
rapid procedure to estimate drug partitioning in biomembranes. Biochemical and
Biophysical Research Communications, 176(3):1079–1085, 1991.
[195] Christopher B Fox, Robert A Horton, and Joel M Harris. Detection of drug- mem-
brane interactions in individual phospholipid vesicles by confocal raman microscopy.
Analytical Chemistry, 78(14):4918–4924, 2006.
[196] Tsutomu Watanabe. Infective heredity of multiple drug resistance in bacteria. Bacteri-
ological Reviews, 27(1):87–115, 1963.
[197] Ida Louise Jørgensen, Gerdi Christine Kemmer, and Thomas Günther Pomorski.
Membrane protein reconstitution into giant unilamellar vesicles: a review on current
techniques. European Biophysics Journal, 46(2):103–119, 2017.
170 References
[198] June-Bum Kim. Channelopathies. Clinical and Experimental Pediatrics, 57(1):1–18,
2014.
[199] Jane C Davies, Eric W F W Alton, and Andrew Bush. Cystic fibrosis. BMJ,
335(7632):1255–1259, 2007.
[200] John R Riordan, Johanna M Rommens, Bat-sheva Kerem, Noa Alon, Richard Rozma-
hel, Zbyszko Grzelczak, Julian Zielenski, Si Lok, Natasa Plavsic, Jia-Ling Chou, et al.
Identification of the cystic fibrosis gene: cloning and characterization of complemen-
tary dna. Science, 245(4922):1066–1073, 1989.
[201] William A Catterall. Dravet syndrome: a sodium channel interneuronopathy. Current
Opinion in Physiology, 2:42–50, 2018.
[202] Arsalan Anwar, Sidra Saleem, Urvish K Patel, Kogulavadanan Arumaithurai, and
Preeti Malik. Dravet syndrome: An overview. Cureus, 11(6):e5006, 2019.
[203] Claire Edmondson and Jane C Davies. Current and future treatment options for cystic
fibrosis lung disease: latest evidence and clinical implications. Therapeutic Advances
in Chronic Disease, 7(3):170–183, 2016.
[204] Thomas E DeCoursey. Voltage and ph sensing by the voltage-gated proton channel,
hv1. Journal of the Royal Society Interface, 15(141):20180108, 2018.
[205] Margaret Fogel and JW Hastings. Bioluminescence: mechanism and mode of control
of scintillon activity. Proceedings of the National Academy of Sciences, 69(3):690–693,
1972.
[206] RC Thomas and RW Meech. Hydrogen ion currents and intracellular ph in depolarized
voltage-clamped snail neurones. Nature, 299(5886):826–828, 1982.
[207] Thomas E DeCoursey. The voltage-gated proton channel: a riddle, wrapped in a
mystery, inside an enigma. Biochemistry, 54(21):3250–3268, 2015.
[208] Thomas E DeCoursey. Voltage-gated proton channels: molecular biology, physiology,
and pathophysiology of the hv family. Physiological Reviews, 93(2):599–652, 2013.
[209] Thomas E DeCoursey and Jonathan Hosler. Philosophy of voltage-gated proton
channels. Journal of The Royal Society Interface, 11(92):20130799, 2014.
[210] Berton C Pressman. Biological applications of ionophores. Annual Review of Bio-
chemistry, 45(1):501–530, 1976.
[211] Catalin Chimerel, Andrew J Murray, Enno R Oldewurtel, David K Summers, and
Ulrich F Keyser. The effect of bacterial signal indole on the electrical properties of
lipid membranes. ChemPhysChem, 14(2):417–423, 2013.
[212] Catalin Chimerel, Christopher M Field, Silvia Piñero-Fernandez, Ulrich F Keyser,
and David K Summers. Indole prevents escherichia coli cell division by modu-
lating membrane potential. Biochimica et Biophysica Acta (BBA)-Biomembranes,
1818(7):1590–1594, 2012.
References 171
[213] Nagendran Tharmalingam, Elamparithi Jayamani, Rajmohan Rajamuthiah, Dawilmer
Castillo, Beth Burgwyn Fuchs, Michael J Kelso, and Eleftherios Mylonakis. Activity
of a novel protonophore against methicillin-resistant staphylococcus aureus. Future
Medicinal Chemistry, 9(12):1401–1411, 2017.
[214] Jai Moo Shin, Keith Munson, Olga Vagin, and George Sachs. The gastric hk-atpase:
structure, function, and inhibition. Pflügers Archiv-European Journal of Physiology,
457(3):609–622, 2009.
[215] Jeremy M Berg, John L Tymoczko, and Lubert Stryer. Biochemistry. W. H. Freeman,
5th edition, 2002.
[216] Peter Mitchell. Coupling of phosphorylation to electron and hydrogen transfer by a
chemi-osmotic type of mechanism. Nature, 191(4784):144–148, 1961.
[217] Philip Shapira, Seokbeom Kwon, and Jan Youtie. Tracking the emergence of synthetic
biology. Scientometrics, 112(3):1439–1469, 2017.
[218] Kerstin Göpfrich, Ilia Platzman, and Joachim P Spatz. Mastering complexity: to-
wards bottom-up construction of multifunctional eukaryotic synthetic cells. Trends in
Biotechnology, 36(9):938–951, 2018.
[219] Nadrian C Seeman. Nucleic acid junctions and lattices. Journal of Theoretical Biology,
99(2):237–247, 1982.
[220] James D Watson and Francis HC Crick. Molecular structure of nucleic acids. Nature,
171(4356):737–738, 1953.
[221] Paul WK Rothemund. Folding dna to create nanoscale shapes and patterns. Nature,
440(7082):297–302, 2006.
[222] Fan Hong, Fei Zhang, Yan Liu, and Hao Yan. Dna origami: scaffolds for creating
higher order structures. Chemical Reviews, 117(20):12584–12640, 2017.
[223] Nicholas AW Bell, Christian R Engst, Marc Ablay, Giorgio Divitini, Caterina Ducati,
Tim Liedl, and Ulrich F Keyser. Dna origami nanopores. Nano Letters, 12(1):512–517,
2012.
[224] Martin Langecker, Vera Arnaut, Thomas G Martin, Jonathan List, Stephan Renner,
Michael Mayer, Hendrik Dietz, and Friedrich C Simmel. Synthetic lipid membrane
channels formed by designed dna nanostructures. Science, 338(6109):932–936, 2012.
[225] Jonathan R Burns, Eugen Stulz, and Stefan Howorka. Self-assembled dna nanopores
that span lipid bilayers. Nano Letters, 13(6):2351–2356, 2013.
[226] Jonathan R Burns, Kerstin Göpfrich, James W Wood, Vivek V Thacker, Eugen
Stulz, Ulrich F Keyser, and Stefan Howorka. Lipid-bilayer-spanning dna nanopores
with a bifunctional porphyrin anchor. Angewandte Chemie International Edition,
52(46):12069–12072, 2013.
[227] Kerstin Göpfrich, Thomas Zettl, Anna EC Meijering, Silvia Hernández-Ainsa, Samet
Kocabey, Tim Liedl, and Ulrich F Keyser. Dna-tile structures induce ionic currents
through lipid membranes. Nano Letters, 15(5):3134–3138, 2015.
172 References
[228] Alexander Ohmann. A synthetic lipid scramblase built from DNA. PhD thesis, The
University of Cambridge, 2019.
[229] Kevin Jahnke. Dna nanotechnology for bottom-up synthetic cell assembly. Master’s
thesis, University of Heidelberg, 2018.
[230] Alexander Ohmann, Kerstin Göpfrich, Himanshu Joshi, Rebecca F Thompson, Diana
Sobota, Neil A Ranson, Aleksei Aksimentiev, and Ulrich F Keyser. Controlling
aggregation of cholesterol-modified dna nanostructures. Nucleic Acids Research,
47(21):11441–11451, 2019.
[231] Thomas Gutsmann, Thomas Heimburg, Ulrich Keyser, Kozhinjampara R Mahendran,
and Mathias Winterhalter. Protein reconstitution into freestanding planar lipid mem-
branes for electrophysiological characterization. Nature Protocols, 10(1):188–198,
2015.
[232] Kerstin Göpfrich and Ulrich F Keyser. Dna nanotechnology for building sensors,
nanopores and ion-channels. In Biological and Bio-inspired Nanomaterials, pages
331–370. Springer, 2019.
[233] Nicholas AW Bell and Ulrich F Keyser. Nanopores formed by dna origami: A review.
FEBS Letters, 588(19):3564–3570, 2014.
[234] Oksana Iamshanova, Pascal Mariot, V’Yacheslav Lehen’Kyi, and Natalia Prevarskaya.
Comparison of fluorescence probes for intracellular sodium imaging in prostate cancer
cell lines. European Biophysics Journal, 45(7):765–777, 2016.
[235] Helmut Offenbacher, Otto S Wolfbeis, and Eva Fürlinger. Fluorescence optical
sensors for continuous determination of near-neutral ph values. Sensors and Actuators,
9(1):73–84, 1986.
[236] Björn Finkler, Christian Spies, Michael Vester, Frederick Walte, Kathrin Omlor,
Iris Riemann, Manuel Zimmer, Frank Stracke, Markus Gerhards, and Gregor Jung.
Highly photostable “super”-photoacids for ultrasensitive fluorescence spectroscopy.
Photochemical & Photobiological Sciences, 13(3):548–562, 2014.
[237] Yuki Kazayama, Tetsuhiko Teshima, Toshihisa Osaki, Shoji Takeuchi, and Taro Toyota.
Integrated microfluidic system for size-based selection and trapping of giant vesicles.
Analytical Chemistry, 88(2):1111–1116, 2016.
[238] Paul Flowers, Klaus Theopold, Richard Langley, and William R Robinson. Chemistry.
OpenStax, 2nd edition, 2019.
[239] Jon V Thomas, Megan R Brimijoin, Thomas R Neault, and Richard F Brubaker. The
fluorescent indicator pyranine is suitable for measuring stromal and cameral ph in
vivo. Experimental Dye Research, 50(3):241–249, 1990.
[240] Yasuhiko Nozaki and Charles Tanford. Proton and hydroxide ion permeability of
phospholipid vesicles. Proceedings of the National Academy of Sciences, 78(7):4324–
4328, 1981.
References 173
[241] David W Deamer. Proton permeation of lipid bilayers. Journal of Bioenergetics and
Biomembranes, 19(5):457–479, 1987.
[242] J Wylie Nichols, Martyn W Hill, Alec D Bangham, and David W Deamer. Mea-
surement of net proton-hydroxyl permeability of large unilamellar liposomes with
the fluorescent ph probe, 9-aminoacridine. Biochimica et Biophysica Acta (BBA)-
Biomembranes, 596(3):393–403, 1980.
[243] John Gutknecht. Proton/hydroxide conductance through phospholipid bilayer mem-
branes: effects of phytanic acid. Biochimica et Biophysica Acta (BBA)-Biomembranes,
898(2):97–108, 1987.
[244] HO Hauser, D Oldani, and MC Phillips. Mechanism of ion escape from phosphatidyl-
choline and phosphatidylserine single bilayer vesicles. Biochemistry, 12(22):4507–
4517, 1973.
[245] John Gutknecht and Anne Walter. Hydrofluoric and nitric acid transport through lipid
bilayer membranes. Biochimica et Biophysica Acta (BBA)-Biomembranes, 644(1):153–
156, 1981.
[246] DB Spry, Alexei Goun, and Michael D Fayer. Deprotonation dynamics and stokes
shift of pyranine (hpts). The Journal of Physical Chemistry A, 111(2):230–237, 2007.
[247] Walter F Boron. Transport of h+ and of ionic weak acids and bases. The Journal of
Membrane Biology, 72(1-2):1–16, 1983.
[248] AP Sharp and RC Thomas. The effects of chloride substitution on intracellular ph in
crab muscle. The Journal of Physiology, 312(1):71–80, 1981.
[249] Noga Barrash-Shiftan, Brina Brauer, and Ehud Pines. Solvent dependence of pyranine
fluorescence and uv-visible absorption spectra. Journal of Physical Organic Chemistry,
11(10):743–750, 1998.
[250] TE Redelmeier, LD Mayer, KF Wong, MB Bally, and PR Cullis. Proton flux in large
unilamellar vesicles in response to membrane potentials and ph gradients. Biophysical
Journal, 56(2):385–393, 1989.
[251] Alireza Mashaghi, Samaneh Mashaghi, Ilya Reviakine, Ron MA Heeren, Vahid
Sandoghdar, and Mischa Bonn. Label-free characterization of biomembranes: from
structure to dynamics. Chemical Society Reviews, 43(3):887–900, 2014.
[252] Juan M Bueno, Francisco J Ávila, and Pablo Artal. Second harmonic generation
microscopy: a tool for quantitative analysis of tissues. In Microscopy and Analysis,
chapter 5, pages 99–120. InTech Open, 2016.
[253] Xiyi Chen, Oleg Nadiarynkh, Sergey Plotnikov, and Paul J Campagnola. Second
harmonic generation microscopy for quantitative analysis of collagen fibrillar structure.
Nature Protocols, 7(4):654–669, 2012.
[254] Murali Krishna Ghatkesar, Hans-Peter Lang, Christoph Gerber, Martin Hegner, and
Thomas Braun. Comprehensive characterization of molecular interactions based on
nanomechanics. PloS One, 3(11):e3610, 2008.
174 References
[255] Gary A Shaw, Andrew M Siegel, Joshua Model, Adam Geboff, Stanislav Soloviev,
Alexey Vert, and Peter Sandvik. Deep uv photon-counting detectors and applications.
In Advanced Photon Counting Techniques III, volume 7320, page 73200J. International
Society for Optics and Photonics, 2009.
[256] RE Stuckey. The applications of ultra-violet absorption spectrophotometry in pharma-
ceutical analysis. Journal of Pharmacy and Pharmacology, 4:345–365, 1952.
[257] Gilbert N Lewis and Melvin Calvin. The color of organic substances. Chemical
Reviews, 25(2):273–328, 1939.
[258] DF Swinehart. The beer-lambert law. Journal of Chemical Education, 39(7):333–335,
1962.
[259] August Beer. Bestimmung der absorption des rothen lichts in farbigen flüssigkeiten.
Annalen der Physik und Chemie, 86:78–88, 1852.
[260] Thomas G Mayerhöfer, Harald Mutschke, and Jürgen Popp. Employing theories far
beyond their limits—the case of the (boguer-) beer–lambert law. ChemPhysChem,
17(13):1948–1955, 2016.
[261] Günter Gauglitz and Tuan Vo-Dinh. Handbook of Spectroscopy, volume 1000. Wiley
Online Library, 2003.
[262] Nadine Barrie Smith and Andrew Webb. Introduction to Medical Imaging: Physics,
Engineering and Clinical Applications. Cambridge University Press, 2010.
[263] Thomas E Renau, Joseph P Sanchez, Jeffrey W Gage, Julie A Dever, Martin A Shapiro,
Stephen J Gracheck, and John M Domagala. Structure- activity relationships of the
quinolone antibacterials against mycobacteria: Effect of structural changes at n-1 and
c-7. Journal of Medicinal Chemistry, 39(3):729–735, 1996.
[264] Kagisha Védaste, Kayitare Egide, Kayumba Pierre Claver, and Eliangiringa Kaale.
Development and validation of high-performance thin-layer chromatographic method
for the simultaneous determination of rifampicin, isoniazid, and pyrazinamide in a
fixed dosage combination tablet. Journal of Planar Chromatography, 27(5):392–397,
2014.
[265] Asol Mehlhorn, Parvaneh Rahimi, and Yvonne Joseph. Aptamer-based biosensors for
antibiotic detection: a review. Biosensors, 8(2):E54, 2018.
[266] Yang Zhang, Bo Shiun Lai, and Mario Juhas. Recent advances in aptamer discovery
and applications. Molecules, 24(5):941, 2019.
[267] Long Ma, Nana Sun, Chunhao Tu, Qian Zhang, and Aipo Diao. Design of an aptamer–
based fluorescence displacement biosensor for selective and sensitive detection of
kanamycin in aqueous samples. RSC Advances, 7(61):38512–38518, 2017.
[268] Katalin Nagy and Ioana-Daria Tiuca. Importance of fatty acids in physiopathology of
human body. In Fatty Acids, chapter 1, pages 3–22. InTech Open, 2017.
References 175
[269] Guenther Boden. Obesity and free fatty acids. Endocrinology and Metabolism Clinics
of North America, 37(3):635–646, 2008.
[270] J Patrick Kampf and Alan M Kleinfeld. Is membrane transport of ffa mediated by
lipid, protein, or both? Physiology, 22(1):7–14, 2007.
[271] Serena Faggiano, Luca Ronda, Samanta Raboni, and Andrea Mozzarelli. Adifab
fluorescence data used for the quantification of free fatty acids in media at different
ph. Data in Brief, 22:158–163, 2019.
[272] RW Albers. Biochemical aspects of active transport. Annual Review of Biochemistry,
36(1):727–756, 1967.

Appendix A
Biophysical Characterisation of OLA
Vesicles
A.1 Microfluidic Chip Design
Fig. A.1. Design of the microfluidic chip used for the experiments in Chapter 3
A.2 Validation of Membrane Unilamellarity
The solution compositions for the membrane unilamellarity experiments are given below.
178 Biophysical Characterisation of OLA Vesicles
Table A.1. Solution composition for confocal micrographs of OLA and electroformed
vesicles.
Solution Composition
Inner Aqueous (IA)
- 200 mM sucrose
- 15% v/v glycerol
in milli-Q water
Outer Aqueous (OA)
- 200 mM sucrose
- 15% v/v glycerol
- 50 mg/mL P-188
in milli-Q water
Lipid-Octanol (LO)
- 4 mg/mL DOPC
- 0.5% m/m 18:1 NBD-PC
in 1-octanol
Low-density dilution stock
- 200 mM glucose
- 15% v/v glycerol
in milli-Q water
Electroformation
- 200 mM sucrose
- 15% v/v glycerol
in milli-Q water
Table A.2. Solution composition for dithionite bleaching assay.
Solution Composition
Inner Aqueous (IA)
- 200 mM sucrose
- 15% v/v glycerol
in PBS
Outer Aqueous (OA)
- 200 mM sucrose
- 15% v/v glycerol
- 50 mg/mL P-188
in PBS
Lipid-Octanol (LO)
- 2 mg/mL DOPC-DOPG
(3:1 ratio mixture)
- 0.5% m/m 16:0 NBD-PC
in 1-octanol
Low-density dilution stock
- 200 mM glucose
- 15% v/v glycerol
in PBS
Dithionite stock solution
1 M Na2S2O4
in Tris buffer (pH 10)
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A.3 Lipid Composition Experiments
A.3.1 Solution Composition
Table A.3. Solution composition for lipid mixture experiments.
Solution Composition
Inner Aqueous (IA)
- 200 mM sucrose
- 15% v/v glycerol
in PBS
Outer Aqueous (OA)
- 200 mM sucrose
- 15% v/v glycerol
- 50 mg/mL P-188
in PBS
Lipid-Octanol (LO)
- 3.6 mg/mL of respective lipid mixture
in 1-octanol
Low-density dilution stock
- 200 mM glucose
- 15% v/v glycerol
in PBS
A.3.2 Preparation of Lipid Stocks
The binary lipid mixtures for the liposome composition experiments were obtained as follows:
• PGPC (DOPG – DOPC): DOPC and DOPG lipid powder was dissolved in 100%
ethanol to a final concentration of 100 mg/mL in separate vials. Furthermore, 18:1-12:0
NBD-PC was dissolved in ethanol to a final concentration of 1 mg/mL. An aliquot
of fluorescently doped DOPC lipid was made by mixing the DOPC and NBD-PC in
a 9:1 ratio, resulting in a total concentration of 90 mg/mL DOPC lipid. Similarly, a
DOPG aliquot was obtained by mixing it in a 9:1 ratio with pure ethanol, resulting in a
total concentration of 90 mg/mL DOPG lipid. The 90 mg/mL DOPG and DOPC/NBD-
PC aliquots were further mixed in 1:3, 2:2 and 3:1 volume ratios and used as lipid
stocks for the OLA experiments. The lipid stocks were stored in the freezer at -20°C.
The binary lipid stocks were further diluted to 3.6 mg/mL in 1-octanol before each
experiment.
• PCPE (DOPC - DOPE): DOPC and DOPE lipid powder was dissolved in 100%
ethanol to a final concentration of 100 mg/mL in separate vials. Furthermore, 16:0 Liss
Rhod PE was dissolved in ethanol to a final concentration of 0.5 mg/mL. An aliquot of
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fluorescently doped DOPE lipid was made by mixing the DOPE and Liss Rhod PE in
a 9:1 ratio, resulting in a total concentration of 90 mg/mL DOPE lipid. Similarly, a
DOPC aliquot was obtained by mixing it in a 9:1 ratio with pure ethanol, resulting in a
total concentration of 90 mg/mL DOPC lipid. The 90 mg/mL DOPC and DOPE/Liss
Rhod PE aliquots were further mixed in 1:3, 2:2 and 3:1 volume ratios and used as
lipid stocks for the OLA experiments. The lipid stocks were stored in the freezer at
-20°C. The binary lipid stocks were further diluted to 3.6 mg/mL in 1-octanol before
each experiment.
• PGPE (DOPG - DOPE): DOPG and DOPE lipid powder was dissolved in 100%
ethanol to a final concentration of 100 mg/mL in separate vials. Furthermore, 16:0 Liss
Rhod PE was dissolved in ethanol to a final concentration of 0.5 mg/mL. An aliquot of
fluorescently doped DOPE lipid was made by mixing the DOPE and Liss Rhod PE in
a 9:1 ratio, resulting in a total concentration of 90 mg/mL DOPE lipid. Similarly, a
DOPC aliquot was obtained by mixing it in a 9:1 ratio with pure ethanol, resulting in a
total concentration of 90 mg/mL DOPG lipid. The 90 mg/mL DOPG and DOPE/Liss
Rhod PE aliquots were further mixed in 1:3, 2:2 and 3:1 volume ratios and used as
lipid stocks for the OLA experiments. The lipid stocks were stored in the freezer at
-20°C. The binary lipid stocks were further diluted to 3.6 mg/mL in 1-octanol before
each experiment.
All chemicals were acquired from Sigma-Aldrich, unless stated otherwise.
A.3.3 Optical Parameters
The confocal images were obtained using the following optical parameters:
• PGPC (DOPG – DOPC): The images were acquired on a Leica TCS SP5 confocal
microscope, equipped with a 488 nm Argon laser. The laser output power was set to
10%. Images were recorded via a 40× oil immersion objective (HCX PL APO CS 40.0,
NA 1.25) with a scan speed of 400 Hz. Pinhole Diameter 67.93 µm, Laser Acousto-
Optic Tunable Filter (AOTF) 40%, Smart Gain (HyD) 302% and Smart Offset disabled.
The microscope was controlled via the Leica Microsystems LAS AF software.
• PGPE (DOPG – DOPE): The images were acquired in an Olympus FV 1000 confocal
microscope, equipped with a LD559 laser (559 nm, 15 mW). The laser output power
was set to 1%. Images were recorded via a 40× oil immersion objective (UPFLN 40×,
NA 1.3) with a scan speed of 2 µs/pixel. Pinhole diameter 80 µm, PMT offset voltage
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645 V and analog PMT offset 0. The microscope was controlled via the Olympus
microscope Fluoview software.
• PCPE (DOPC – DOPE): The images were acquired in an Olympus FV 1000 confocal
microscope, equipped with a LD559 laser (559 nm, 15 mW). The laser output power
was set to 1%. Images were recorded via a 40× oil immersion objective (UPFLN 40×,
NA 1.3) with a scan speed of 2 µs/pixel. Pinhole diameter 80 µm, PMT offset voltage
645 V and analog PMT offset 0. The microscope was controlled via the Olympus
microscope Fluoview software.
A.3.4 Image Panels of Binary Lipid Systems
Representative images of GUVs obtained for the different binary lipid systems are shown
in Figures A.2, A.3 and A.4, along with boxplots of their corresponding mean fluorescence
intensity analyses. A clear increase in intensity of the vesicles for the different lipid mixtures
can be observed. In the analysis, we performed a linear regression on the fluorescence
intensities of each lipid system and then normalised the fluorescence values to the slope of
the linear function we obtained. This results in a gradient of +1 for the normalised intensity
values with increasing relative concentrations of fluorescently doped lipid. For the 3:1, 2:2
and 1:3 lipid mixtures this translates into values of 1, 2 and 3, respectively, if the lipid
composition of the LO phase is maintained in the vesicle.
For the PGPC and PCPE systems, the normalised intensity shows a linear 1-2-3 increase, as
expected. Stable PGPE vesicles could only be formed in the 2:2 and 1:3 ratio.
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Fig. A.2. Panel showing representative confocal images of PGPC liposomes. The 1:3 ratio
vesicles show the highest fluorescence intensity, whereas the 3:1 vesicles show the lowest
fluorescence intensity. The vesicles with a 2:2 lipid ratio lie between the two. The boxplot
shows the results of the mean fluorescence intensity analysis. The intensity scales in a linear
manner in accordance with the relative concentration of fluorescently labelled NBD-PC in
the LO phase.
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Fig. A.3. Panel showing representative confocal images of PCPE liposomes. The 1:3 ratio
vesicles show the highest fluorescence intensity, whereas the 3:1 vesicles show the lowest
fluorescence intensity. The vesicles with a 2:2 lipid ratio lie between the two. The boxplot
shows the results of the mean fluorescence intensity analysis. The intensity scales in a linear
manner in accordance with the relative concentration of fluorescently labelled Liss Rhod PE
in the LO phase.
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Fig. A.4. Panel showing representative confocal images of PGPE liposomes. The 1:3
ratio vesicles show the highest fluorescence intensity, whereas the 2:2 vesicles show lower
fluorescence intensity. We were not able to form stable PGPE vesicles in 3:1 ratio. However,
the fluorescence intensity of the other two lipid mixtures scales in a linear manner in
accordance with the relative concentration of fluorescently labelled Liss Rhod PE in the LO
phase.
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A.4 Lateral Diffusion Experiments
A.4.1 Comparison of GUV Production Technique at Varying P-188
Concentrations
The composition of the solutions used to prepare the vesicles are listed in Table A.4. We
formed GUVs via electroformation in two chemical environments. One environment was
devoid of the poloxamer P-188 in the vesicle solution (‘no P-188 environment’), and one
environment contained 50 mg/mL P-188 (‘high P-188 environment’). Similarly, we formed
OLA vesicles in two chemical environments with varying P-188 concentrations. In one case,
we prepared GUVs with 50 mg/mL P-188 encapsulated within (IA) and outside (OA) of
the vesicles (‘high P-188 environment’). However, since OLA vesicles cannot be formed
without the presence of P-188 we were not able to create an environment completely devoid
of P-188. Instead we formed the OLA GUVs in a ‘low P-188 environment’ where the inner
aqueous (IA) solution contained no P-188 and the outside solution contained 50 mg/mL. The
vesicle aliquots had to be further diluted for imaging. The exact solution compositions in
which the FRAP measurements were performed are listed in Table A.4.
Table A.4. Solution compositions used for GUV formation. After production, 20 µL of the
vesicle stock solution is extracted and diluted in 50 µL of glucose solution. The lower density
of the surrounding medium causes the GUVs to sink to the bottom of the incubation chamber
which facilitates confocal imaging. The components were mixed in ion free milli-Q water, as
this increases liposome yield during electroformation.
Inner Aqueous (IA) Outer Aqueous (OA) Dilution Stock
Electroformation
‘no P-188’
-200 mM sucrose
-15% v/v glycerol
-200 mM sucrose
-15% v/v glycerol
-200 mM glucose
-15% v/v glycerol
Electroformation
‘high P-188’
-200 mM sucrose
- 15% v/v glycerol
-50 mg/mL P-188
- 200 mM sucrose
-15% v/v glycerol
- 50 mg/mL P-188
-200 mM glucose
-15% v/v glycerol
OLA
‘low P-188’
-200 mM sucrose
-15% v/v glycerol
-200 mM sucrose
-15% v/v glycerol
-200 mM glucose
-15% v/v glycerol
OLA
‘high P-188’
-200 mM sucrose
-15% v/v glycerol
-50 mg/mL P-188
-200 mM sucrose
-15% v/v glycerol
- 50 mg/mL P-188
-200 mM glucose
-15% v/v glycerol
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For visualisation, we mixed 20 µL of the vesicle stock with 50 µL of the low-density dilution
stock in an incubation chamber (Grace Bio-Labs FlexWell, Sigma-Aldrich) with a wide bore
pipette. The density mismatch causes the GUVs to sink to the bottom of the chamber, where
they could be imaged. However, by diluting the vesicle stock with P-188 free glucose solution,
we reduced the effective P-188 concentration in the outside of the vesicles. The effective
solution compositions that the FRAP measurements were carried out in are summarised in
Table A.5.
Table A.5. Effective solution composition encapsulated within the vesicles and outside at
which the FRAP measurements were performed. We measure the lateral lipid diffusion
coefficients in a high and a low P-188 environment for both GUV formation techniques.
P-188 could not be completely removed from the outside solution for the OLA sets, as this
technique requires a certain amount of P-188 for successful liposome formation.
Encapsulated solution Outside solution
Electroformation
‘no P-188 environment’
- 200 mM sucrose
- 15% v/v glycerol
- 200 mM sucrose
- 15% v/v glycerol
Electroformation
‘high P-188 environment’
- 200 mM sucrose
- 15% v/v glycerol
- 50 mg/mL P-188
- 200 mM sucrose
- 15% v/v glycerol
- 14 mg/mL P-188
OLA
‘low P-188 environment’
- 200 mM sucrose
- 15% v/v glycerol
- 200 mM sucrose
- 15% v/v glycerol
- 14 mg/mL P-188
OLA
‘high P-188 environment’
- 200 mM sucrose
- 15% v/v glycerol
- 50 mg/mL P-188
- 200 mM sucrose
- 15% v/v glycerol
- 14 mg/mL P-188
Table A.6. Summary of measured lateral lipid diffusion coefficients (mean ± std. dev.)
for the GUVs investigated. All measured lateral diffusion coefficients are on the order of
1 µm2/s.
DOPC POPC
Electroformation
‘no P-188 environment’
1.0 ± 0.2 µm2/s
N = 17
0.8 ± 0.2 µm2/s
N = 28
Electroformation
‘high P-188 environment’
1.0 ± 0.2 µm2/s
N = 14
1.3 ± 0.4 µm2/s
N = 20
OLA
‘low P-188 environment’
1.1 ± 0.2 µm2/s
N = 34
1.0 ± 0.3 µm2/s
N = 49
OLA
‘high P-188 environment’
1.0 ± 0.3 µm2/s
N = 30
0.9 ± 0.3 µm2/s
N = 27
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A.4.2 Effect of Glycerol and Temperature on Lipid Lateral Diffusion
In order to determine the effect of glycerol and temperature on the lateral lipid diffusion
coefficient, we conducted FRAP experiments on electroformed DOPC vesicles with varying
glycerol content and at two different temperatures. Sucrose/glucose solutions similar to the
‘no P-188 environment’ with and without 15% glycerol were prepared. FRAP measurements
were conducted at room temperature (approx. 20°C) as well as at 37°C, but with the same
optical parameters. Temperature control was performed with the cellVivo incubation system.
The obtained values are presented in Table A.7.
Table A.7. Lateral diffusion coefficients (mean ± std. dev) of electroformed DOPC vesicle
membranes at different temperatures and varying glycerol concentrations. The diffusion
coefficient increases from 1.0 ± 0.2 µm2/s (mean ± std. dev, N = 17) at 20°C and 15% glycerol
to 1.6 ± 0.2 µm2/s (N = 12) without the presence of glycerol. At 37°C, the coefficients rise to
1.9 ± 0.6 µm2/s (N = 19) with 15% glycerol and 2.2 ± 0.5 µm2/s without glycerol.
DOPC (electroformation)
Room temperature (approx. 20°C)
15% v/v glycerol
1.0 ± 0.2 µm2/s
N = 17
Room temperature (approx. 20°C)
0 % v/v glycerol
1.6 ± 0.2 µm2/s
N = 12
37°C
15% v/v glycerol
1.9 ± 0.6 µm2/s
N = 19
37°C
0% v/v glycerol
2.2 ± 0.5 µm2/s
N = 7
A.4.3 Statistical Tests
The following tables show the results of the statistical tests performed on the lateral diffusion
coefficients of the vesicles in different chemical environments (Tables A.8, A.9, A.13 and
A.14), as well as with and without a visible octanol pocket attached (Tables A.10, A.11, A.12,
A.15, A.16 and A.17).
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DOPC
Table A.8. ANOVA on lateral lipid diffusion coefficients of DOPC vesicles in the different
chemical environments. At the 0.01 level, the population means are not significantly different.
N Analysis N Missing Mean StandardDeviation SE of Mean
Electroformation
‘’‘no P-188’ 17 0 1.0066 0.18878 0.04579
Electroformation
‘high P-188’ 14 0 1.2347 0.40438 0.10807
OLA
‘low P-188’ 34 0 1.10313 0.21012 0.03604
OLA
‘high P-188’ 30 0 0.9801 0.25758 0.04703
DF Sum ofSquares
Mean
Square F Value Prob >F
Model 3 0.72666 0.24222 3.62715 0.01593
Error 91 6.077 0.06678
Total 94 6.80366
R-square Coeff Var Root MSE Data Mean
0.1068 0.24233 0.25842 1.06639
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Table A.9. Two sample t-tests comparing lateral lipid diffusion coefficients of DOPC vesicles
in ‘no/low’ and ‘high’ P-188 environments. At the 0.01 level, the means are not significantly
different from one another.
Comparison of lateral diffusion coefficent p-value(2 sample t-test with Welch’s correction)
Electroformation ‘no P-188’ vs.
Electroformation ‘high P-188’ 0.06812
Electroformation ‘no P-188’ vs.
OLA ‘low P-188’ 0.10644
Electroformation ‘no P-188’ vs.
OLA ‘high P-188’ 0.68838
Electroformation ’no P-188’ vs.
OLA ’high P-188’ 0.04441
Electroformation ‘no P-188’ vs.
OLA ‘low P-188’ 0.26509
OLA ‘low P-188’ vs.
OLA ‘high P-188’ 0.04244
Table A.10. ANOVA on lateral lipid diffusion coefficients of DOPC vesicles in a ‘high’
P-188 environment with and without a visible octanol pocket attached. At the 0.05 level, the
population means are not significantly different.
N Analysis N Missing Mean StandardDeviation SE of Mean
Octanol pocket
‘high P-188’ 13 1 0.87757 0.17093 0.04741
No Octanol pocket
‘high P-188’ 17 2 1.0585 0.28856 0.06999
DF Sum ofSquares
Mean
Square F Value Prob >F
Model 1 0.24115 0.24115 4.01219 0.05494
Error 28 1.68289 0.0601
Total 29 1.92404
R-square Coeff Var Root MSE Data Mean
0.12533 0.25014 0.24516 0.9801
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Table A.11. ANOVA on lateral lipid diffusion coefficients of DOPC vesicles in a ‘low’
P-188 environment with and without a visible octanol pocket attached. At the 0.05 level, the
population means are not significantly different.
N Analysis N Missing Mean StandardDeviation SE of Mean
Octanol pocket
‘low P-188’ 15 3 1.06813 0.20468 0.05285
No Octanol pocket
‘low P-188’ 19 2 1.13075 0.21572 0.04949
DF Sum ofSquares
Mean
Square F Value Prob >F
Model 1 0.03287 0.03287 0.73853 0.39652
Error 32 1.42411 0.0445
Total 33 1.45697
R-square Coeff Var Root MSE Data Mean
0.02256 0.19124 0.21096 1.10313
Table A.12. Two sample t-test comparing lateral lipid diffusion coefficients of DOPC
vesicles with and without a visible octanol pocket attached. At 0.01 level, the means are not
significantly different from one another.
Comparison of lateral diffusion coefficent p-value(2 sample t-test with Welch’s correction)
OLA octanol pocket attached vs.
OLA octanol poclet separated (‘low P-188’) 0.39379
OLA octanol pocket attached vs.
OLA octanol pocket separated (‘high P-188’) 0.04166
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POPC
Table A.13. ANOVA on lateral lipid diffusion coefficients of POPC vesicles in the different
chemical environments. At the 0.001 level, the difference in the population means are
statistically significant.
N Analysis N Missing Mean StandardDeviation SE of Mean
Electroformation
‘no P-188’ 28 0 0.79702 0.20225 0.03822
Electroformation
‘high P-188’ 28 0 1.34993 0.43119 0.09642
OLA
‘low P-188’ 49 0 0.97925 0.2719 0.03884
OLA
‘high P-188’ 27 0 0.93057 0.13276 0.02555
DF Sum ofSquares
Mean
Square F Value Prob >F
Model 3 0.72666 0.24222 3.62715 0.01593
Error 91 6.077 0.063378
Total 94 6.80366
R-square Coeff Var Root MSE Data Mean
0.30166 0.27185 0.26839 0.98729
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Table A.14. Two sample t-tests comparing lateral lipid diffusion coefficients of POPC
vesicles in ‘no/low’ and ‘high’ P-188 environments. At the 0.001 level, the lateral lipid
diffusion coefficient of electroformed vesicles in a ‘high P-188’ environment is significantly
different from electroformed vesicles without P-188, as well as OLA vesicles with ‘high
P-188’. All remaining diffusion coefficients are not significantly different from one another.
Comparison of lateral diffusion coefficent
p-value
(2 sample t-test with Welch’s correction)
Electroformation ‘no P-188’ vs.
Electroformation ‘high P-188’ 1.58549E-5
Electroformation ‘no P-188’ vs.
OLA ‘low P-188’ 0.00133
Electroformation ‘no P-188’ vs.
OLA ‘high P-188’ 0.00559
Electroformation ‘no P-188’ vs.
OLA ‘high P-188’ 3.76001E-4
Electroformation ‘no P-188’ vs.
OLA ‘low P-188’ 0.00147
OLA ‘low P-188’ vs.
OLA ‘high P-188’ 0.29855
Table A.15. ANOVA on lateral lipid diffusion coefficients of POPC vesicles in a high P-188
environment with and without a visible octanol pocket attached. At the 0.05 level, the
population means are not significantly different.
N Analysis N Missing Mean StandardDeviation SE of Mean
Octanol pocket
‘high P-188’ 17 1 0.94456 0.13026 0.03159
No Octanol pocket
‘high P-188’ 9 2 0.88763 0.13453 0.04484
DF Sum ofSquares
Mean
Square F Value Prob >F
Model 1 0.01907 0.01907 1.09968 0.30478
Error 24 0.41627 0.01734
Total 25 0.43534
R-square Coeff Var Root MSE Data Mean
0.30166 0.27185 0.26839 0.98729
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Table A.16. ANOVA on lateral lipid diffusion coefficients of POPC vesicles in a low P-188
environment with and without a visible octanol pocket attached. At the 0.05 level, the
population means are not significantly different.
N Analysis N Missing Mean StandardDeviation SE of Mean
Octanol pocket
‘low P-188’ 32 11 0.93381 0.28302 0.05003
No Octanol pocket
‘low P-188’ 17 5 1.06477 0.23388 0.05672
DF Sum ofSquares
Mean
Square F Value Prob >F
Model 1 0.19039 0.19039 2.66451 0.10929
Error 47 3.35829 0.07145
Total 48 3.54868
R-square Coeff Var Root MSE Data Mean
0.05365 0.27297 0.26731 0.97925
Table A.17. Two sample t-tests comparing lateral lipid diffusion coefficients of POPC
vesicles with and without a visible octanol pocket attached. At 0.05 level, the means are not
significantly different from one another.
Comparison of lateral diffusion coefficent p-value(2 sample t-test with Welch’s correction)
OLA octanol pocket attached vs.
OLA octanol poclet separated (‘low P-188’) 0.09139
OLA octanol pocket attached vs.
OLA octanol pocket separated (‘high P-188’) 0.25367
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B.1 Microfluidic Chip Designs
Fig. B.1. Chip design of microfluidic permeability assay. Two different chip designs were
used for the measurements. Design B has a longer outlet, leading to the T-junction, which
can be used as reservoir for more GUVs.
B.2 Scatter Plots of Permeability Measurements
The scatter plots of the individual permeability measurements obtained via the microfluidic
platform are given below.
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Fig. B.2. Scatter plots of ∆I vs R for norfloxacin in 5 mM acetic acid buffer with 200 mM
sucrose at pH 5. No significant transport of the drug through the PGPC vesicles can be
detected in any of the experiments, since no significant change of ∆I was detected between
the different time points.
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Fig. B.3. Scatter plots of ∆I vs R for norfloxacin in PBS with 200 mM sucrose at pH 7.4.
Significant transport of the drug through the PGPC vesicles can be detected in all experiments,
visible by the gap in ∆I between the two time points.
B.2 Scatter Plots of Permeability Measurements 199
Fig. B.4. Scatter plots of ∆I vs R for norfloxacin in PBS with 200 mM sucrose at pH 7.4.
Significant transport of the drug through the PGPC vesicles can be detected in all experiments,
visible by the gap in ∆I between the two time points.
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Fig. B.5. Scatter plots of ∆I vs R for ciprofloxacin in PBS with 200 mM sucrose at pH 7.4.
Significant transport of the drug through the PGPC vesicles can be detected in all experiments,
visible by the gap in ∆I between the two time points.
Appendix C
DNA Nanopores
C.1 Strand Sequence of the DNA Pore
The strand sequence of the DNA pore is given in Table C.1.
Table C.1. Sequence of individual DNA strands forming the nanopore.
Name Sequence (5’ to 3’) Length (nt)
Sc1 CCTTTCCACGAACACAGGGTTGTCCGATCCTATATTACGACTCCTTT 47
Sc2 TTTGGGAAGGGGTTCGCAAGTCGCACCCTAAACG 34
Sc3 TCTTATCCTGCATCGAAAGCTCAATCATGCATCTTT 36
Sc4 TTTATGTTGAAGGCTCAGGATGC 23
St1 TTTATCGGACATTCAACATGGAGTCGTGGTGCGACT 36
St2 TGCGAACAGGATAAGACGTTTAGAATATAGGTTT 34
St3 TTTTTCGATGCCCCTTCCCGATGCATGAAGGGCATCCTGAGCCACCC 47
St4 TGTGTTCGTGGAATTGAGCTTTT 23
C.2 Folding Protocol
All DNA strands were acquired from Integrated DNA Technology (IDT). The DNA strands
were mixed to a final concentration of 1 µM in TE20 buffer (10 mM Tris, pH 8.0, 0.1 mM
EDTA) containing an additional 20 mM MgCl2 in an Eppendorf tube. The mixture of DNA
strands then underwent a heating protcol using a ProFlex™ PCR thermal cycler (Thermo
Fisher Scientific). The mixture was heated to 85°C for 5 minutes and subsequently cooled to
25°C over 18 hours. After assembly, the structures were stored at 4°C.
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C.3 Polyacrylamide Gel Electrophoresis (PAGE) 1
We used polyacrylamide gel electrophoresis (PAGE) to validate successful assembly of
the DNA structures before every experiment, following an established protocol [228, 229].
In this technique, an electric field is applied across a gel of cross-linked polymers. The
negatively charged DNA structures migrate against the direction of the electric field. The
distance the DNA structures are able to travel depends primarily of the size and shape of
the structure. By comparing the distances by which the nanostructures migrated to that of
a known reference (DNA ladder), the correct assembly of the DNA pores can be assessed.
Figure C.1 shows an example PAGE of correctly assembled DNA pores.
Fig. C.1. Polyacrylamide gel electrophoresis to validate the correct assembly of the DNA
structures. The leftmost lane displays a DNA ladder of known base pairs which are used
as the reference. The remaining lanes depict unlabelled as well as labelled 0C, 1C and 2C
structures. The strong bands indicate the successful assembly of the pore. The small steps
between the 0C, 1C and 2C structures stems from their additional mass due to the cholesterol
tags, again suggesting successful assembly of the structure. Image from [229].
1PAGE was either performed by K. Jahnke or A. Ohmann.
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C.4 Solution Composition
The base stock solution consisted of 200 mM sucrose, 15% v/v glycerol in PBS (pH 7.4).
The OLA solutions were made up as follows:
• IA: Base stock + 50 µM HPTS
• OA: Base stock + 50 mg/mL P-188
• LO: 4 mg/mL DOPC in 1-Octanol
The solutions for the perfusion steps are listed in Tables C.2 and C.3.
Table C.2. Solutions used in the different perfusion steps in Experiment 1
Perfusion 1 Perfusion 2
DNA pore chamber
Base stock (pH 7.4)
50 nM DNA pores
20 mM MgCl2
Buffer chamber
Base stock (pH 7.4)
20 mM MgCl2
All chambers
Base stock (pH 5.9)
20 µM HPTS
20 mM MgCl2
Table C.3. Solutions used in the different perfusion steps in Experiment 2 and 3
Perfusion 1 Perfusion 2
DNA pore chamber
Base stock (pH 7.4)
50 nM DNA pores
20 mM MgCl2
Buffer chamber
Base stock (pH 7.4)
20 mM MgCl2
All chambers
Base stock (pH 5.9)
5 µM HPTS
20 mM MgCl2
C.5 Detailed Protocol of Chip Operation
The perfusion assay is operated using two pressure-driven pumps (MFCS, Fluigent SA,
France), as well as one flow-driven syringe pump (neMESYS, Cetoni GmbH, Germany)
equipped with a 250 µL glass syringe (ILS, Germany). One of the Fluigent pumps is needed
to drive the flows at the OLA junction and enable vesicle production. The second Fluigent
pump is needed to flush in a substance of interest via the perfusion inlets. The syringe
pump is required for applying suction via the outlet A, thereby forcing the GUVs from the
second-level connector chip into the perfusion chambers where the vesicle traps are located.
Furthermore, one Fluigent switch (2-switch, Fluigent SA, France) connected to outlet B is
necessary to control the open and close the outlet on demand.
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The microfluidic device is initially filled with air and needs to be filled in a controlled manner
in order to avoid the presence of air bubbles in the microfluidic chip that disturb the flow
pattern. The following procedure enables successful chip operation:
1. The Fluigent containing the OLA solutions is connected to the OLA inlets. However,
no pressure is applied yet. The perfusion inlets are left unconnected for now. The
neMESYS syringe pump is filled with 100 µL of base stock solution and connected to
outlet A. The 2-Switch is set the “open” state and connected to Outlet B.
2. The syringe pump is used to fill the microfluidic device with the base stock liquid via
outlet A. For this, a positive flow rate (flow into the chip) of approximately 50 µL/h is
applied. The chip fills with liquid via outlet A, pushing the air that is initially present
in the perfusion chambers into the connector chip. Furthermore, the liquid will move
towards the perfusion inlets and fill the biopsy punches that serve as fluid access ports.
This process takes approximately 30 minutes.
3. When the trapping chambers and the perfusion access ports are filled with liquid,
the positive flow from the syringe pump is reduced to 3-5 µL/h. The Fluigent pump
containing the perfusion solutes is connected, however, no pressure is applied via these
inlets yet. Since the fluid access ports are filled with liquid before the Fluigent is
connected, no air bubbles are introduced to the system via the perfusion inlets once
pressure is applied here. Furthermore, the connected Fluigent effectively blocks further
fluid flow in the direction and the entire fluid flow stemming from the syringe pump is
directed upwards into the connector chip.
4. The OLA pressures are applied using the Fluigent that is connected to the corresponding
inlets. The fluid flows likewise push the air that is present in the OLA channels into the
connector chip. Since both the fluid flows from the OLA junction, as well as the flow
from the perfusion chambers are directed into the chip, all fluids and the remaining
air bubbles in the connector chip are driven towards outlet B where they leave the
microfluidic device.
5. The pressures at the OLA junction fine-tuned such that vesicle formation starts. Pres-
sures vary from device to device, but typically the IA and LO flows are set to 10-
15 mbar, while the OA flow is in the range of 100 mbar.
6. Once GUV formation at the OLA junction is established and all air bubbles are pushed
out of the chip, the syringe pump is switched from pushing mode to suction. A negative
flow rate of 10 µL/h is applied. The negative flow rate (suction of liquid out of the
device via outlet A) drives the GUVs that are present in the connector chip down into
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the perfusion chambers where the vesicle traps are located. The GUVs have typically
lost their octanol pocket by this point, as described in Section 5.3.4.
7. Steady vesicle production and suction via Outlet A is maintained until the vesicle
traps are sufficiently filled. We typically aimed to fill the chambers to at least 80%
occupancy. Depending on the vesicle production and filling rate, this process can take
up to 4-5 hours.
8. Once a sufficient number of vesicles are trapped, the GUV production is halted by
reducing the OLA flows to 0 mbar. The 2-switch is set to the “blocked” state, which
stops any fluid flow out of Outlet B. The syringe pump is disconnected from outlet A
which is now the only open outlet.
9. The first perfusion step containing the DNA pores is started by applying pressure via
the perfusion inlets. In the first experiment we applied perfusion pressures of 10 mbar
per chamber. In the subsequent experiments we reduced this to 8 mbar and 4 mbar
respectively, in order to avoid flushing vesicles out of the traps by applying too high a
flow rate.
10. The solutes of the first perfusion are flushed for 1 h. After that the pressures are
reduced to 0 mbar. The fluid vials containing the DNA pore solution are unscrewed
from the Fluiwell system and replaced with the low pH solution which is to be flushed
in the second perfusion step. After switching the vials, the perfusion is restarted by
applying the same perfusion pressures as before.
11. The different recording positions are programmed into the piezo stage and recording
is started. Every position is scanned either every 30 s or every minute (EM gain 100,
10 ms exposure, bin 1, 10% LED power).
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C.6 Calcuation of Proton Flux through DNA Pore
In this secion, we provide a simple back of the envelope calculation of the proton flux through
a DNA nanopore. Note that in the following calculations, we do not consider any effects of
the PBS buffer used in the experiment. Furthermore, we assume that diffusion is solely driven
by a concentration gradient and neglect the effect of any electric potential that arises from
the separation of ions. Nevertheless, the following calculation gives us an idea of the number
of ions and the time scales of the proton transport through the nanopore in our experiment.
According to Fick’s law of diffusion, the flux between two reservoirs is determined by the
diffusion coefficient DH of the particle (in this case protons), as well as the concentration
gradient ∆c and the distance the ion has to travel L.
JProton ≈ DH ∆cL (C.1)
If we remember the definition of pH:
pH =− log10 c(H+) (C.2)
we obtain the proton concentration (in mol/l) from
c(H+) = 10−pH (C.3)
A pH gradient from pH 5.9 to pH 7.4, hence results in
∆c = 10−5.9−10−7.4 = 1.2×10−6 mol/l (C.4)
Using Avogadros’s number NA, we see that this corresponds to:
1.2×10−6 mol/l = 1.2×10−6 NA
l
= 7.2×10−7 protons
nm3
(C.5)
With a bilayer thickness of L = 5 nm and a diffusion coefficient DH = 2.4×10−3cm2/s we
receive from Equation C.1
JProton ≈ 3.5×104 protonsnm2 (C.6)
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With an area of the nanopores APore = 0.5 nm2 the number of protons passing through the
pore is thus:
dNProton
dt
= JProtonAPore ≈ 2×104 protonss (C.7)
Under the assumption that proton transport occurs exclusively through one pore, we can
calculate the time necessary to equlibrate the pH in a ∅ 25 µm vesicle.
From Equation C.5 we know
1.2×10−6 mol/l = 722 protons
µm3
(C.8)
Multiplied with the volume of the GUV, this gives us the necessary number of protons
722
protons
µm3
× 4
3
π(12.5µm)3 ≈ 6×106 protons (C.9)
Using the number of protons passing through the pore per second we obtained in Equation C.7,
we receive
6×106 protons
2×104 protons/s = 300s = 5min (C.10)
C.7 Designs of Microfluidic Chip
The designs of the microfluidic perfusion platform are given below.
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Fig. C.2. Chip design of the microfluidic perfusion platform used for Experiment 1. Connec-
tor chip not shown.
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Fig. C.3. Chip design of the microfluidic perfusion platform used for Experiments 2 and 3.
Connector chip not shown.
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Fig. D.1. Design of the microfluidic chip used for the experiments with the UV absorbance
assay. Image from [153]
